

NAME: Patient m0bwvya ACC #: m0bwvya DOB: 1/1/1900 SEX:

SPECIMEN DETAILS

ORDERED BY

SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE: 11/11/2022

FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE

Complete Panel

Risk Management

Type III Hyperlipoproteinemia

Not Associated with Type III Hyperlipoproteinemia

The patient is negative for both the APOE c.388 T>C (Cys130Arg) and c.526 C>T (Arg176Cys) mutations. The patient's genotype is wild-type, which is the most common genotype in the general population (frequency: >60%).

A patient with wild-type genotype does not have a defect in the apolipoprotein E (APOE), which is an integral structure of lipoprotein particles that have critical roles in blood lipid metabolism and transport. The APOE $\epsilon 3/\epsilon 3$ genotype is not associated with increased risk of cardiovascular disease. No action is needed when a patient is normolipidemic.

Hyperhomocysteinemia - Depression

No Increased Risk of Hyperhomocysteinemia

The patient does not carry the MTHFR c.665C>T variant. MTHFR enzyme activity is normal.

Patients diagnosed with depression often have low folate levels and homocysteine is a highly sensitive marker of folate status. Functional folate deficiency is indicated by elevated homocysteine. With a normal MTHFR activity, this patient can process folate normally and is unlikely to have elevated plasma levels of homocysteine.

<u>Patients diagnosed with depression</u>: as lower folate levels are associated with poorer antidepressant response, and baseline levels of folate within the normal range predict antidepressant response, testing for homocysteine levels and serum folate levels may be informative for this patient before prescribing methylfolate as an antidepressant-augmenting agent.

Thrombophilia

Normal Risk of Thrombosis

The patient does not carry the F5 c.1601G>A variant (also known as Factor V Leiden) or the F2 c.*97G>A variant (also known as Factor II 20210G>A). The patient's risk of thrombosis is not increased (average risk of clotting is about 1 in 1000 for anyone in a year). However, because this test cannot find all of the inherited reasons for abnormal clotting, other factors may affect this risk assessment.

Assess thrombotic risk based on other genetic and/or circumstantial risk factors such as smoking, obesity, malignancy, prolonged immobilization or surgery.

Estrogen-containing contraceptive and hormone replacement therapy: unless other genetic and/or circumstantial risk factors are present, consider standard prescribing and monitoring practices.

Hyperhomocysteinemia - Thrombosis

No Increased Risk of Hyperhomocysteinemia

The patient does not carry the MTHFR c.665C>T variant or MTHFR c.1286A>C variant. MTHFR enzyme activity is normal.

Based on results for the MTHFR c.665C>T and c.1286A>C variants, the patient has normal MTHFR activity and is unlikely to have elevated plasma levels of homocysteine. Hyperhomocysteinemia is associated with a risk for venous thromboembolism (VTE). Unless other risk factors are present, the patient is not expected to have an increased risk for VTE.

MTHFR enzyme activity is normal.

A medication has potentially reduced efficacy, increased toxicity or the patient has an increased risk for the indicated condition. Guidelines exist for adjusting dosage, increased vigilance or the patient has a moderate risk for the indicated condition.	ACTIONABLE	Recommendations based upon publications by international pharmacogenetic expert groups, consortia or regulatory bodies (CPIC, DPWG, FDA. EMA). Recommendations are suitable for implementation in a clinical setting. Guidelines may change as knowledge arises.
The medication can be prescribed according to standard regimens or the patient's risk for the indicated condition is not increased.	INFORMATIVE	There are insufficient or contradictory findings documenting the impact of a given genetic polymorphism or drug interaction. Recommendations are informative and implementation in a clinical setting is optional.





PATIENT INFORMATION

SPECIMEN DETAILS

NAME: Patient m0bwvya ACC #: m0bwvya DOB: 1/1/1900 SEX: SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE:

N DATE: DATE: ATE: 11/11/2022

Potentially Impacted Medications

CATEGORY	DRUG CLASS	STANDARD PRECAUTIONS	USE WITH CAUTION	CONSIDER ALTERNATIVES
Anticancer Agents	Antifolates	Methotrexate (Trexall®)		
	Angiotensin II Receptor Antagonists	Azilsartan (Edarbi®, Edarbyclor®) Candesartan (Atacand®) Eprosartan (Teveten®) Irbesartan (Avapro®) Losartan (Cozaar®, Hyzaar®) Olmesartan (Benicar®) Telmisartan (Micardis®) Valsartan (Diovan®, Entresto®)		
	Antiarrhythmics	Amiodarone (Nexterone®, Pacerone®) Disopyramide (Norpace®) Quinidine (Quinidine®) Sotalol (Betapace®, Sorine®, Sotylize®)		
Cardiovascular	Anticoagulants	Apixaban (Eliquis®) Betrixaban (Bevyxxa®) Dabigatran Etexilate (Pradaxa®) Edoxaban (Savaysa®) Fondaparinux (Arixtra®) Rivaroxaban (Xarelto®) Warfarin (Coumadin®)		
	Antiplatelets	Prasugrel (Effient®) Ticagrelor (Brilinta®) Vorapaxar (Zontivity®)		Clopidogrel (Plavix®)
	Beta Blockers	Atenolol (Tenormin®) Bisoprolol (Zebeta®) Labetalol (Normodyne®, Trandate®)		
	Diuretics	Torsemide (Demadex [®])		
	Statins		Fluvastatin (Lescol®) Pravastatin (Pravachol®) Rosuvastatin (Crestor®)	Atorvastatin (Lipitor®) Lovastatin (Mevacor®, Altoprev®, Advicor®) Pitavastatin (Livalo®) Simvastatin (Zocor®)
	Meglitinides	Nateglinide (Starlix®) Repaglinide (Prandin®, Prandimet®)		
Diabetes	Sulfonylureas	Chlorpropamide (Diabinese®) Glimepiride (Amaryl®) Glipizide (Glucotrol®) Glyburide (Micronase®) Tolbutamide (Orinase®)		
	Antiemetics	Aprepitant (Emend-oral®) Dronabinol (Marinol®) Fosaprepitant (Emend-IV®) Rolapitant (Varubi®)		



	anohoct	PATIENT INFORMATION	SPECIMEN DETAILS	ORDERED BY
	anchest niversity	SEX:	SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE: 11/11/202	2
FOR ACADEMIC PUP	RPOSES ONLY - NOT FOR CLINICAL L	ISE		
CATEGORY	DRUG CLASS	STANDARD PRECAUTIONS	USE WITH CAUTION	CONSIDER ALTERNATIVES
Gastrointestinal	Proton Pump Inhibitors	Dexlansoprazole (Dexilant®, Kapidex®) Esomeprazole (Nexium®) Lansoprazole (Prevacid®) Omeprazole (Prilosec®) Pantoprazole (Protonix®) Rabeprazole (Aciphex®)		
Infections	Antifungals	Amphotericin B (AmBisome®, Abelcet®) Anidulafungin (Eraxis®) Caspofungin (Cancidas®) Fluconazole (Diflucan®) Isavuconazonium (Cresemba®) Itraconazole (Sporanox®) Micafungin (Mycamine®) Posaconazole (Noxafil®) Voriconazole (Vfend®)		
	Anti-HIV Agents	Dolutegravir (Tivicay®, Triumeq®) Doravirine (Pifeltro®) Etravirine (Edurant®) Raltegravir (Isentress®, Dutrebis®) Rilpivirine (Intelence®)	Efavirenz (Sustiva®)	
	Antimalarials	Proguanil (Malarone®)		
	Fibromyalgia Agents	Milnacipran (Savella®)		
	Muscle Relaxants	Carisoprodol (Soma®) Cyclobenzaprine (Flexeril®, Amrix®) Metaxalone (Skelaxin®) Methocarbamol (Robaxin®)	Tizanidine (Zanaflex®)	
Pain	NSAIDs	Celecoxib (Celebrex®) Diclofenac (Voltaren®) Flurbiprofen (Ansaid®) Ibuprofen (Advil®, Motrin®) Indomethacin (Indocin®) Ketoprofen (Orudis®) Ketorolac (Toradol®) Meloxicam (Mobic®) Nabumetone (Relafen®) Naproxen (Aleve®) Piroxicam (Feldene®) Sulindac (Clinoril®)		



∇ M	anchest	PATIENT INFORMATION	SPECIMEN DETAILS	ORDERED BY
	iversity	NAME: Patient m0bwvya ACC #: m0bwvya DOB: 1/1/1900 SEX:	SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE: 11/11/2022	
FOR ACADEMIC PUR	POSES ONLY - NOT FOR CLINICAL L	JSE		
CATEGORY	DRUG CLASS	STANDARD PRECAUTIONS	USE WITH CAUTION	CONSIDER ALTERNATIVES
	Opioids	Alfentanil (Alfenta®) Buprenorphine (Butrans®, Buprenex®) Fentanyl (Actiq®) Hydrocodone (Vicodin®) Hydromorphone (Dilaudid®, Exalgo®) Levorphanol (Levo Dromoran®) Meperidine (Demerol®) Morphine (MS Contin®) Oxymorphone (Opana®, Numorphan®) Sufentanil (Sufenta®) Tapentadol (Nucynta®)	Methadone (Dolophine®)	
	Antiaddictives		Bupropion (Wellbutrin®, Zyban®, Aplenzin®, Contrave®) Naltrexone (Vivitrol®, Contrave®)	
	Anti-ADHD Agents	Amphetamine (Adderall®, Evekeo®) Clonidine (Kapvay®) Dextroamphetamine (Dexedrine®) Guanfacine (Intuniv®) Lisdexamfetamine (Vyvanse®)	Dexmethylphenidate (Focalin®) Methylphenidate (Ritalin®, Aptensio XR®, Concerta®, Metadate ER®, Quillivant ER®)	
	Anticonvulsants	Brivaracetam (Briviact®) Cannabidiol (Epidiolex®) Carbamazepine (Tegretol®, Carbatrol®, Epitol®) Eslicarbazepine (Aptiom®) Ethosuximide (Zarontin®) Ezogabine (Potiga®) Felbamate (Felbatol®) Fosphenytoin (Cerebyx®) Gabapentin (Neurontin®) Lacosamide (Vimpat®) Lamotrigine (Lamictal®) Levetiracetam (Keppra®) Oxcarbazepine (Trileptal®, Oxtellar XR®) Perampanel (Fycompa®) Phenytoin (Dilantin®) Pregabalin (Lyrica®) Rufinamide (Banzel®) Tiagabine (Gabitril®) Topiramate (Topamax®) Valproic Acid (Depakene®)	Phenobarbital (Luminal®) Primidone (Mysoline®) Zonisamide (Zonegran®)	
Psychotropic		vigabatini (Sabin 🌒		

(V) Manchost		PATIENT INFORMATION	SPECIMEN DETAILS	ORDERED BY
	anchest	SEX:	SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE: 11/11/2022	
FOR ACADEMIC PUR	POSES ONLY - NOT FOR CLINICAL U	ISE		
CATEGORY	DRUG CLASS	STANDARD PRECAUTIONS	USE WITH CAUTION	CONSIDER ALTERNATIVES
	Antidepressants	Amitriptyline (Elavil®) Citalopram (Celexa®) Clomipramine (Anafranil®) Doxepin (Silenor®) Duloxetine (Cymbalta®) Escitalopram (Lexapro®) Imipramine (Tofranil®) Levomilnacipran (Fetzima®) Mirtazapine (Remeron®) Sertraline (Zoloft®) Trazodone (Oleptro®) Trimipramine (Surmontil®) Vilazodone (Viibryd®)		
	Antipsychotics	Asenapine (Saphris®) Cariprazine (Vraylar®) Fluphenazine (Prolixin®) Loxapine (Loxitane®, Adasuve®) Lurasidone (Latuda®) Pimavanserin (Nuplazid®) Quetiapine (Seroquel®) Thiothixene (Navane®) Trifluoperazine (Stelazine®) Ziprasidone (Geodon®)	Clozapine (Clozaril®) Olanzapine (Zyprexa®)	
	Benzodiazepines	Alprazolam (Xanax®) Clonazepam (Klonopin®) Diazepam (Valium®)	Clobazam (Onfi®)	
	Other Neurological Agents	Flibanserin (Addyi®)		
Rheumatology	Anti-Hyperuricemics and Anti-Gout Agents	Colchicine (Mitigare®) Febuxostat (Uloric®)		
	Immunomodulators	Apremilast (Otezla®) Tofacitinib (Xeljanz®)	Leflunomide (Arava®)	
Transplantation	Immunosuppressants		Tacrolimus (Prograf®)	
	5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia	Dutasteride (Avodart®) Finasteride (Proscar®)		
Urologicals	Alpha-Blockers for Benign Prostatic Hyperplasia	Alfuzosin (UroXatral®) Doxazosin (Cardura®) Silodosin (Rapaflo®) Terazosin (Hytrin®)		
orologicals	Antispasmodics for Overactive Bladder	Oxybutynin (Ditropan®) Solifenacin (Vesicare®) Trospium (Sanctura®)		
	Phosphodiesterase Inhibitors for Erectile Dysfunction	Avanafil (Stendra®) Sildenafil (Viagra®) Tadalafil (Cialis®) Vardenafil (Levitra®)		





Dosing Guidance

\otimes	Atorvastatin Lipitor®	Increased Atorvastatin Exposure (SLCO1B1: Decreased Function) The patient's genotype is associated with possible increased atorvastatin exposure. Patients may be at an	ACTIONABLE increased
		myopathy risk. Consider starting atorvastatin at doses ≤40 mg. If doses >40 mg are needed, consider combination thera atorvastatin plus a non-statin guideline directed therapy).	py (e.g.,
\otimes	Clopidogrel	Reduced Exposure to Clopidogrel Active Metabolite (CYP2C19: Intermediate Metabolizer)	ACTIONABLE
	Plavix®	The patient's genotype is associated with possible decreased clopidogrel exposure. Patients may be at an for adverse cardiac and cerebrovascular events.	increased risk
		ACS, PCI, and Neurovascular Indications: Consider an alternative such as prasugrel (contraindicated in TIA/stroke) or ticagrelor. In patients with ACS clopidogrel cannot be avoided, alternative dosing strategies exist and may be considered.	S or PCI, if
\otimes	Lovastatin	Increased Lovastatin Exposure (SLCO1B1: Decreased Function)	ACTIONABLE
	Mevacor [®] , Altoprev [®] ,	The patient's genotype is associated with possible increased lovastatin exposure. Patients may be at an in myopathy risk.	creased
	Advicor®	Consider an alternative statin based on disease-specific guidelines. If lovastatin use is warranted, consider ≤20 mg per day.	limiting dose to
\otimes	Pitavastatin	Increased Pitavastatin Exposure (SLCO1B1: Decreased Function)	ACTIONABLE
_	Livalo®	The patient's genotype is associated with possible increased pitavastatin exposure. Patients may be at an myopathy risk with doses >1 mg per day.	increased
		Consider starting pitavastatin at doses ≤2 mg. If doses >2 mg are needed, consider an alternative statin o therapy (e.g., pitavastatin plus a non-statin guideline directed medical therapy).	r combination
\otimes	Simvastatin	Increased Simvastatin Exposure (SLCO1B1: Decreased Function)	ACTIONABLE
	Zocor®	The patient's genotype is associated with possible increased simvastatin exposure. Patients may be at an i myopathy risk with doses >20 mg.	ncreased
		Consider an alternative statin. If simvastatin use is warranted, consider limiting dose to <20 mg.	
<u>^!</u>	Bupropion	Altered Bupropion Exposure (CYP2B6: Intermediate Metabolizer)	INFORMATIVE
	Wellbutrin®, Zyban®, Aplenzin®, Contrave®	The genotype result indicates that the patient is likely to have increased bupropion exposure, but decreas the active metabolite (hydroxybupropion). This metabolite contributes to the therapeutic effects of bupro as a smoking cessation agent or as an antidepressant. This decrease in exposure of hydroxybupropion ma decreased therapeutic efficacy.	pion when used
		Smoking Cessation : There is insufficient data to allow calculation of dose adjustment. Consider standard closer monitoring.	prescribing and
		Major Depressive Disorder and Prevention of Seasonal Affective Disorder : There is insufficient data t calculation of dose adjustment. Therapeutic monitoring of bupropion-hydroxybupropion levels may be coguide dosing adjustments.	
<u>^</u>	Clobazam Onfi®	Possible Sensitivity to Clobazam (CYP2C19: Intermediate Metabolizer)	ACTIONABLE
	Powered By	Genetic Test Results For Patient m0bwvya	D 6 6
S 5	software	FOR ACADEMIC PURPOSES ONLY - DO NOT DISTRIBUTE - NOT FOR CLINICAL USE	Page 6 of 57

ORDERED BY

NAME: Patient m0bwvya ACC #: m0bwvya **DOB:** 1/1/1900

SEX:

PATIENT INFORMATION

SPECIMEN DETAILS

COLLECTION DATE: **RECEIVED DATE:** REPORT DATE: 11/11/2022

SPECIMEN TYPE:



SPECIMEN DETAILS	ORDER
SPECIMEN TYPE: COLLECTION DATE:	
RECEIVED DATE: REPORT DATE: 11/11/2022	
	SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE:

RED BY

FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE

		In CYP2C19 intermediate metabolizers, plasma levels of the active metabolite N-desmethylclobazam were than those found in CYP2C19 normal metabolizers. The dose adjustment for intermediate metabolizers is established, and therefore the recommendation for poor metabolizers is proposed. The starting dose show mg/day, and dose titration should proceed slowly according to weight. Patients should be titrated initially (\leq 30 kg body weight) or 20 mg/day ($>$ 30 kg body weight). If necessary and based upon clinical response, titration to the maximum doses 20 mg/day (\leq 30 kg body weight) or 40 mg/day ($>$ 30 kg body weight) matched and the maximum doses 20 mg/day (\leq 30 kg body weight) or 40 mg/day ($>$ 30 kg body weight) matched and the maximum doses 20 mg/day (\leq 30 kg body weight) or 40 mg/day ($>$ 30 kg body weight) matched and a 21.	not well uld be 5 to 10 mg /day an additional
	Clozapine	Non-Response to Clozapine (CYP1A2: Normal Metabolizer - Higher Inducibility)	INFORMATIVE
	Clozaril®	Smokers have a high risk for non-response at standard doses and may require higher doses. There is an a between high clozapine doses and the risk of seizures, and therefore careful monitoring is recommended adjustment. Smoking cessation will increase plasma drug levels, leading to adverse events. Therefore, there monitoring accompanied by dose reduction is recommended in patients who have quit smoking.	during dosing
<u>^!</u>	Dexmethylphenid ate	Decreased Response to Dexmethylphenidate (COMT: Intermediate COMT Activity)	INFORMATIVE
	Focalin®	The patient's genotype result predicts a less optimal response to dexmethylphenidate. Dosage should be according to the needs and response of the patient. Therapy should be initiated in small doses, with grading increments.	
<u>^</u>	Efavirenz	Increased Efavirenz Exposure (CYP2B6: Intermediate Metabolizer)	ACTIONABLE
	Sustiva®	The genotype result indicates that the patient is likely to have higher dose-adjusted trough concentration following standard dosing. This may result in increased risk of CNS adverse events. Consider initiating efair decreased dose of 400 mg/day. If therapeutic drug monitoring is available and a decreased efavirenz dose consider obtaining steady-state plasma efavirenz concentrations to ensure concentrations are in the sugg therapeutic range (~1 to 4 μ g/mL).	virenz with a e is prescribed,
	Fluvastatin	Increased Fluvastatin Exposure (SLCO1B1: Decreased Function; CYP2C9: Normal	ACTIONABLE
	Lescol®	Metabolizer) The patient's genotype is associated with possible increased fluvastatin exposure. Fluvastatin can be prese standard label-recommended dosage and administration, but patients may be at an increased risk for my doses >40 mg per day.	
	Leflunomide	Increased Exposure to Leflunomide (CYP2C19: Intermediate Metabolizer)	INFORMATIVE
	Arava®	Leflunomide is metabolized by CYP2C19 and CYP1A2 to its active metabolite teriflunomide. Preliminary st that patients with decreased CYP2C19 activity have a higher risk of developing gastrointestinal side effect hepatotoxicity. There is insufficient data to calculate dose adjustment. If leflunomide is prescribed at stand monitor closely the patient's response and be alert to increased side effects.	s and
		Full blood cell count (CBC) and liver function parameters should be checked no more than 6 months befo treatment, and every month for the initial 6 months of therapy. Blood pressure should be checked before treatment and periodically thereafter.	5 5
<u>^</u>	Methadone	Increased Methadone Exposure (CYP2B6: Intermediate Metabolizer)	INFORMATIVE
	Dolophine [®]	The patient's genotype may be associated with an increased methadone exposure following standard dos	ing.
		For Addiction Treatment : There is limited evidence indicating that intermediate metabolizers require low therefore, a dose adjustment cannot be calculated.	ver doses,
		For Pain Management : There are no studies documenting the effect of CYP2B6 genetic variations on me exposure when this drug is used as an analgesic. Consider standard prescribing and monitoring practices.	thadone
<u>^!</u>	Methylphenidate	Decreased Response to Methylphenidate (COMT: Intermediate COMT Activity)	INFORMATIVE
	Powered By	Genetic Test Results For Patient m0bwvya	
S S	oftware	FOR ACADEMIC PURPOSES ONLY - DO NOT DISTRIBUTE - NOT FOR CLINICAL USE	Page 7 of 57



PATIENT INFORMATION	SPECIMEN DETAILS
NAME: Patient m0bwvya	SPECIMEN TYPE:
ACC #: m0bwvya	COLLECTION DATE:
DOB: 1/1/1900	RECEIVED DATE:
SEX:	REPORT DATE: 11/11/2022

Ritalin®, Aptensio XR®, The patient's genotype result predicts a less optimal response to methylphenidate. Dosage should be individualized

	Concerta®, Metadate ER®, Quillivant ER®	according to the needs and response of the patient. Therapy should be initiated in small doses, with gradu increments.	ial weekly
	Naltrexone	Altered Response to Naltrexone (OPRM1: Normal OPRM1 Function)	INFORMATIVE
	Vivitrol®, Contrave®	<u>Treatment of alcohol dependence</u> : the patient has the OPRM1 118AA wild-type genotype that is associate outcome with naltrexone therapy. Naltrexone-treated patients not carrying the OPRM1 118A>G G allele arrespond to this drug, and may have higher relapse rates than those who are carriers of this allele. This associate reported consistently across studies.	e less likely to
	Olanzapine	Non-Response to Olanzapine (CYP1A2: Normal Metabolizer - Higher Inducibility)	INFORMATIVE
	Zyprexa ®	There is little evidence regarding the impact of CYP1A2 genetic variants on olanzapine response. Smokers for non-response at standard doses. Careful monitoring is recommended during dosing adjustment. Smok may increase plasma drug levels, leading to adverse events. Therefore, therapeutic drug monitoring accome dose reduction may be needed in patients who have quit smoking.	king cessation
	Phenobarbital	Possible Sensitivity to Phenobarbital (CYP2C19: Intermediate Metabolizer)	INFORMATIVE
	Luminal®	CYP2C19 is partly involved in the metabolism of phenobarbital, and although CYP2C19 intermediate meta lower clearance of phenobarbital than normal metabolizers, no significant changes in clinical outcome has with this antiepileptic drug. Therefore, phenobarbital can be prescribed at standard label-recommended d administration with a closer monitoring for adverse events.	been reported
	Pravastatin	Increased Pravastatin Exposure (SLCO1B1: Decreased Function)	ACTIONABLE
	Pravachol®	The patient's genotype is associated with possible increased pravastatin exposure. Pravastatin can be pres standard label-recommended dosage and administration, but patients may be at an increased myopathy r >40 mg per day.	
<u>^</u>	Primidone	Possible Sensitivity to Primidone (CYP2C19: Intermediate Metabolizer)	INFORMATIVE
	Mysoline®	CYP2C19 is partly involved in the metabolism of primidone, and although CYP2C19 intermediate metaboli lower clearance of phenobarbital (active metabolite) than normal metabolizers, no significant changes in c has been reported with this antiepileptic drug. Therefore, primidone can be prescribed at standard label-re dosage and administration with a closer monitoring for adverse events.	linical outcome
	Rosuvastatin	Increased Rosuvastatin Exposure (SLCO1B1: Decreased Function)	ACTIONABLE
	Crestor [®]	The patient's genotype is associated with possible increased rosuvastatin exposure. Rosuvastatin can be pi standard label-recommended dosage and administration, but patients may be at an increased myopathy r >20 mg.	
	Tacrolimus	Insufficient Response to Tacrolimus (CYP3A5: Intermediate Metabolizer)	ACTIONABLE
	Prograf®	The genotype result predicts that the patient expresses the CYP3A5 protein. Therefore, the patient may me tacrolimus more rapidly, resulting in low tacrolimus trough levels. Studies have shown patients with this ge at increased risk for acute transplant rejection while taking a standard dose of tacrolimus. Therefore, increas dose 1.5 to 2 times recommended starting dose with close monitoring is strongly recommended to achieve effect. Total starting dose should not exceed 0.3mg/kg/day.	enotype may be asing starting
<u>^!</u>	Tizanidine	Possible Non-Response to Tizanidine (CYP1A2: Normal Metabolizer - Higher Inducibility)	INFORMATIVE
	Zanaflex®	······································	

(\mathbf{X})	Manchester
V	University

PATIENT INFORMATION		
NAME:	Patient m0bwvya	
ACC #:	m0bwvya	
DOB:	1/1/1900	

SPECIMEN DETAILS SPECIMEN TYPE: COLLECTION DATE:

ORDERED BY

	DOB: 1/1/1900 RECEIVED DATE:	
FOR ACADEMIC PURPOSES ONLY - I	SEX: REPORT DATE: 11/11/2022 NOT FOR CLINICAL USE 11/11/2022 11/11/2022	
	There is little evidence regarding the impact of CYP1A2 genetic variants on tizanidine respons for non-response and may require higher doses. There is an association between high tizanidi and the risk of hypotension and excessive sedation. Therefore, careful monitoring is recomme adjustment. Smoking cessation may increase plasma drug levels, leading to excessive hypoter monitoring accompanied by dose reduction may be needed in patients who have quit smokir	ne plasma concentrations nded during dosing Ision and sedation. Careful
Zonisamide	Possible Sensitivity to Zonisamide (CYP2C19: Intermediate Metabolizer)	INFORMATIV
Zonegran [®]	CYP2C19 is partly involved in the metabolism of zonisamide, and although preliminary studies intermediate metabolizers have a slightly lower (15%) zonisamide clearance than normal meta change in the clinical outcome has been reported with this antiepileptic drug. Therefore, zonis standard label-recommended dosage and administration with a closer monitoring for adverse	abolizers, no significant samide can be prescribed at
/ Alfentanil	Normal Response to Alfentanil	INFORMATIV
Alfenta ®	Pharmacogenetic guidance : alfentanil is primarily metabolized by CYP3A4 and CYP3A5. Stud showed that CYP3A5 genotype had no effect on the systemic or apparent oral clearances, or p alfentanil. Polypharmacy guidance : Alfentanil should be used with caution when prescribed inhibitors or inducers.	pharmacodynamics of
Alfuzosin	Normal Response to Alfuzosin	INFORMATIV
UroXatral®	Pharmacogenetic guidance: No genetically-guided drug selection or dosing recommendation Polypharmacy guidance: Alfuzosin is extensively metabolized by CYP3A4 into pharmacologi Alfuzosin is contraindicated with strong CYP3A4 inhibitors, as the risk for QTc prolongat increased at higher concentrations. Take caution when this drug is prescribed with CYP3A4 drug levels may increase.	cally inactive metabolites. ion induced by this drug i
Alprazolam	Normal Response to Alprazolam	INFORMATIV
Xanax®	Pharmacogenetic guidance: Alprazolam is primarily eliminated by metabolism via CYP3A4 a polymorphisms of these genes are not expected to affect the efficacy or safety profiles of this guidance: The concomitant use of alprazolam with CYP3A4 inhibitors may result in increased prolonged sedation. Impairment of motor skills are also observed with some combinations. M exaggerated sedative effects. If possible, alprazolam should be avoided in patients receiving s such as ketoconazole, itraconazole and ritonavir. Drugs that induce CYP3A enzymes may decr which results in a loss of efficacy.	drug. Polypharmacy alprazolam levels and onitor patients for trong inhibitors of CYP3A4
Amiodarone	Normal Exposure to Amiodarone	INFORMATIV
Nexterone®, Pacerone®	Pharmacogenetic guidance : Amiodarone is metabolized to N-desethylamiodarone. This pro by CYP3A. No genetically guided drug selection or dosing adjustments are recommended. Pc administration of amiodarone with drugs that are, a strong inducer or inhibitor of CYP3A may In addition, co-administration of amiodarone with drugs known to prolong QT interval can pr QT syndrome.	lypharmacy guidance: Co affect drug plasma levels.
Amitriptyline	Normal Amitriptyline Exposure (CYP2C19: Intermediate Metabolizer) The patient's reduced CYP2C19 activity is unlikely to result in increased amitriptyline exposure	ACTIONABL
	Psychiatric Conditions: Amitriptyline therapy can be prescribed according to standard recon administration. Consider therapeutic drug monitoring to guide dose adjustments.	nmended dosage and
	Neuropathic Pain: Amitriptyline therapy can be prescribed according to standard recommen administration.	ded dosage and
Amphetamine Adderall®, Evekeo®	Good Response to Amphetamine salts (COMT: Intermediate COMT Activity)	INFORMATIV
Powered By	Genetic Test Results For Patient m0bwvya	
software		Page 9 of 5



PATIENT	INFORMATIO

NAME: Patient m0bwvya ACC #: m0bwvya **DOB:** 1/1/1900 SEX:

SPECIMEN DETAILS

ORDERED BY

SPECIMEN TYPE: **COLLECTION DATE: RECEIVED DATE:** REPORT DATE: 11/11/2022

FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE

The patient's genotype result predicts a favorable response to amphetamine stimulants. Amphetamines should be administered at the lowest effective dose, and dosage should be individually adjusted.

√	Amphotericin B AmBisome®, Abelcet®	Normal Response to Amphotericin B Pharmacogenetic guidance: Amphotericin B is excreted very slowly (over weeks to months) by the kidn of a given dose being excreted in the biologically active form. Details of possible metabolic pathways are genetically guided drug selection or dosing recommendations are available. Polypharmacy guidance: N medications such as aminoglycosides, cyclosporine, and pentamidine may enhance the potential for amp induced renal toxicity, and should be used concomitantly only with great caution. Intensive monitoring or is recommended in patients requiring any combination of nephrotoxic medications.	unknown. No Jephrotoxic hotericin B-
\checkmark	Anidulafungin	Normal Response to Anidulafungin	ACTIONABLE
	Eraxis®	Pharmacogenetic guidance: Anidulafungin undergoes slow chemical degradation to a peptide that lack activity and which is subsequently converted to peptidic degradants and eliminated. Hepatic metabolism has not been observed. Anidulafungin is not a substrate, inducer, or inhibitor of cytochrome P450 enzym genetically guided drug selection or dosing recommendations are available.	of anidulafungin
\checkmark	Apixaban	Normal Response to Apixaban	INFORMATIVE
	Eliquis®	Pharmacogenetic guidance: Apixaban is not extensively metabolized and only ~20% of the dose is met primarily by CYP3A4 and CYP3A5, with minor contributions from CYP1A2 and CYP2J2. This drug is a subs efflux transport proteins P-gp (ABCB1) and BCRP (ABCG2). While these enzymes and transporters are pol genetic variations are unlikely to have a clinically significant impact on apixaban exposure, and no genoty dosing adjustments are recommended. Polypharmacy guidance: Exposure to apixaban increases by 100 administered with ketoconazole, a strong CYP3A/P-gp inhibitor. This translates into an increased bleedim increase). Hence, for patients receiving 5 mg twice daily, apixaban dose should be decreased to 2.5 mg tw is coadministered with drugs that are strong dual inhibitors of CYP3A4 and P-gp (e.g., ketoconazole, itrace ritonavir, and clarithromycin). In patients already taking 2.5 mg twice daily, coadministration of apixaban inhibitors. Co-administration with rifampin, a strong CYP3A/P-gp inducer, results in halving of apixaban. There is no clinical experience at these reduced exposures. Hence, concomitant administration CYP3A/P-gp inducers should be avoided.	trate for the ymorphic, ype-based 0% when co- g risk (70% vice daily when it conazole, with strong dual istered with exposure to
	Apremilast	Normal Response to Apremilast	ACTIONABLE
-	Otezla®	Pharmacogenetic guidance: Apremilast is primarily eliminated via both hydrolysis and cytochrome P450 oxidative metabolism (with subsequent glucuronidation). Cytochrome P450-metabolism is mediated by C minor contributions from CYP1A2 and CYP2A6. Genetic polymorphisms of these enzymes are not expecte efficacy or safety profiles of apremilast. Polypharmacy guidance: The use of metabolizing enzyme indurifampin, phenobarbital, carbamazepine, phenytoin) with apremilast is not recommended.	CYP3A4, with ed to affect the
1	Aprepitant	Normal Response to Aprepitant	ACTIONABLE
-	Emend-oral®	Pharmacogenetic guidance: Aprepitant undergoes extensive metabolism via N- and O-dealkylations. The are primarily catalyzed by CYP3A4 with minor involvement from CYP1A2 and CYP2C19. The drug is also go by UGT1A4 and UGT1A3. No genetically guided drug selection or dosing recommendations are available Guidance: In presence of moderate and strong CYP3A4 inhibitors, a significantly increased exposure of a expected which may lead to adverse reactions. These drugs should be avoided with aprepitant. Strong CY can significantly decrease aprepitant exposure resulting in a loss of efficacy. These drugs should also be a aprepitant. Aprepitant is a moderate (dose-dependent) inhibitor, and an inducer of CYP3A4 and an induce Some substrates of these enzymes are contraindicated with aprepitant while others should be closely more doing adjusted when coadministered with this antiemetic medication.	Jucuronidated Polypharmacy prepitant is (P3A4 inducers avoided with ther of CYP2C9.
\checkmark	Asenapine Saphris®	Normal Response to Asenapine	INFORMATIVE
	Powered By Franslational software	Genetic Test Results For Patient m0bwvya	Page 10 of 57

FOR ACADEMIC PURPOSES ONLY - DO NOT DISTRIBUTE - NOT FOR CLINICAL USE

\bigtriangledown	٦Ло	noho	ester	PATIEN	IT INFORMATION
N	TATS		SIGT.	NAME:	Patient m0bwvya
	Un	vers	I V	ACC #:	m0bwvya
•				DOB:	1/1/1900
				CEX.	

SPECIMEN DETAILS

ORDERED BY

vya SEX:

SPECIMEN TYPE: COLLECTION DATE: **RECEIVED DATE:** REPORT DATE: 11/11/2022

FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE

	FOR ACADEMIC PURPOSES UNLY - NO	I FOR CLINICAL USE	
		Pharmacogenetic Guidance: Asenapine is extensively metabolized to more than 38 inactive metabolited metabolism route occurs via direct glucuronidation catalyzed by UGT1A4. Also important but less prono demethylation pathway as well as the oxidative reactions catalyzed by CYP1A2 with contributions from C CYP2D6. There are no studies documenting the effect of genetic polymorphisms of these metabolizing e asenapine disposition and there are no available genetically guided drug selection or dosing recommen Asenapine should be prescribed based on the clinical response and tolerability of the individual patient. guidance: Coadministration of asenapine with CYP1A2 inhibitors such as fluvoxamine should be approar as asenapine plasma concentrations will increase resulting in more side effects. Cigarette smoking, which activity, has a limited effect on asenapine plasma concentrations. Asenapine is a weak inhibitor of CYP2D coadministration with paroxetine (both a substrate and an inhibitor of CYP2D6) should be approached w -term therapy with strong enzyme inducers (e.g. carbamazepine, phenytoin, rifampin) may decrease asen and dosage adjustment may be needed.	unced is the CYP3A4 and enzymes on dations. Polypharmacy ched with caution n induces CYP1A2 D6 and its <i>v</i> ith caution. Long
./	Atenolol	Normal Response to Atenolol	INFORMATIVE
·	Tenormin ®	Pharmacogenetic guidance: The bioavailability of atenolol is approximately 40–50% and renal excretio approximately 90% of the absorbed drug in its unchanged form. A negligible amount of the drug is met Atenolol is a substrate of several organic anion and cation transporters including SLC22A1, SLC22A2, SLC SLC47A2. No genetically-guided drug selection or dosing recommendations are available.	abolized.
1	Avanafil	Normal Response to Avanafil	INFORMATIVE
	Stendra®	Pharmacogenetic guidance: no genetically guided drug selection or dosing recommendations are avai Polypharmacy guidance: Avanafil is extensively metabolized by CYP3A4, therefore Avanafil should no strong CYP3A4 inhibitors such as ketoconazole, itraconazole, voriconazole, ritonavir, atazanavir, clarith indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, and telithromycin. If taking a moderate CYP3A as erythromycin, amprenavir, aprepitant, diltiazem, fluconazole, fosamprenavir, or verapamil, the dose sh than 50 mg in a 24-hour period. Inducers of CYP3A4 may decrease the concentrations of avanafil.	ot be used with romycin, 4 inhibitor, such
./	Azilsartan	Normal Azilsartan Exposure (CYP2C9: Normal Metabolizer)	INFORMATIVE
V	Edarbi®, Edarbyclor®	Azilsartan medoxomil is hydrolyzed to azilsartan, its active metabolite, in the gastrointestinal tract during Azilsartan is further metabolized to inactive metabolites by CYP2C9. Consider standard label-recommen- administration.	g absorption.
	Betrixaban	Normal Response to Betrixaban	ACTIONABLE
	Bevyxxa®	Pharmacogenetic guidance: The predominant metabolic pathway of betrixaban is amide hydrolysis with cytochrome P450 enzymes-based metabolism (less than 1% of the drug is metabolized by CYP1A1, CYP CYP2C9, CYP2C19, CYP2D6 and CYP3A4). The main elimination pathway of the drugs is biliary excretion urinary excretion. Betrixaban is a substrate for the efflux transport protein P-gp (ABCB1) and while this tr polymorphic, genetic variations are unlikely to have a clinically significant impact on betrixaban exposure genotype-based dosing adjustments are available. Polypharmacy guidance: Concomitant use with P-g as amiodarone, azithromycin, verapamil, ketoconazole, clarithromycin results in increased plasma levels increased risk of bleeding. Dosing reduction and close monitoring are recommended in presence of P-g	1A2, CYP2B6, followed by ansporter is e, and no p inhibitors such of betrixaban and
	Bisoprolol	Normal Response to Bisoprolol	INFORMATIVE
-	Zebeta®	Pharmacogenetic guidance: Bisoprolol is eliminated by renal and non-renal pathways with 50% of the metabolized in the liver and 50% being excreted via the kidneys unchanged. Bisoprolol is predominantly CYP3A4 with smaller contribution from CYP2D6. Limited studies suggest that bisoprolol plasma concent beta-adrenergic inhibition are not affected by CYP2D6 genetic variability. No genetically-guided drug se recommendations are available.	metabolized by rations and its
√	Brivaracetam	Normal Sensitivity to Brivaracetam (CYP2C19: Intermediate Metabolizer)	ACTIONABLE
-	Briviact®	Brivaracetam is primarily metabolized by hydrolysis and to a minor extent by hydroxylation, which is me CYP2C19. In CYP2C19 intermediate metabolizers, the plasma concentration of brivaracetam is increased change is not clinically significant. Brivaracetam can be prescribed at the standard label recommended c	by 22%, but this
	Powered By	Genetic Test Results For Patient m0bwvya	
S S	oftware	FOR ACADEMIC PURPOSES ONLY - DO NOT DISTRIBUTE - NOT FOR CLINICAL USE	Page 11 of 57



NAME: Patient m0bwvya ACC #: m0bwvya DOB: 1/1/1900 SPECIMEN DETAILS

SPECIMEN TYPE: COLLECTION DATE: ORDERED BY

RECEIVED DATE: SEX: REPORT DATE: 11/11/2022 FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE INFORMATIVE Buprenorphine Normal Response to Buprenorphine Pharmacogenetic guidance: no genetically guided drug selection or dosing recommendations are available. Butrans[®], Buprenex[®] Buprenorphine is primarily metabolized by CYP3A4 to norbuprenorphine and by UGT enzymes (mainly UGT1A1 and 2B7). The effects of genetic variants in these enzymes on its response have not been studied. Polypharmacy guidance: The concomitant use of buprenorphine with all CYP3A4 inhibitors may result in an increase in the drug levels, which could increase or prolong adverse drug effects. Monitor patients receiving buprenorphine with a CYP3A4 inhibitor. CYP and UGT inducers may decrease buprenorphine levels. Candesartan ACTIONABLE Normal Sensitivity to Candesartan Cilexetil Pharmacogenetic guidance: Candesartan cilexetil is hydrolyzed to candesartan its active metabolite in the Atacand® gastrointestinal tract during absorption. Candesartan undergoes minor hepatic metabolism by O-deethylation to an inactive metabolite. Genetic variability of the cytochrome P450 genes is not expected to affect the patient's response to candesartan cilexetil. No genotype-based dosing adjustments are available. Cannabidiol INFORMATIVE Normal Response to Cannabidiol Pharmacogenetic guidance: Cannabidiol is metabolized to oxidative metabolites by CYP3A4 and CYP2C19 and by direct **Epidiolex**® glucuronidation. There are insufficient studies documenting the impact of genetic polymorphisms of these metabolizing enzymes on cannabidiol response. No genetically guided drug selection or dosing recommendations are available. Polypharmacy guidance: Enzyme-inducing drugs increase cannabidiol clearance significantly, and careful titration is recommended when the drug is prescribed with enzyme-inducing-antiepileptic drugs. Coadministration of CYP3A4 inhibitors increase cannabidiol exposure by 2-fold, and a dose reduction should be considered in presence of CYP3A inhibitors. INFORMATIVE Carbamazepine Normal Response to Carbamazepine Tegretol[®], Carbatrol[®], Pharmacogenetic guidance: Genotype results obtained from the pharmacogenetic test performed in this patient cannot be used to identify patients at risk for severe cutaneous adverse reactions such as anticonvulsant hypersensitivity **Epitol**® syndrome, Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Carbamazepine, a drug with a narrow therapeutic window, is extensively metabolized by CYP3A4/5 to its active epoxide metabolite, which is further metabolized by epoxide hydrolase (EPHX1) to an inactive metabolite. Preliminary studies indicate that carbamazepine plasma concentrations are 30% higher in individuals with the CYP3A5*3/*3 genotype compared to those with CYP3A5*1/*1 or *1/*3 genotypes. The clinical impact of this change is poorly documented. Polypharmacy guidance: The dosage of carbamazepine should be decreased in patients receiving CYP3A4 inhibitors. Enzyme-inducing drugs significantly decrease carbamazepine levels, and dose adjustments are recommended when the drug is used with other inducers. ACTIONABLE Cariprazine Normal Response to Cariprazine **Pharmacogenetic guidance:** Cariprazine is extensively metabolized by CYP3A4 and, to a lesser extent, by CYP2D6. Vraylar[®]

Pharmacogenetic guidance: Cariprazine is extensively metabolized by CYP3A4 and, to a lesser extent, by CYP2D6. Genetic variants of CYP2D6 do not have clinically relevant effect on pharmacokinetics of cariprazine and its metabolites. No genetically guided dosing recommendations are available. **Polypharmacy guidance:** CYP3A4 inhibitors or inducers may affect cariprazine plasma concentrations. Cariprazine dose may have to be reduced to half if cariprazine and a strong CYP3A4 inhibitor are used concomitantly. Concomitant use of Cariprazine and a CYP3A4 inducer has not been evaluated and is not recommended.



Cancidas[®]



PATIENT INFORMATION				
NAME:	Patient m0bwvya			
ACC #:	m0bwvya			

1/1/1900

ORD

11/11/2022

SPECIMEN DETAILS

SPECIMEN TYPE:

RECEIVED DATE:

REPORT DATE:

COLLECTION DATE:

ORDERED BY

		Pharmacogenetic guidance: Caspofungin is cleared slowly and is metabolized by hydrolysis and N-acc undergoes also spontaneous chemical degradation. Distribution, rather than excretion or biotransforma dominant mechanism influencing plasma clearance. No genetically guided drug selection or dosing rec are available. Polypharmacy guidance: Co-administration of caspofungin with metabolizing enzyme ir rifampin, efavirenz, nevirapine, phenytoin, or carbamazepine) may result in clinically meaningful reduction caspofungin concentrations which may require dosing adjustment.	tion, is the ommendations nducers (e.g.,
\checkmark	Celecoxib	Normal Celecoxib Exposure (CYP2C9: Normal Metabolizer)	ACTIONABLE
-	Celebrex [®]	Celecoxib therapy can be initiated at standard label-recommended dosage and administration.	
		Consider initiating treatment at the lowest end of the dosing range in geriatric patients. A dosage adjus warranted when celecoxib is administered with CYP2C9 inhibitors or inducers.	tment may be
		Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, Acute Pain, Primary Dysmenorrheat the lowest effective dosage for the shortest duration consistent with the patient treatment goals.	Consider using
		Acute Migraine: Consider using for the fewest number of days per month, as needed.	
		Osteoarthritis and Hypertension (co-formulation with amlodipine) : Consider using the lowest effect the shortest duration consistent with the patient treatment goals.	tive dosage for
\checkmark	Chlorpropamide	Normal Exposure to Chlorpropamide	INFORMATIVE
-	Diabinese ®	Pharmacogenetic guidance : Chlorpropamide is metabolized mainly by CYP2C9 and to a lesser extent While this clearance pathway is diminished in subjects with reduced CYP2C9 activity, such a change has to be clinically significant. No genetically guided drug selection or dosing recommendations are availab guidance : Co-administration of chlorpropamide with a strong CYP2C9 and/or CYP2C19 inhibitors may chlorpropamide concentrations possibly leading to hypoglycemia. Co-administration with a strong CYP CYP2C19 inducers may result in lower chlorpropamide concentrations and a lack of efficacy.	not been shown le. Polypharmacy result in higher
\checkmark	Citalopram Celexa®	Normal sensitivity to Citalopram (CYP2C19: Intermediate Metabolizer)	ACTIONABLE
	Celexa	Citalopram can be prescribed at standard label-recommended dosage and administration.	
	Clomipramine	Normal Clomipramine Exposure (CYP2C19: Intermediate Metabolizer)	ACTIONABLE
V	Anafranil®	The patient's reduced CYP2C19 activity is unlikely to result in increased clomipramine exposure.	
		Psychiatric Conditions: Clomipramine therapy can be prescribed according to standard recommended administration. Consider therapeutic drug monitoring to guide dose adjustments.	l dosage and
\checkmark	Clonazepam	Normal Response to Clonazepam	INFORMATIVE
	Klonopin ®	Pharmacogenetic guidance: No genetically guided drug selection or dosing recommendations are ava Polypharmacy guidance: clonazepam is extensively metabolized by CYP3A4 to an amino metabolite the acetylated by N-acetyltransferases. This drug should be used with caution when prescribed with CYP3A4 inducers.	nat is further
\checkmark	Clonidine Kapvay®	Normal Exposure to Clonidine	INFORMATIVE



DATI	ENT	INEC	DM	ΑΤΙΟΝ
		IL UL V		

SPECIMEN DETAILS

ORDERED BY

 NAME:
 Patient m0bwvya

 ACC #:
 m0bwvya

 DOB:
 1/1/1900

 SEX:
 Comparison

SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE:

ATE: TE: 11/11/2022

FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE

Pharmacogenetic guidance: Clonidine is metabolized by CYP2D6 along with CYP3A4 and CYP1A2. About 40-60% of the dose is excreted in urine as unchanged drug. Preliminary studies indicate that individuals lacking CYP2D6 activity, have increased clonidine exposure compared to subjects with normal CYP2D6 activity. The clinical relevance of this changed is not well understood and there is insufficient data to calculate dose adjustments. Other preliminary studies indicate that individuals with high CYP2D6 activity (pregnant women), have decreased clonidine exposure and may require higher doses to reach target therapeutic plasma concentrations and respond to therapy. No genetically guided drug selection or dosing adjustments are recommended. **Polypharmacy guidance**: Co-administration of clonidine with inhibitors of CYP2D6 or CYP3A4 may cause an increase in clonidine plasma concentrations. Caution should be used when co-administering drugs that can affect renal function.

Normal Response to Colchicine

Colchicine *Mitigare*®


Pharmacogenetic guidance: Colchicine in eliminated both by renal excretion and metabolism. While 50% of the absorbed dose is eliminated unchanged in urine, less than 20% is metabolized by CYP3A4. Glucuronidation is also a metabolic pathway for colchicine. Colchicine is a substrate of P-glycoprotein (encoded by ABCB1 gene) and its efflux by this transporter is important in its disposition. Colchicine has a narrow therapeutic index. Preliminary and limited studies indicate a lack of an effect of CYP3A4 or ABCB1 genetic polymorphisms on clinical response to colchicine in individuals with familial Mediterranean fever (FMF). There are no available genetically-guided drug selection or dosing recommendations. **Polypharmacy guidance:** Because colchicine is a substrate for both the CYP3A4 metabolizing enzyme and the P-glycoprotein efflux transporter, inhibition of either of these pathways may lead to colchicine-related toxicity. Inhibition of both CYP3A4 and P-gp by dual inhibitors such as clarithromycin has been reported to produce life-threatening or fatal colchicine toxicity due to significant increases in systemic colchicine levels. Therefore, concomitant use of colchicine and inhibitors of CYP3A4 or P-glycoprotein should be avoided.

INFORMATIVE Cyclobenzaprine Normal Response to Cyclobenzaprine Pharmacogenetic guidance: No genetically guided drug selection or dosing recommendations are available. Flexeril®, Amrix® Cyclobenzaprine is excreted primarily as a glucuronide via the kidneys, and as an N-demethylated metabolite by CYP3A4, CYP1A2, and to a lesser extent CYP2D6. Due to the minor involvement of CYP2D6 in the metabolism of cyclobenzaprine, the polymorphism of this enzyme is not of concern in its the clinical use. Dabigatran INFORMATIVE Normal Response to Dabigatran Etexilate Pradaxa® Pharmacogenetic guidance: Dabigatran is eliminated primarily unchanged by the kidneys. After oral administration, dabigatran etexilate is converted to its active form dabigatran by esterases. A small portion (20%) of dabigatran dose is also conjugated to form pharmacologically active acyl glucuronides. Dabigatran is not a substrate, inhibitor, or inducer of CYP450 enzymes. Dabigatran etexilate is a substrate of the efflux transporter P-gp (ABCB1). Common genetic polymorphism of the ABCB1 gene (2677G>T/A and 3435 C>T) do not appear to affect dabigatran exposure. Polypharmacy guidance: <u>1-Reduction in Risk of Stroke and Systemic Embolism in Non-valvular AF</u>: In patients with

moderate renal impairment (CrCl 30-50 mL/min), concomitant use of the P-gp inhibitor dronedarone or systemic ketoconazole can be expected to produce dabigatran exposure similar to that observed in severe renal impairment. Consider reducing the dose of dabigatran to 75 mg twice daily. Dose adjustment is not necessary when coadministered with other P-gp inhibitors. In patients with CrCl<30 mL/min, avoid use of concomitant P-gp inhibitors with dabigatran. <u>2-Treatment of DVT and PE Reduction in the Risk of Recurrence of DVT and PE</u>: Avoid use of concomitant P-gp inhibitors with dabigatran with dabigatran in patients with CrCl <50 mL/min.

Dexlansoprazole Dexilant[®], Kapidex[®] Increased Exposure to Dexlansoprazole (CYP2C19: Intermediate Metabolizer)

The patient's genotype may be associated with a slightly increased dexlansoprazole exposure following standard dosing. Consider prescribing dexlansoprazole at standard label-recommended dosage and administration. Once efficacy is achieved, in the setting of chronic PPI therapy (beyond 12 weeks), consider a 50% reduction in the daily dose to minimize the risk of adverse events from prolonged acid suppression.



INFORMATIVE

INFORMATIVE

INFORMATIVE



ne

	/ Manal	hester	PATIENT INFORMATION	SPECIMEN DETAIL	.s	ORDERED BY
V	Univer	sity	NAME: Patient m0bwvya ACC #: m0bwvya DOB: 1/1/1900 SEX:	SPECIMEN TYPE: COLLECTION DATE RECEIVED DATE: REPORT DATE:	: 11/11/2022	
	FOR ACADEMIC PURPOSES ONLY - NO	OT FOR CLINICAL USE				
	Dexedrine [®]		type result predicts a favorable e lowest effective dose, and dos			troamphetamine should be
\	Diazepam Valium®		ivity to Diazepam (CYP2C19			INFORMATIV
		Diazepam can be p	prescribed at standard label-reco	ommended dosage and	administration.	
\checkmark	Diclofenac Voltaren®	Normal Diclofen	ac Exposure guidance: Diclofenac is extensi			INFORMATIV
		50% of diclofenac i CYP2C8, CYP2C19 drug is also directly affect the response Polypharmacy gu toxicity of whereas	is eliminated as a 4-hydroxymet and CYP3A4 are also involved ir y glucuronidated by UGT2B7 an to diclofenac. No dosing recon idance : Co-administration of di co-administration with CYP2C9 e warranted when diclofenac is a	abolite, a reaction medi the formation of a 5-hy d UGT2B4. Genetic poly mendations or genetic clofenac with CYP2C9 in inducers may lead to co	ated by CYP2C9. C ydroxymetabolite. morphisms of CYP ally guided drug s hibitors may enha ompromised effica	Other CYP enzymes including A substantial portion of the 2C9 have not been found to election are recommended. nce the drug exposure and cy of diclofenac. A dosage
	Disopyramide	Normal Exposur	e to Disopyramide			INFORMATIV
		CYP2D6 have not b adjustments are re	excreted in urine as unchanged been found to affect patient resp commended. No genetically gui	oonse to disopyramide. ded drug selection or d	No genetically gui osing adjustments	ded drug selection or dosing are recommended.
		disopyramide plas	idance: Co-administration of di ma concentrations, which could ase in disopyramide plasma con nction.	result in a fatal interacti	on. Co-administra	tion with CYP3A4 inducers
 ✓ 	Dolutegravir	disopyramide plası may cause a decrea can affect renal fur	ma concentrations, which could ase in disopyramide plasma con	result in a fatal interacti	on. Co-administra	tion with CYP3A4 inducers a co-administering drugs tha
✓	Dolutegravir Tivicay®, Triumeq®	disopyramide plass may cause a decrea can affect renal fur Normal Respons Pharmacogenetic contribution from 0 have increased plas required for dolute	ma concentrations, which could ase in disopyramide plasma con action.	result in a fatal interacti centrations. Caution sho nated mainly through m metabolizers or patients changes are not clinica in UGT1A1. Polypharm	on. Co-administra buld be used when netabolism by UGT s taking inhibitors illy significant. No nacy guidance : Co	tion with CYP3A4 inducers a co-administering drugs that ACTIONABL TA1 and a minor of UGT1A1 activity dosing adjustments are administration of
✓ ✓	Tivicay®, Triumeq®	disopyramide plass may cause a decrea can affect renal fur Normal Respons Pharmacogenetic contribution from 0 have increased plas required for dolute dolutegravir with d of this drug.	ma concentrations, which could ase in disopyramide plasma con action. Se to Dolutegravir guidance: Dolutegravir is elimi CYP3A. Although UGT1A1 poor sma levels of dolutegravir, these egravir due to genetic variations Irugs that are strong enzyme inc	result in a fatal interacti centrations. Caution sho nated mainly through m metabolizers or patients changes are not clinica in UGT1A1. Polypharm	on. Co-administra buld be used when netabolism by UGT s taking inhibitors illy significant. No nacy guidance : Co	tion with CYP3A4 inducers a co-administering drugs that ACTIONABL TA1 and a minor of UGT1A1 activity dosing adjustments are administration of uced plasma concentrations
✓ ✓	-	disopyramide plass may cause a decrea can affect renal fur Normal Respons Pharmacogenetic contribution from (have increased plas required for dolute dolutegravir with d of this drug. Normal Exposur Pharmacogenetic dosing recomment with drugs that are occur, which may c	ma concentrations, which could ase in disopyramide plasma con action. Se to Dolutegravir guidance: Dolutegravir is elimi CYP3A. Although UGT1A1 poor sma levels of dolutegravir, these gravir due to genetic variations Irugs that are strong enzyme inc	result in a fatal interacti centrations. Caution sho nated mainly through m metabolizers or patients changes are not clinica in UGT1A1. Polypharm lucers, such as rifampin, lucers, such as rifampin, as significant decrease ravirine. Co-administrati	on. Co-administra buld be used when hetabolism by UGT s taking inhibitors illy significant. No hacy guidance : Co , may result in redu A. No genetically g ine is contraindica s in doravirine plas	tion with CYP3A4 inducers a co-administering drugs that ACTIONABL TA1 and a minor of UGT1A1 activity dosing adjustments are badministration of uced plasma concentrations ACTIONABL guided drug selection or ted when co-administered sma concentrations may
✓ ✓ ✓	Tivicay®, Triumeq® Doravirine Pifeltro®	disopyramide plass may cause a decrea can affect renal fur Normal Respons Pharmacogenetic contribution from 0 have increased plas required for dolute dolutegravir with d of this drug. Normal Exposur Pharmacogenetic dosing recommend with drugs that are occur, which may co of CYP3A may resu	ma concentrations, which could ase in disopyramide plasma con- nction. Se to Dolutegravir guidance: Dolutegravir is elimi CYP3A. Although UGT1A1 poor sma levels of dolutegravir, these gravir due to genetic variations lrugs that are strong enzyme inco- e to Doravirine guidance: Doravirine is primari dations are available. Polypharr strong CYP3A enzyme inducers lecrease the effectiveness of do lt in increased plasma concentra-	result in a fatal interacti centrations. Caution sho nated mainly through m metabolizers or patients changes are not clinica in UGT1A1. Polypharm lucers, such as rifampin, lucers, such as rifampin, as significant decrease ravirine. Co-administrati	on. Co-administra buld be used when hetabolism by UGT s taking inhibitors illy significant. No hacy guidance : Co , may result in redu A. No genetically g ine is contraindica s in doravirine plas	tion with CYP3A4 inducers a co-administering drugs that ACTIONABL TA1 and a minor of UGT1A1 activity dosing adjustments are badministration of uced plasma concentrations ACTIONABL guided drug selection or ted when co-administered sma concentrations may
✓ ✓ ✓	Tivicay®, Triumeq® Doravirine	disopyramide plass may cause a decrea can affect renal fur Normal Respons Pharmacogenetic contribution from 0 have increased plas required for dolute dolutegravir with d of this drug. Normal Exposur Pharmacogenetic dosing recommento with drugs that are occur, which may co of CYP3A may resu Normal Respons Pharmacogenetic Polypharmacy gui	ma concentrations, which could ase in disopyramide plasma con- nction. Se to Dolutegravir guidance: Dolutegravir is elimi CYP3A. Although UGT1A1 poor sma levels of dolutegravir, these gravir due to genetic variations lrugs that are strong enzyme inco- e to Doravirine guidance: Doravirine is primari dations are available. Polypharr strong CYP3A enzyme inducers lecrease the effectiveness of do lt in increased plasma concentra-	result in a fatal interacti centrations. Caution sho nated mainly through m metabolizers or patients changes are not clinica in UGT1A1. Polypharm lucers, such as rifampin, lucers, such as rifampin, as significant decrease ravirine. Co-administrati ations of doravirine.	on. Co-administra buld be used when hetabolism by UGT s taking inhibitors illy significant. No hacy guidance : Co , may result in redu A. No genetically g ine is contraindica s in doravirine plat ion of doravirine w	tion with CYP3A4 inducers a co-administering drugs tha ACTIONABL TA1 and a minor of UGT1A1 activity dosing adjustments are administration of uced plasma concentrations ACTIONABL guided drug selection or ted when co-administered sma concentrations may ith drugs that are inhibitors INFORMATIV ons are available.

	7 Manal	hostor	PATIENT INFORMATION	SPECIMEN DETAILS	ORDERED BY
V	Mancl Univer	sity	NAME: Patient m0bwvya ACC #: m0bwvya DOB: 1/1/1900	SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: BEDORT DATE: 11/11/202	2
	FOR ACADEMIC PURPOSES ONLY - NO	OT FOR CLINICAL USE	SEX:	REPORT DATE: 11/11/202	2
				o result in increased doxepin expo rescribed according to standard re	
		administration. Cor	nsider therapeutic drug monitor	5	2
./	Dronabinol		nol Exposure (CYP2C9: Nor		ACTIONABL
V	Marinol®	The patient's geno		netabolic activity. Dronabinol can l	
\checkmark	Duloxetine	Normal Exposur	e to Duloxetine		ACTIONABL
	Cymbalta®	these clearance par to be clinically sign Polypharmacy gu i	thways are diminished in subjec ificant. No genetically guided d idance: Co-administration of du	rug selection or dosing recommend loxetine with a CYP1A2 inhibitor sl	ese changes have not been shown
\checkmark	Dutasteride	Normal Respons	e to Dutasteride		INFORMATIVI
	Avodart®	Polypharmacy gui CYP3A4 inhibitors	idance: Dutasteride is extensive on dutasteride has not been stu		A4 and CYP3A5. The effect of potent Irug-drug interactions, use caution
\checkmark	Edoxaban	Normal Respons	e to Edoxaban		INFORMATIVI
	Savaysa ®	via hydrolysis (med the efflux transport Studies indicate tha edoxaban or its act	liated by carboxylesterase 1; CES er P-gp and its active metabolit at the two common variants SLC ive metabolite. There are no ge	51), conjugation, and oxidation by (e (formed by CES1) is a substrate c	
	Eprosartan	Normal Sensitivi	ty to Eprosartan		ACTIONABL
	Teveten®	Eprosartan is not m	netabolized by the cytochrome F		primarily as unchanged compound. f the cytochrome P450 genes is not djustments are available.
√	Escitalopram			9: Intermediate Metabolizer)	ACTIONABLI
	,	Escitalopram can b	e prescribed at standard label-r	ecommended dosage and adminis	tration.
\checkmark	Eslicarbazepine	Normal Respons	e to Eslicarbazepine		INFORMATIVE
-	Aptiom®	be used to identify syndrome, Stevens converted by a red excretion unchange are available. Poly	patients at risk for severe cutan -Johnson syndrome (SJS) and to uctase to its active metabolite, e ed and as a glucuronide conjuga	eous adverse reactions such as ant xic epidermal necrolysis (TEN). Esli slicarbazepine. Eslicarbazepine is e ate. No genetically guided drug sel sence of enzyme-inducing drugs,	carbazepine acetate (prodrug) is liminated primarily by renal ection or dosing recommendations
	rowered By		Genetic Test Results For Patier	nt m0bwvya	

(\mathbf{X})	Manchester
	University


 NAME:
 Patient m0bwvya

 ACC #:
 m0bwvya

 DOB:
 1/1/1900

SPECIMEN DETAILS

SPECIMEN TYPE: COLLECTION DATE: ORDERED BY



	7 Mano	hostor	PATIENT INFORMATION	SPECIMEN DETAILS	ORDERED BY
		hester sity	NAME: Patient m0bwvya ACC #: m0bwvya DOB: 1/1/1900 SEX:	SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE: 11/11/20	122
	FOR ACADEMIC PURPOSES ONLY - N				
	Finasteride	Normal Respons			INFORMATIV
	Proscar®	Polypharmacy gui moderate CYP3A4 i	dance: Finasteride is extensively nhibitors on finasteride have no	d drug selection or dosing recom y metabolized in humans by CYP3 of been studied. Because of the p taking CYP3A4 enzyme inhibitors	BA4. The effects of potent or otential for drug-drug interactions,
	Flibanserin	Normal Exposure	e to Flibanserin (CYP2C19: lı	ntermediate Metabolizer)	ACTIONABL
-	Addyi®	Flibanserin is prima	rily metabolized by CYP3A4 and to have a normal clearance and	-	ual desire disorder (HSDD): The genotype results predict that the Use label-recommended dosage and
	Fluconazole	Normal Respons	e to Fluconazole		ACTIONABL
	Diflucan®	approximately 80% pharmacokinetics o or dosing recomme CYP2C9 and CYP2C therapeutic window	of the administered dose appe of fluconazole is markedly affect endations are available. Polyph 19 enzymes. Fluconazole treate w metabolized by CYP2C9, CYP2	aring in the urine as unchanged c ed by reduction in renal function. armacy guidance: Fluconazole is d patients who are concomitantly	ated primarily by renal excretion, wit lrug and 11% as metabolites. The No genetically guided drug selectior a moderate inhibitor of CYP3A4, r treated with drugs with a narrow ored. The enzyme inhibiting effect of fe.
	Fluphenazine	•	e to Fluphenazine		INFORMATIV
	Prolixin ®	polymorphisms of (selection or dosing inhibitors of CYP3A CYP3A4 inducers m	CYP2D6 have not been found to adjustments are recommended 4 may cause an increase in flup ay cause a decrease in fluphena	affect patient response to fluphe . Polypharmacy guidance : Co-a henazine plasma concentrations v izine plasma concentrations. The	(P3A4 and other enzymes. Genetic enazine. No genetically guided drug dministration of fluphenazine with while the co-administration with co-administration of fluphenazine osure to a clinically relevant extent.
	Flurbiprofen	Normal Flurbipro	ofen Exposure (CYP2C9: No	rmal Metabolizer)	ACTIONABL
	Ansaid [®]			rofen therapy can be initiated at tive dosage for the shortest dura	standard label-recommended dosage tion consistent with the patient
			treatment at the lowest end of t rbiprofen is administered with (nts. A dosage adjustment may be
	Fondaparinux	Normal Respons	e to Fondaparinux		INFORMATIV
	Arixtra®	CYPs, and therefore profiles. No genetic concomitant use of may enhance the ri	e genetic variations in these met cally guided drug selection or do fondaparinux with aspirin or N	abolizing enzymes are not expect osing recommendations are availa SAIDS may enhance the risk of he tion of therapy with fondaparinus	excretion and is not metabolized by ted to affect its efficacy or toxicity able. Polypharmacy guidance: The morrhage. Discontinue agents that a unless essential. If co-administration
	Fosaprepitant	Normal Respons	e to Fosaprepitant		ACTIONABL



DATIENIT	INFORMATION
PATIENT	INFORMATION

NAME: Patient m0bwvya ACC #: m0bwvya DOB: 1/1/1900 SEX: SPECIMEN DETAILS

ORDERED BY

SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE: 11/11/2022

FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE

		Pharmacogenetic guidance: Fosaprepitant is a prodrug of aprepitant which is rapidly converted to intravenous administration. Its antiemetic effects are attributable to aprepitant. Aprepitant undergoes metabolism via N- and O-dealkylations. These pathways are primarily catalyzed by CYP3A4 with mind CYP1A2 and CYP2C19. The drug is also glucuronidated by UGT1A4 and UGT1A3. No genetically guid dosing recommendations are available. Polypharmacy Guidance: In presence of moderate and stro inhibitors, a significantly increased exposure of aprepitant is expected which may lead to adverse rea should be avoided with fosaprepitant. Strong CYP3A4 inducers can significantly decrease aprepitant a loss of efficacy. These drugs should also be avoided with fosaprepitant. Aprepitant is a moderate (d inhibitor, and an inducer of CYP3A4 and an inducer of CYP2C9. Some substrates of these enzymes ar with fosaprepitant while others should be closely monitored and their doing adjusted when coadmin antiemetic medication.	s extensive or involvement from ed drug selection or ng CYP3A4 ctions. These drugs exposure resulting in lose-dependent) e contraindicated
\checkmark	Fosphenytoin	Normal Phenytoin (Fosphenytoin Active Metabolite) Exposure (CYP2C9: Normal Metabolizer)	ACTIONABLE
	Cerebyx [®]	Fosphenytoin is a prodrug of phenytoin. The genotype results indicate that the patient is expected to CYP2C9 enzyme activity. Fosphenytoin can be prescribed at a standard loading dose and a standard Consider therapeutic drug monitoring and evaluate the patient's response to optimize the maintenar	maintenance dose.
√	Gabapentin	Normal Response to Gabapentin	INFORMATIVE
•	Neurontin®	Pharmacogenetic guidance: no genetically guided drug selection or dosing recommendations are a Polypharmacy guidance: Gabapentin is eliminated primarily through renal excretion and is not met Genetic variations in these metabolizing enzymes are not expected to affect its efficacy or toxicity pro can be prescribed at standard label-recommended dosage and administration.	abolized by CYPs.
	Glimepiride	Normal Exposure to Glimepiride	ACTIONABLE
	Amaryl®	Pharmacogenetic guidance : Glimepiride is metabolized by CYP2C9. While this clearance pathway is subjects with reduced CYP2C9 activity, such a change has not been shown to be clinically significant. guided drug selection or dosing adjustments are recommended. Polypharmacy guidance : Co-admi glimepiride with a strong CYP2C9 inhibitor may result in higher glimepiride concentrations possibly hypoglycemia. Co-administration with a strong CYP2C9 inducer may result in lower glimepiride concentrations of efficacy.	No genetically nistration of eading to
	Glipizide	Normal Exposure to Glipizide	INFORMATIVE
	Glucotrol®	Pharmacogenetic guidance : Glipizide is metabolized by CYP2C9. While this clearance pathway is din with reduced CYP2C9 activity, such a change has not been shown to be clinically significant. No gene selection or dosing recommendations are available. Polypharmacy guidance : Co-administration of strong CYP2C9 inhibitor may result in higher glipizide concentrations possibly leading to hypoglycen administration with a strong CYP2C9 inducer may result in lower glipizide concentrations and a lack of	tically guided drug glipizide with a nia. Co-
\	Glyburide	Normal Exposure to Glyburide	ACTIONABLE
•	Micronase ®	Pharmacogenetic guidance : Glyburide is partially metabolized by CYP2C9 and to a lesser extent by clearance pathways are diminished in subjects with reduced enzyme activity, these changes have not clinically significant. No genetically guided drug selection or dosing recommendations are recommer guidance : Co-administration of glyburide with strong CYP2C9 and/or CYP3A4 inhibitors may result in concentrations, leading to possible hypoglycemia. Co-administration with strong CYP2C9 and/or CYP3R4 inhibitors may result in lower glyburide concentrations and a lack of efficacy.	been shown to be nded. Polypharmacy n higher glyburide
\checkmark	Guanfacine Intuniv®	Normal Response to Guanfacine	INFORMATIVE



PATIEN	IT INFORMATION
NAME:	Patient m0bwvya
ACC #:	m0bwvya
DOB:	1/1/1900
SEX:	

SPECIMEN DETAILS

ORDERED BY

wvya

SPECIMEN TYPE: COLLECTION DATE: **RECEIVED DATE:** REPORT DATE: 11/11/2022

FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE

		Pharmacogenetic guidance: Guanfacine is predominantly metabolized by CYP3A4. No genetically guid or dosing recommendations are available and guanfacine extended-release should be titrated based on response and tolerability of the individual patient. Polypharmacy guidance : The dose of guanfacine ex- should be reduced to one half of the standard dose when co-medicated with a strong CYP3A4 inhibitor ketoconazole, itraconazole, indinavir, ritonavir, nefazodone). When the strong CYP3A4 inhibitor is discorr should be increased to the standard recommended dose. Guanfacine dose should be increased up to do recommended dose when used in combination with a strong CYP3A4 inducer (e.g., phenytoin, carbamaz St. John's wort etc.). When the CYP3A4 inducer is discontinued, the dose should be reduced to the standard recommended dose within 7-14 days.	the clinical tended-release or (e.g., itinued, the dose puble the repine, rifampin,
\checkmark	Hydrocodone	Good Response to Hydrocodone (OPRM1: Normal OPRM1 Function)	INFORMATIVE
_	Vicodin®	The patient does not carry the OPRM1 118A>G variant. Acute postoperative and cancer pain: the patien experience good analgesia with standard or increased hydrocodone doses, without an increase in side e	
	Hydromorphone	Normal Response to Hydromorphone	INFORMATIVE
	Dilaudid®, Exalgo®	No genetically guided drug selection or dosing recommendations are available. Hydromorphone is not CYPs, and genetic variations in these metabolizing enzymes are not expected to affect its efficacy or toxic Hydromorphone can be prescribed at standard label-recommended dosage and administration.	
	Ibuprofen	Normal Ibuprofen Exposure (CYP2C9: Normal Metabolizer)	ACTIONABLE
	Advil®, Motrin®	Pain, Dysmenorrhea, Rheumatoid Arthritis, Osteoarthritis, Fever and Other Anti-Inflammatory Use therapy can be initiated at standard label-recommended dosage and administration. Consider using the dosage for the shortest duration consistent with the patient treatment goals.	
		Consider initiating treatment at the lowest end of the dosing range in geriatric patients. A dosage adjust warranted when ibuprofen is administered with CYP2C9 inhibitors or inducers.	ment may be
\checkmark	Imipramine	Normal Imipramine Exposure (CYP2C19: Intermediate Metabolizer)	INFORMATIVE
	Tofranil®	The patient's reduced CYP2C19 activity is unlikely to result in increased imipramine exposure.	
		Psychiatric Conditions: Imipramine therapy can be prescribed according to standard recommended do administration. Consider therapeutic drug monitoring to guide dose adjustments.	sage and
1	Indomethacin	Normal Indomethacin Exposure	INFORMATIVE
	Indocin®	Pharmacogenetic guidance : Indomethacin is metabolized mainly by O-demethylation to its inactive metabolized by CYP2C9. Genetic polymorphisms of CYP2C9 have not be affect the response to indomethacin. No genetically guided drug selection or dosing recommendations	een found to
\checkmark	Irbesartan	Normal Irbesartan Exposure (CYP2C9: Normal Metabolizer)	INFORMATIVE
	Avapro®	Irbesartan can be prescribed at standard label-recommended dosage and administration.	
\checkmark	Isavuconazonium	Normal Response to Isavuconazonium	ACTIONABLE
	Cresemba®	Pharmacogenetic guidance: Isavuconazonium sulfate is a prodrug that is rapidly hydrolyzed in plasma butylcholinesterase into its active moiety isavuconazole. Isavuconazole is extensively metabolized CYP3A and Common genetic polymorphism of these metabolizing enzymes gene are not expected to affect isa exposure. No genetically guided drug selection or dosing recommendations are available. Polypharmac Isavuconazole is a sensitive CYP3A4 substrate and its use with strong CYP3A4 inhibitors or inducers cont	4 and CYP3A5 vuconazole cy guidance:
\checkmark	Itraconazole	Normal Response to Itraconazole	ACTIONABLE
	Powered By [ranslational	Genetic Test Results For Patient m0bwvya	D 00 (
	software	FOR ACADEMIC PURPOSES ONLY - DO NOT DISTRIBUTE - NOT FOR CLINICAL USE	Page 20 of 57

	enester						
	ehester rsity	NAME:Patient m0bwvyaACC #:m0bwvyaDOB:1/1/1900SEX:	SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE: 11/11	1/2022			
FOR ACADEMIC PURPOSES ONLY -							
Sporanox®	metabolite is hydri concentrations of recommendations may decrease the Therefore, adminis should be avoided bioavailability of it Itraconazole inhibi in increased plasm elevated plasma co using concomitant	boxy-itraconazole, which has in v this metabolite are about twice are available. Polypharmacy g bioavailability of itraconazole ar tration of potent CYP3A4 induc 2 weeks before and during trea raconazole and these drugs sho t the metabolism of drugs meta a concentrations of these drugs pocentrations may increase or p	tro antifungal activity compara hose of itraconazole. No gener Jidance: Coadministration of it d hydroxy-itraconazole to such ers with itraconazole is not reco tment with itraconazole. Poten uld be used with caution when bolized by CYP3A4 or transpor and/or their active metabolited rolong both therapeutic and ac	netabolites by CYP3A4. The main ble to itraconazole; trough plasma tically guided drug selection or dosing traconazole with potent CYP3A4 induce on an extent that efficacy may be reduced ommended and the use of these drugs it CYP3A4 inhibitors may increase the coadministered with this antifungal. ted by P-glycoprotein, which may result (s) when they are coadministered. These dverse effects of these drugs. When he consulted for information on possible			
Ketoprofen	Normal Pospon	se to Ketoprofen		INFORMATI			
Orudis [®]	Pharmacogenetic and no major impl	guidance: Ketoprofen is prima	olism of this drug has been den	ion (by UGT1A3, UGT1A9 and UGT2B7) nonstrated. No genetically guided drug			
Ketorolac	Normal Respons	se to Ketorolac		INFORMATI			
Toradol®	Pharmacogenetic	guidance: Ketorolac is metabo		enzymes) and oxidation but the enzyme election or dosing recommendations are			
Labetalol	Normal Respons	Normal Response to Labetalol INFORM					
Normodyne®, Trandate®	metabolites. Prelin -fold higher in Chi clinical impact of t	ninary studies indicate that follo nese individuals with the CYP2C	wing a single 200-mg oral dose 19 *2/*2 genotype than those v armacy guidance: Cimetidine i	GT1A1, and CYP2C19 to inactive e, labetalol plasma concentrations are 2. with the CYP2C19 *1/*1 genotype. The increases the bioavailability of labetalol,			
Lacosamide	Normal Exposur	e to Lacosamide		ACTIONABI			
Vimpat [®]	and CYP2C19. Whi have not been sho recommended. Po	le these clearance pathways are wn to be clinically significant. N	diminished in subjects with rec o genetically guided drug selec inistration of lacosamide, in pa	atients with reduced renal function, with			
Lamotrigine	Normal Respons	se to Lamotrigine		INFORMATIV			
Lamictal®	Pharmacogenetic be used to identify syndrome, Stevens glucuronidation, w insufficient studies response. No gene Enzyme-inducing o maintain therapeu lamotrigine levels	guidance: Genotype results ob y patients at risk for severe cutar s-Johnson syndrome (SJS) and to which is mediated primarily by U documenting the impact of genetically guided drug selection or drugs increase lamotrigine clear tic concentrations. Coadministration	eous adverse reactions such as oxic epidermal necrolysis (TEN). GT1A4 with some contribution netic polymorphisms of these n dosing recommendations are a ance significantly, and higher d tion of valproic acid, an inhibit igine adverse effects (neurolog	from UGT1A1 and UGBT2B7. There are netabolizing enzymes on lamotrigine available. Polypharmacy guidance: loses of this drug are required to or of UGT enzymes, increases gical and cutaneous). A low starting dose			
Lansoprazole	Increased Expos	ure to Lansoprazole (CYP20	19: Intermediate Metaboliz	zer) INFORMATI\			
Prevacid ®							



PATIENT INFORMATION	SPECIMEN DETAILS
NAME: Patient m0bwvya	SPECIMEN TYPE:
ACC #: m0bwvya	COLLECTION DATE:
DOB: 1/1/1900	RECEIVED DATE:
SEX:	REPORT DATE:

11/11/2022

		SEX: REPORT DATE: 11/11/2022	
I	FOR ACADEMIC PURPOSES ONLY - NOT I	FOR CLINICAL USE The patient's genotype may be associated with a slightly increased lansoprazole exposure following Consider prescribing lansoprazole at standard label-recommended dosage and administration. Once in the setting of chronic PPI therapy (beyond 12 weeks), consider a 50% reduction in the daily dose t adverse events from prolonged acid suppression.	efficacy is achieved,
	Levetiracetam	Normal Response to Levetiracetam	INFORMATIVE
•	Keppra®	Pharmacogenetic guidance: No genetically guided drug selection or dosing recommendations are Polypharmacy guidance: Levetiracetam is minimally metabolized by non-CYP enzymes (esterases) a excreted unchanged in urine. Coadministration of enzyme-inducing antiepileptic drugs produce mod levetiracetam plasma levels.	and is primarily
	Levomilnacipran	Normal Response to Levomilnacipran	INFORMATIVE
•	F etzima®	Pharmacogenetic guidance: Levomilnacipran is moderately metabolized by desethylation, which is by CYP3A4, with minor contributions by CYP2C8, CYP2C19, CYP2D6, and CYP2J2. More than 58% of t in urine as unchanged levomilnacipran, and 18% as N-desethyl levomilnacipran. Genetic polymorphi expected to have a significant impact on levomilnacipran exposure. no genetically guided drug select recommendations are available. Polypharmacy guidance : the daily levomilnacipran dose should no coadministered with strong CYP3A4 inhibitors, such as ketoconazole, itrazonazole, and ritonavir.	the dose is excreted sms of CYPs are not tion or dosing
/	Levorphanol	Normal Response to Levorphanol	INFORMATIVE
	Levo Dromoran®	Pharmacogenetic guidance: Levorphanol is metabolized by glucuronidation which is mediated by l studies documenting the impact of genetic polymorphisms of this metabolizing enzyme on levorpha no genetically guided drug selection or dosing recommendations are available. Polypharmacy guid inducing drugs are expected to increase levorphanol clearance significantly.	nol response. And
/	Lisdexamfetamine	Good Response to Lisdexamfetamine (COMT: Intermediate COMT Activity)	INFORMATIVE
_	Vyvanse ®	The patient's genotype result predicts a favorable response to amphetamine stimulants. Lisdexamfet administered at the lowest effective dose, and dosage should be individually adjusted.	amine should be
/	Losartan	Normal Response to Losartan (CYP2C9: Normal Metabolizer)	INFORMATIVE
	Cozaar®, Hyzaar®	Losartan is metabolized to its active metabolite by CYP2C9 and CYP3A4. The patient's genotype prece exposure to losartan and its active metabolite. Losartan can be prescribed at label-recommended do administration.	
/	Loxapine	Normal Response to Loxapine	INFORMATIVE
-	Loxitane®, Adasuve®	Pharmacogenetic guidance: Loxapine is metabolized extensively in the liver following oral administ metabolites formed. Loxapine metabolism occurs via hydroxylation and oxidation catalyzed by CYP1. contributions from CYP3A4, CYP2D6 and FMO. There are no studies documenting the effect of gener these metabolizing enzymes on Loxapine disposition and there are no available genetically-guided of dosing recommendations. Polypharmacy guidance: Loxapine is a central nervous system (CNS) dep concurrent use of Loxapine with other CNS depressants (<i>e.g.</i> , alcohol, opioid analgesics, benzodiazeg antidepressants, general anesthetics, phenothiazines, sedative/hypnotics, muscle relaxants, and/or ill can increase the risk of respiratory depression, hypotension, profound sedation, and syncope. Theref reduction/modification of CNS depressants if used concomitantly with Loxapine. Loxapine has antich concomitant use with other anticholinergic drugs can increase the risk of adverse reactions, including glaucoma and urinary retention.	A2 along with tic polymorphisms of lrug selection or oressant. The bines, tricyclic icit CNS depressants) ore, consider dose polinergic activity and
/	Lurasidone Latuda®	Normal Response to Lurasidone	ACTIONABLE

Powered By Translational



PATIENT	INFORM	ΜΑΤΙΟΝ

SPECIMEN DETAILS

ORDERED BY

NAME: Patient m0bwvyaACC #: m0bwvyaDOB: 1/1/1900SEX:

SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE: 11/11/2022

FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE

		Pharmacogenetic guidance: Lurasidone is metabolized by CYP3A4. No genotype-based dosing adjust available. Polypharmacy guidance: The concomitant use of lurasidone with all CYP3A4 inhibitors may increase in lurasidone plasma concentrations, which could increase or prolong adverse drug effects. Lu not be administered with strong CYP3A4 inhibitors . Lurasidone dose should not exceed 40 mg who with moderate CYP3A4 inhibitors. Monitor patients receiving lurasidone and any CYP3A4 inhibitor. Rif strong inducers of CYP3A should not be administered with lurasidone. If lurasidone is used conco moderate CYP3A4 inducer, it may be necessary to increase lurasidone dose after chronic treatment (7 the CYP3A4 inducer.	y result in an urasidone should en administered ampin or other omitantly with a
1	Meloxicam	Normal Meloxicam Exposure (CYP2C9: Normal Metabolizer)	ACTIONABLE
	Mobic [®]	Pain, Rheumatoid Arthritis and Osteoarthritis : Meloxicam therapy can be initiated at standard label dosage and administration. Consider using the lowest effective dosage for the shortest duration consist patient treatment goals.	
		Consider initiating treatment at the lowest end of the dosing range in geriatric patients. A dosage adjuwarranted when meloxicam is administered with CYP2C9 inhibitors or inducers.	istment may be
\checkmark	Memantine	Normal Response to Memantine	INFORMATIVE
	Namenda ®	Pharmacogenetic Guidance: Memantine is excreted predominantly unchanged in the urine. This drug hepatic metabolism to three inactive metabolites (N-glucuronide, 6hydroxy metabolite, and 1-nitrost metabolite). CYP450 enzymes do not play a significant role in the metabolism of memantine. There are documenting the effects of genetic variability in metabolizing enzymes or organic cationic transporter response. No genetically guided drug selection or dosing recommendations are available. Polypharm Memantine is predominantly renally eliminated, and drugs that are substrates and/or inhibitors of the not expected to interact with memantine. Because memantine is eliminated in part by tubular secretio of drugs that use the same renal cationic system, including hydrochlorothiazide, triamterene, metform ranitidine, quinidine, and nicotine, could potentially result in altered plasma levels of both agents.	o-deaminated e no studies s on memantine acy Guidance: CYP450 system are n, coadministration
\checkmark	Meperidine	Normal Response to Meperidine	INFORMATIVE
_	Demerol®	Pharmacogenetic guidance: no genetically guided drug selection or dosing recommendations are avis metabolized to normeperidine by multiple CYPs, including CYP2B6, CYP3A4, and CYP2C19. The effect variants in these enzymes have not been studied. Polypharmacy guidance: In patients taking strong meperidine metabolism is increased resulting in higher levels of its neurotoxic metabolite normeperidir ritonavir, meperidine's exposure is significantly reduced while normeperidine concentrations are increased these findings, the risk of narcotic-related adverse effects from this combination appears to be minima increased concentrations of normeperidine suggest a potential for toxicity with increased dosages or I This combination should be avoided is possible.	cts of genetic CYP inducers , ine. In presence of ased. Based on al. However,
	Metaxalone	Normal Response to Metaxalone	INFORMATIVE
	Skelaxin®	Pharmacogenetic guidance: Metaxalone is extensively metabolized by multiple CYP enzymes, includi CYP2D6, CYP2E1, and CYP3A4. Genetic polymorphisms of these enzymes are unlikely to affect its exponented of the second s	
√	Methocarbamol	Normal Response to Methocarbamol	INFORMATIVE
	Robaxin®	Pharmacogenetic guidance: Methocarbamol is metabolized via dealkylation and hydroxylation. The responsible for the metabolism of this drug have not been characterized. No genetically guided drug s recommendations are available.	
√	Methotrexate	Normal Risk for Methotrexate Toxicity (MTHFR: Normal MTHFR Activity)	INFORMATIVE
-	Trexall®	The patient does not carry the MTHFR c.665C>T variant, and unless other risk factors are present, the expected to have an increased risk for methotrexate toxicity. Consider using label-recommended dosa administration.	

	Manchester University		PATIENT INFORMATION SPECIMEN DETAILS		ORDERED BY
	FOR ACADEMIC PURPOSES ONLY - NO		NAME: Patient m0bwvya ACC #: m0bwvya DOB: 1/1/1900 SEX:	SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE: 11/11/2	022
	Micafungin	Normal Response	e to Micefungin		ACTIONABL
V	Mycamine [®]	Pharmacogenetic P450 enzymes. Ever	guidance: Micafungin is metabo n though micafungin is a substra vay for micafungin metabolism i	te for and a weak inhibitor of C	O-methyltransferase and cytochrome YP3A in vitro, hydroxylation by CYP3A
√	Milnacipran Savella®	in urine. No genetic	guidance: milnacipran is minima ally guided drug selection or do	sing recommendations are avai	INFORMATIV es and primarily excreted unchanged lable. Polypharmacy guidance: to affect the exposure of milnacipran.
✓	Mirtazapine Remeron®	clearance pathways clinically significant guidance : Co-admi changes. While co-a	guidance: Mirtazapine is metab are diminished in subjects with No genetically guided drug sel nistration of mirtazapine with C	reduced enzyme activity, these ection or dosing recommendation YP inhibitors did not result in cli	ACTIONABLE P1A2 and CYP3A4. While these changes have not been shown to be ons are recommended. Polypharmacy nically relevant pharmacokinetics azepine, rifampicin) may result in lower
√	Morphine MS Contin®	The patient does no experience good ar		ant. Acute postoperative and ca oses. The dosing regimen needs	INFORMATIV ancer pain: the patient is expected to s to be individualized for each patient,
✓	Morphine MS Contin®	The patient carries of average to low dose		hich translates to a reduced CO n control. The dosing regimen r	INFORMATIVI MT function. The patient may require needs to be individualized for each
√	Nabumetone Relafen®	Pharmacogenetic that is further meta (i.e CYP2C9 poor m altered drug respor Guidance: CYP1A2 the therapeutic effe	bolized by CYP2C9 to an inactive etabolizers) may have higher lev ise. No genetically guided drug inhibitors may inhibit the activa	e metabolite. Theoretically, indiv rels of the active metabolite, but selection or dosing recommend tion of nabumetone to its active and, CYP1A2 inducers (i.e smoking	INFORMATIVE P1A2 to an active metabolite (6-MNA) viduals with reduced CYP2C9 activity : it is unknown whether this results in ations are available. Polypharmacy e metabolite resulting in a reduction in ng) may result in higher levels of
√	Naproxen Aleve®	elimination pathway desmethylnaproxer	guidance: UGT2B7 is responsibl y for this drug (60% of total clea but this pathway is not the prin been found to affect the responsi	rance). CYP2C9 and CYP1A2 are nary pathway for the eliminatior	INFORMATIVI curonidation, which is the primary responsible for the formation of O- n for naproxen. Genetic polymorphism guided drug selection or dosing
✓	Nateglinide Starlix®	The patient carries	ty to Nateglinide (SLCO1B1: one copy of the SLCO1B1 521T> prescribed at label-recommende	C variant, which is associated w	INFORMATIV ith intermediate transporter function. stration.
√	Nateglinide	Normal Nateglin	ide Exposure (CYP2C9: Norr	nal Metabolizer)	INFORMATIV
	rowered By ranslational oftware		Genetic Test Results For Patien		Page 24 of 5

N. 💙	? Manch	actor	PATIENT INFORMATION	SPECIMEN DETAILS	ORDERED BY
V	Manch Univers	sity	NAME: Patient m0bwvya ACC #: m0bwvya DOB: 1/1/1900 SEX:	SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE: 11/11/2	2022
FO	R ACADEMIC PURPOSES ONLY - NOT F	FOR CLINICAL USE	SEX:		2022
9	Starlix®	The patient's genoty dosage and adminis		o nateglinide, and this drug ca	n be prescribed at label-recommended
-	Olmesartan Benicar®	Pharmacogenetic g gastrointestinal trac	enes is not expected to affect th	nil is hydrolyzed to olmesartan ually no further metabolism of	ACTIONABLE its active metabolite in the olmesartan. Genetic variability of the rtan medoxomil. No genotype-based
	Omeprazole Prilosec®	The patient's genoty Consider prescribing in the setting of chro	omeprazole at standard label-	ghtly increased omeprazole exp ecommended dosage and adm	r) INFORMATIVE posure following standard dosing. ninistration. Once efficacy is achieved, in the daily dose to minimize the risk of
7	Oxcarbazepine Trileptal®, Oxtellar XR®	Pharmacogenetic g be used to identify p syndrome, Stevens by a reductase to its eliminated by direct or dosing recommen	patients at risk for severe cutane lohnson syndrome (SJS) and to» active monohydroxylated activ renal excretion, glucuronidation	ous adverse reactions such as a ic epidermal necrolysis (TEN). (e metabolite: 10-hydroxycarbaz n, and hydroxylation (minimal). r macy guidance: In the preser	INFORMATIVE tic test performed in this patient cannot anticonvulsant hypersensitivity Dxcarbazepine (prodrug) in converted zepine (MHD). This active metabolite is No genetically guided drug selection nee of enzyme-inducing drugs, the
_	Oxybutynin	Normal Response		drug colection or desing resou	INFORMATIVE
L	Ditropan [®]	Polypharmacy guid CYP3A4 strong inhib	juidance: no genetically guidec lance: Oxybutynin is extensively bitor (itraconazole) increases oxy g to patients taking CYP3A4 enz	metabolized in humans by CY butynin serum concentrations.	P3A4, and coadministration of a
		Polypharmacy guid CYP3A4 strong inhik prescribing this drug	lance: Oxybutynin is extensively bitor (itraconazole) increases oxy g to patients taking CYP3A4 enz	metabolized in humans by CY butynin serum concentrations.	P3A4, and coadministration of a Therefore, use caution when
/ (Ditropan® Oxymorphone Opana®, Numorphan®	Polypharmacy guid CYP3A4 strong inhib prescribing this drug Normal Response No genetically guide CYPs, and genetic va	ance: Oxybutynin is extensively bitor (itraconazole) increases oxy g to patients taking CYP3A4 enz e to Oxymorphone ed drug selection or dosing reco	metabolized in humans by CY butynin serum concentrations. yme inhibitors. mmendations are available. Ox nzymes are not expected to af	P3A4, and coadministration of a Therefore, use caution when INFORMATIVE symorphone is not metabolized by fect its efficacy or toxicity profiles.
	Oxymorphone	Polypharmacy guid CYP3A4 strong inhik prescribing this drug Normal Response No genetically guide CYPs, and genetic va Oxymorphone can b Increased Exposu The patient's genoty Consider prescribing in the setting of chro	Aance: Oxybutynin is extensively bitor (itraconazole) increases oxy g to patients taking CYP3A4 enz et o Oxymorphone ed drug selection or dosing reco ariations in these metabolizing e be prescribed at standard label-r re to Pantoprazole (CYP2C1 ype may be associated with a sli g pantoprazole at standard labe	metabolized in humans by CY butynin serum concentrations. yme inhibitors. mmendations are available. Ox nzymes are not expected to af ecommended dosage and adm 9: Intermediate Metabolize ghtly increased pantoprazole ex- recommended dosage and ac	P3A4, and coadministration of a Therefore, use caution when INFORMATIVE symorphone is not metabolized by fect its efficacy or toxicity profiles. ninistration.
	Oxymorphone Opana®, Numorphan® Pantoprazole Protonix®	Polypharmacy guid CYP3A4 strong inhik prescribing this drug Normal Response No genetically guide CYPs, and genetic va Oxymorphone can b Increased Exposu The patient's genoty Consider prescribing in the setting of chru adverse events from	lance: Oxybutynin is extensively bitor (itraconazole) increases oxy g to patients taking CYP3A4 enz e to Oxymorphone ed drug selection or dosing reco ariations in these metabolizing e pe prescribed at standard label-r re to Pantoprazole (CYP2C1 ype may be associated with a sli g pantoprazole at standard labe ponic PPI therapy (beyond 12 wer prolonged acid suppression.	metabolized in humans by CY butynin serum concentrations. yme inhibitors. mmendations are available. Ox nzymes are not expected to af ecommended dosage and adm 9: Intermediate Metabolize ghtly increased pantoprazole ex- recommended dosage and ac	P3A4, and coadministration of a Therefore, use caution when INFORMATIVE kymorphone is not metabolized by fect its efficacy or toxicity profiles. ninistration. INFORMATIVE xposure following standard dosing. dministration. Once efficacy is achieved,
	Oxymorphone Opana®, Numorphan® Pantoprazole	Polypharmacy guid CYP3A4 strong inhik prescribing this drug Normal Response No genetically guide CYPs, and genetic va Oxymorphone can b Increased Exposu The patient's genoty Consider prescribing in the setting of chru adverse events from Normal Response Pharmacogenetic g and CYP3A5. No gen Enzyme-inducing d should be increased Coadministration with	Aance: Oxybutynin is extensively bitor (itraconazole) increases oxy o to patients taking CYP3A4 enz e to Oxymorphone ed drug selection or dosing reco ariations in these metabolizing e be prescribed at standard label- re to Pantoprazole (CYP2C1 ype may be associated with a sli g pantoprazole at standard labe onic PPI therapy (beyond 12 we prolonged acid suppression. e to Perampanel puidance: Perampanel is elimina hetically guided drug selection of rugs decrease perampanel plasr when it is added to a stable the th strong enzyme-inducers othe	metabolized in humans by CY butynin serum concentrations. yme inhibitors. mmendations are available. Ox nzymes are not expected to af ecommended dosage and adm 9: Intermediate Metabolize ghtly increased pantoprazole er- recommended dosage and ac eks), consider a 50% reduction tted either unchanged or follow r dosing recommendations are na concentrations by 50-60%, a rapy regimen containing enzyr rs than antiepileptic drugs (e.g	P3A4, and coadministration of a Therefore, use caution when INFORMATIVE symorphone is not metabolized by fect its efficacy or toxicity profiles. ninistration. er) INFORMATIVE xposure following standard dosing. dministration. Once efficacy is achieved, in the daily dose to minimize the risk of INFORMATIVE ving oxidative metabolism by CYP3A4 e available. Polypharmacy guidance: and the initial dosage of the drug me-inducing antiepileptic drugs.
	Oxymorphone Opana®, Numorphan® Pantoprazole Protonix® Perampanel	Polypharmacy guid CYP3A4 strong inhik prescribing this drug Normal Response No genetically guide CYPs, and genetic va Oxymorphone can b Increased Exposu The patient's genoty Consider prescribing in the setting of chra adverse events from Normal Response Pharmacogenetic g and CYP3A5. No gen Enzyme-inducing d should be increased Coadministration wi by 20%.	Aance: Oxybutynin is extensively bitor (itraconazole) increases oxy o to patients taking CYP3A4 enz e to Oxymorphone ed drug selection or dosing reco ariations in these metabolizing e be prescribed at standard label- re to Pantoprazole (CYP2C1 ype may be associated with a sli g pantoprazole at standard labe onic PPI therapy (beyond 12 we prolonged acid suppression. e to Perampanel puidance: Perampanel is elimina hetically guided drug selection of rugs decrease perampanel plasr when it is added to a stable the th strong enzyme-inducers othe	metabolized in humans by CY butynin serum concentrations. yme inhibitors. mmendations are available. Ox nzymes are not expected to af ecommended dosage and adm 9: Intermediate Metabolize ghtly increased pantoprazole et -recommended dosage and ac eks), consider a 50% reduction ted either unchanged or follow or dosing recommendations are na concentrations by 50-60%, a rapy regimen containing enzyr rs than antiepileptic drugs (e.g A4 inhibitors such as ketocona	P3A4, and coadministration of a Therefore, use caution when INFORMATIVE symorphone is not metabolized by fect its efficacy or toxicity profiles. ninistration. er) INFORMATIVE xposure following standard dosing. dministration. Once efficacy is achieved, in the daily dose to minimize the risk of INFORMATIVE ving oxidative metabolism by CYP3A4 e available. Polypharmacy guidance: and the initial dosage of the drug me-inducing antiepileptic drugs. I, rifampin) should be avoided.
	Oxymorphone Opana®, Numorphan® Pantoprazole Protonix® Perampanel Fycompa®	Polypharmacy guid CYP3A4 strong inhik prescribing this drug Normal Response No genetically guide CYPs, and genetic va Oxymorphone can b Increased Exposu The patient's genoty Consider prescribing in the setting of chra adverse events from Normal Response Pharmacogenetic g and CYP3A5. No gen Enzyme-inducing d should be increased Coadministration wi by 20%.	ance: Oxybutynin is extensively bitor (itraconazole) increases oxy to patients taking CYP3A4 enz et to Oxymorphone ed drug selection or dosing reco ariations in these metabolizing e be prescribed at standard label-r re to Pantoprazole (CYP2C1 rype may be associated with a sli g pantoprazole at standard labe bnic PPI therapy (beyond 12 wer prolonged acid suppression. et to Perampanel guidance: Perampanel is elimina hetically guided drug selection of rugs decrease perampanel plass when it is added to a stable the th strong enzyme-inducers othe th perampanel with strong CYP3	metabolized in humans by CY butynin serum concentrations. yme inhibitors. mmendations are available. Ox nzymes are not expected to af ecommended dosage and adm 9: Intermediate Metabolize ghtly increased pantoprazole er- recommended dosage and ac eks), consider a 50% reduction ted either unchanged or follow or dosing recommendations are na concentrations by 50-60%, a rapy regimen containing enzyr rs than antiepileptic drugs (e.g eA4 inhibitors such as ketocona Il Metabolizer)	P3A4, and coadministration of a Therefore, use caution when INFORMATIVE symorphone is not metabolized by fect its efficacy or toxicity profiles. hinistration. INFORMATIVE xposure following standard dosing. Iministration. Once efficacy is achieved, in the daily dose to minimize the risk of INFORMATIVE ving oxidative metabolism by CYP3A4 e available. Polypharmacy guidance: and the initial dosage of the drug me-inducing antiepileptic drugs. h, rifampin) should be avoided. azole increases perampanel exposure

	7) Monal	noctor	PATIE	NT INFORMATION	SPECIMEN DETAILS		ORDERED BY
	Manch Univer	sity		Patient m0bwvya m0bwvya 1/1/1900	SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE: 1	1/11/2022	
	FOR ACADEMIC PURPOSES ONLY - NO	T FOR CLINICAL USE				, , ,	
	Dilantin®	prescribed at a stand	lard load		ard maintenance dose. Con		e activity. Phenytoin can be utic drug monitoring and
/	Pimavanserin Nuplazid®	by CYP2J2, CYP2D6, major active metabo Polypharmacy guid QT prolongation or i (e.g., quinidine, proc (e.g., ziprasidone, ch of pimavanserin with drug is coadminister	uidance and othe lite (AC- ance: Pi ance: Pi ainamide lorprom CYP3A ed with	Pimavanserin is prece er CYP and FMO enzy 279). There are no ava mavanserin prolongs nation with other drug or Class 3 antiarrhy azine, thioridazine), ar i inhibitor increases p	nes. CYP3A4 is the major e ilable genetically-guided d the QT interval and its use s gs known to prolong QT int hmics (e.g., amiodarone, sc d certain antibiotics (e.g., g mavanserin exposure and a rs. Coadministration of pim	nzyme respon rug selection (should be avo rerval including otalol), certain atifloxacin, ma a dose reduction	
/	Piroxicam	Normal Pirovicam	Evnos	ure (CYP2C9: Norm	al Metabolizer)		ACTIONABL
	Feldene®	Rheumatoid Arthri	tis and C	Osteoarthritis : Piroxic			abel-recommended dosage
		5			he dosing range in geriatri P2C9 inhibitors or inducers		losage adjustment may be
	Posaconazole Noxafil®	and feces account for direct glucuronidatio glycoprotein are enz drug selection or do inducers may affect	uidance or approx on, mino ymes an sing reco posacon	: Posaconazole is clea kimately 17% of the ac r oxidation and dealky d transporters that pla pommendations are ava	Iministered dose. The meta lation. CYP3A4 (and possib ay a role in the elimination ilable. Polypharmacy guid rations. Concomitant use of	bolic pathway ly CYP1A1 and of this antifun dance: UGT ar	ACTIONABL creted metabolites in urine s for posaconazole include d CYP3A5), UGT1A4, and P- gal. No genetically guided nd P-glycoprotein inhibitors o e and these agents should be
/	Prasugrel	Normal Response	to Pra	suarel			ACTIONABL
	Effient®	Pharmacogenetic g converted to the act Prasugrel active met efficacy or safety pro drug selection or do	uidance ive meta abolite e ofile are a sing reco	e: Prasugrel is a prodru bolite primarily by CY exposure and platelet also unaffected by CYI		lesser extent y CYP2C19 ge genetic variar	thiolactone, which is then by CYP2C9 and CYP2C19. netic variants. Prasugrel
	Pregabalin	Normal Response	to Pre	gabalin			INFORMATIV
_	Lyrica®	Polypharmacy guid Genetic variations in	ance: Pi these m	egabalin is eliminated etabolizing enzymes a	ed drug selection or dosing I primarily through renal ex are not expected to affect it age and administration.	cretion and is	

(\mathbf{X})	Manche	ster
\checkmark	Universi	ty

ράτι	ENT	INFC	DRM.	ATION

NAME: Patient m0bwvya ACC #: m0bwvya

SPECIMEN DETAILS

SPECIMEN TYPE:

ORDERED BY

Y	Univer:	sity	ACC #: m0bwvya DOB: 1/1/1900	wvya SPECIMEN TYPE: COLLECTION DAT RECEIVED DATE:	E:	
	FOR ACADEMIC PURPOSES ONLY - NOT		SEX:	REPORT DATE:	11/11/2022	
		Pharmacogenetic of cycloguanil. Prelimin exposure compared proguanil metabolic and there is insuffic recommendations a	nary studies indicate t I to subjects with norr c ratios across CYP2C ient data to calculate are available. Polypha	is a pro-drug that is primarily me that individuals with reduced CYI mal CYP2C19 function, but there 19 metabolizer status. The clinica dose adjustments. No geneticall armacy guidance: Co-administra (higher proguanil) exposure.	22C19 function, have reduce is considerable overlap of c Il relevance of this change is y guided drug selection or	ed cycloguanil cycloguanil and s not well understoo dosing
	Quetiapine	Normal Response	e to Quetiapine			INFORMATIV
	Seroquel®	CYP2D6 are also res compared to CYP3A effect) is further me CYP3A4, CYP2D6 ar metabolite N-desall genetically guided of the clinical response reduced to one sixt itraconazole, indina by 6 fold. Quetiapin treatment (e.g. > 7-	sponsible for quetiapi A4. N-desalkylquetiap tabolized by CYP2D6 ad CYP3A5 enzymes n kylquetiapine. Howev drug selection or dosi e and tolerability of th th of original dose w vir, ritonavir, nefazodo le dose should be incu 14 days) of a potent (e is predominantly metabolized t ne metabolism but their role in t ine, a pharmacologically active n and CYP3A4. Preliminary studies may be responsible in variable ex er, the clinical significance of the ing recommendations are available individual patient. Polypharm when co-medicated with a potent one). When the CYP3A4 inhibitor reased up to 5 fold of the origina CYP3A4 inducer (e.g., phenytoin, d, the dose should be reduced to	he overall metabolism of the netabolite (responsible of the s have shown that genetic p posures to quetiapine and t se changes is not establishe ole. Quetiapine dose should acy guidance : Quetiapine c CYP3A4 inhibitor (e.g., ketw is discontinued, the dose s al dose when used in combi- carbamazepine, rifampin, S	is drug is minor ne antidepressant olymorphisms of to its active ed yet and no be titrated based or dose should be oconazole, hould be increased nation with a chroni t. John's wort etc.).
√	Quinidine Quinidine®	metabolizing enzym Polypharmacy gui plasma concentratio	guidance : In vitro stu ne for quinidine. No g dance : Co-administra	idies using human liver microson genetically guided drug selection ition of drugs/herbs that are kno may result in adverse events or s	or dosing adjustments are wn to induce or inhibit CYP	recommended. 3A can change
	Rabeprazole	Slightly Increased	d Exposure to Rabe	eprazole (CYP2C19: Intermed	liate Metabolizer)	INFORMATIV
	Aciphex [®]			d with a slightly increased rabep dard label-recommended dosag		tandard dosing.
	Raltegravir	Normal Response	e to Raltegravir			ACTIONABL
V	Isentress®, Dutrebis®	Pharmacogenetic of metabolizers or pat are not clinically sig UGT1A1. Polyphare	guidance: Raltegravir ients taking inhibitors nificant. No dosing ac macy guidance: Coac	r is eliminated mainly through m s of UGT1A1 activity have increas djustments are required for ralted dministration of raltegravir with o a concentrations of this drug.	ed plasma levels of raltegra gravir in patients who carry	bugh UGT1A1 poor wir, these changes genetic variants of
	Repaglinide	Normal Sensitivit	ty to Repaglinide (!	SLCO1B1: Decreased Function	n)	INFORMATIV
	Prandin®, Prandimet®			1B1 521T>C variant. This genoty at label-recommended standard	-	•
	Rilpivirine	Normal Exposure	to Rilpivirine			ACTIONABL
•	Intelence ®	Pharmacogenetic selection or dosing	guidance: Rilpivirine i recommendations are	is primarily eliminated by metable e available. Polypharmacy guid the plasma concentrations of ril	ance: Co-administration of	ically guided drug
√	Rivaroxaban	Normal Response	e to Rivaroxaban			INFORMATIV
	Powered By Translational		Genetic Test Results	For Patient m0bwvya		
S S	oftware	FOR ACADE	MIC PURPOSES ONLY - DO	NOT DISTRIBUTE - NOT FOR CLINICAL US	E	Page 27 of 5

(V) Manahaa	PATIENT INFORMATION	SPECIMEN DETAILS	ORDERED BY
Wanches Universit	ACC #: m0bwvya DOB: 1/1/1900 SEX:	SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE: 11/11/20.	22
FOR ACADEMIC PURPOSES ONLY - NOT FOR CLIN			
(ABCI safety stron conce phen as co increa	nacogenetic guidance: Rivaroxaban is met 1) and BCRP (ABCG2) transporters. Genetic profiles of rivaroxaban. Polypharmacy gui CYP3A4 inhibitors (e.g., ketoconazole, itrac mitant use of rivaroxaban with drugs that a toin, rifampin, and St. John's wort). Patients nbined P-gp and moderate CYP3A4 inhibitor sed exposure compared with patients with kaban exposure may increase bleeding risk.	polymorphisms of these genes are dance: Avoid concomitant use of r conazole, lopinavir/ritonavir, ritonav re combined P-gp and strong CYP3 with renal impairment coadministeors (e.g., diltiazem, verapamil, drone	not expected to affect the efficacy or ivaroxaban with combined P-gp and vir, indinavir, and conivaptan). Avoid A4 inducers (e.g., carbamazepine, ered rivaroxaban with drugs classified darone, and erythromycin) have
V Rolapitant Norr	al Response to Rolapitant		ACTIONABLE
Varubi® Phar hydro select decre mode while media glyco	nacogenetic guidance: Rolapitant is metabolic kylated rolapitant). Rolapitant is eliminated on or dosing recommendations are availab ase rolapitant exposure resulting in a loss of rate CYP2D6 inhibitor and some CYP2D6 su others should be closely monitored and the ation. Rolapitant is an inhibitor two major orotein (P-gp). Increased plasma concentrat ons when coadministered with rolapitant.	primarily through the hepatic/biliar le. Polypharmacy Guidance: Stron efficacy. These drugs should be av bstrates (e.g. thioridazine, pimozide ir doing adjusted when coadministed drug efflux transporters: breast-can	y route. No genetically guided drug ng CYP3A4 inducers can significantly oided with rolapitant. Rolapitant is a e) are contraindicated with rolapitant ered with this antiemetic cer-resistance protein (BCRP) and P-
Rufinamide Norr	al Response to Rufinamide		INFORMATIVE
Poly not ir effica rufina Patier	hacogenetic guidance: No genetically guid harmacy guidance: Rufinamide is extensiv volved in its metabolism. Therefore, genetic y or toxicity profiles. Coadministration of en mide plasma levels, while coadministration ts stabilized on rufinamide should begin va rly, patients on valproate should begin rufir	ely metabolized by carboxylesterase variations in these metabolizing er nzyme-inducing antiepileptic drugs of valproate increases the drug leve lproate therapy at a low dose, and	es. Cytochrome P450 enzymes are nzymes are not expected to affect its produce modest decreases in els and requires dose adjustment.
Zoloft®	al Sensitivity to Sertraline (CYP2C19:		ACTIONABLE
Serue	line can be prescribed at standard label-rec	ommended dosage and administra	uon.
V Sildenafil Norr	al Response to Sildenafil		INFORMATIVE
Viagra® Phari CYP3. unkny patie	nacogenetic guidance: Preliminary finding 5*3/*3 genotype compared to those with C wn. Polypharmacy guidance: Sildenafil is nts taking strong CYP3A inhibitors, silder seed a maximum single dose of 25 mg in	YP3A5*1/*1 genotype. The clinical metabolized by CYP3A4 (major rou nafil exposure is significantly incr	significance of this change is te) and CYP2C9 (minor route). In eased, and it is recommended not
Silodosin Norr	al Response to Silodosin		INFORMATIVE
Rapaflo® Phare metal silod	nacogenetic guidance: silodosin is extensive olites. no genetically guided drug selection osin is contraindicated with potent CYP3A4 ntrations. Use caution when this drug is pre	or dosing recommendations are av inhibitors, as the risk for serious adv	vailable. Polypharmacy guidance: verse events is increased at higher
✓ Solifenacin Norr Vesicare ®	al Response to Solifenacin		INFORMATIVE

(\mathbf{X})	Manchester
	University

SPECIMEN DETAILS
SPECIMEN TYPE: COLLECTION DATE:
RECEIVED DATE:
REPORT DATE: 11/11/2022

ORDERED BY

FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE

 \checkmark

 \checkmark

 \checkmark

	Pharmacogenetic guidance: no genetically guided drug selection or dosing reco Polypharmacy guidance: Coadministration of a CYP3A4 strong inhibitor increase concentrations significantly. Therefore, it is recommended not to exceed a 5 m coadministered with strong CYP3A4 inhibitors, as the risk for QTc prolongat at higher concentrations. Although the effects of moderate CYP3A4 inhibitors w this drug is administered with moderate CYP3A4 inhibitors.	es solifenacin serum ng daily dose of solifenacin when ion induced by this drug is increased
Sotalol	Normal Exposure to Sotalol	INFORMATIVE
Betapace®, Sotylize®	Sorine (*), Pharmacogenetic guidance : Excretion of sotalol is predominantly via the kidney lower doses are necessary in conditions of renal impairment. No genetically guide are recommended. Polypharmacy guidance : Co-administration of sotalol with d can increase the patient's risk for developing drug induced long QT syndrome.	ed drug selection or dosing adjustments
Sufentani	Normal Response to Sufentanil	INFORMATIVE
Sufenta®	Pharmacogenetic guidance: No genetically guided drug selection or dosing reco Polypharmacy guidance: Sufentanil is primarily metabolized by CYP3A4 and so s prescribed with CYP3A4 inhibitors or inducers.	
Sulindac	Normal Response to Sulindac	INFORMATIVE
Clinoril®	Pharmacogenetic guidance: Sulindac is primarily eliminated by glucuronidation including UGT1A3, UGT1A9 and UGT2B7. The role of CYP2C9 in sulindac metaboli guided drug selection or dosing recommendations are available.	
Tadalafil	Normal Response to Tadalafil	INFORMATIVE
Cialis®	Pharmacogenetic guidance: no genetically guided drug selection or dosing recc Polypharmacy guidance: Tadalafil is extensively metabolized by CYP3A4. Tadala taking concomitant potent inhibitors of CYP3A4, such as ketoconazole or ritonavi vardenafil is 10 mg, not to exceed once every 72 hours. Tadalafil for Once Daily strong inhibitors of CYP3A4, the maximum recommended dose is 2.5 mg. Althoug studied, other CYP3A4 moderate inhibitors would likely increase tadalafil exposure when coadministered with rifampin or other CYP3A4 inducers. This can be anticip for once-daily use, though the magnitude of decreased efficacy is unknown.	afil for Use as Needed — For patients r, the maximum recommended dose of Use — For patients taking concomitant gh specific interactions have not been e. The exposure of tadalafil is reduced
Tapentad	ol Normal Response to Tapentadol	INFORMATIVE
Nucynta®	No genetically guided drug selection or dosing recommendations are available. The and genetic variations in these metabolizing enzymes are not expected to affect in Tapentadol can be prescribed at standard label-recommended dosage and administrations of the prescribed at standard label-recommended dosage and administrations are available.	ts efficacy or toxicity profiles.
Telmisart	an Normal Sensitivity to Telmisartan	ACTIONABLE
Micardis ®	Pharmacogenetic guidance: Telmisartan is metabolized by conjugation to form glucuronide. Telmisartan is not metabolized by the cytochrome P450 isoenzymes. P450 genes is not expected to affect the patient's response to telmisartan. No ger available.	Genetic variability of the cytochrome
Terazosin	Normal Response to Terazosin	INFORMATIVE
Hytrin®	Pharmacogenetic guidance: no genetically guided drug selection or dosing reco Polypharmacy guidance: The enzymes involved in metabolizing terazosin have r	
Thiothixe Navane®	ne Normal Response to Thiothixene	INFORMATIVE
Powered By	Genetic Test Results For Patient m0hwwa	

(\mathbf{X})	Manchester
V	University

PATIENT INFORMATION	

 NAME:
 Patient m0bwvya

 ACC #:
 m0bwvya

 DOB:
 1/1/1900

SPECIMEN DETAILS

SPECIMEN TYPE:

COLLECTION DATE:

ORDERED BY

		 DOB: 1/1/1900 RECEIVED DATE: SEX: REPORT DATE: 11/11/2022 	
	FOR ACADEMIC PURPOSES ONLY -		
		Pharmacogenetic guidance: Thiothixene is metabolized by UGTs and by cytochrome P450 er CYP3A4). No genetically guided drug selection or dosing recommendations are available. Poly likely that strong enzyme inducers may lead to substantial decreases in thiothixene plasma cor potential for reduced effectiveness. Consider increasing the dose of thiothixene when concomi CYP3A4 inducers (e.g., carbamazepine).	<pre>vpharmacy guidance: It is ncentrations with the</pre>
	Tiagabine	Normal Response to Tiagabine	INFORMATI
	Gabitril®	Pharmacogenetic guidance: no genetically guided drug selection or dosing recommendation Polypharmacy guidance: Tiagabine is extensively metabolized by CYP3A4, and therefore this caution when prescribed with CYP3A4 inhibitors. Inducers of CYP3A4 increase tiagabine clearar initial dosage of the drug should be considered carefully when added to a stable therapy regin inducing antiepileptic drugs.	drug should be used with nce by 2-fold, and the
	Ticagrelor	Normal Response to Ticagrelor	INFORMATIV
	Brilinta®	Pharmacogenetic guidance: Ticagrelor is extensively metabolized by CYP3A4 and CYP3A5 to metabolites, and this drug does not require bioactivation to achieve its antiplatelet effect. The P-glycoprotein, encoded by the ABCB1 gene. Studies have shown that the efficacy and safety p depend on CYP2C19 or CYP3A5 metabolizer statuses. Moreover, preliminary studies indicate th variants within the ABCB1, SLCO1B1, CYP3A4 and UGT2B7 genes do not affect ticagrelor expose profiles. No genetically-guided drug selection or dosing recommendations are available. Poly presence of strong CYP3A4 inhibitors, significantly increased exposure to ticagrelor is expected adverse reactions such as dyspnea or bleeding. These drugs should be avoided with ticagrelor. can significantly decrease ticagrelor exposure (resulting in a loss of efficacy) and these drugs sl Ticagrelor is a weak inhibitor of CYP3A4 and P-glycoprotein and some substrates of these prot monitored and their dosing adjusted when coadministered with this medication.	drug is also a substrate of profile of ticagrelor do not hat relevant genetic sure, efficacy or safety pharmacy guidance: In d which may lead to . Strong CYP3A4 inducers hould also be avoided.
	Tofacitinib	Normal Exposure to Tofacitinib	INFORMATIV
	Xeljanz®	Pharmacogenetic guidance : Tofacitinib is metabolized primarily by CYP3A4 with some contri Genetic variations in the CYP2C19 gene do not significantly influence tofacitinib exposure. Tofa at standard dosing, but consider a dose reduction if a CYP2C19 poor metabolizer is also prescr such as ketoconazole, erythromycin, diltiazem, troleandomycin, nefazodone, fluconazole, verap inhibitors. Polypharmacy guidance : Tofacitinib dose should be reduced if a patient is taking s (e.g., ketoconazole), or if a patient is taking a moderate CYP3A4 inhibitor (e.g., alprazolam) with inhibitor (e.g., fluconazole).	acitinib may be prescribed ribed a CYP3A4 inhibitor pamil or HIV protease strong CYP3A4 inhibitors
	Tolbutamide	Normal Exposure to Tolbutamide	ACTIONABL
	Orinase ®	Pharmacogenetic guidance : Tolbutamide is extensively metabolized by CYP2C9. While this cl diminished in subjects with reduced CYP2C9 activity, such a change has not been shown to be genetically guided drug selection or dosing adjustments are recommended. Polypharmacy gu of tolbutamide with a strong CYP2C9 inhibitor may result in higher tolbutamide concentrations hypoglycemia. Co-administration with a strong CYP2C9 inducer may result in lower tolbutamic lack of efficacy.	clinically significant. No uidance: Co-administration s possibly leading to
√	Topiramate	Normal Response to Topiramate	INFORMATIV
-	Topamax®	Pharmacogenetic guidance: no genetically guided drug selection or dosing recommendation Polypharmacy guidance: About 50% of absorbed topiramate dose appears unchanged in unit is present as metabolites and conjugates. Topiramate metabolism by cytochrome P450 enzyme elimination when the drug is given as a monotherapy. However, this pathway is enhanced by c	ne, and an additional 50% es is minor for its
		inducing antiepileptic drugs, and may result in reduced topiramate plasma concentrations. Thu titrated slowly, and dose adjustment must be considered in presence of inducers. Concomitant acid and topiramate has been associated with hyperammonemia with and without encephalop	t administration of valproic
✓	Torsemide	titrated slowly, and dose adjustment must be considered in presence of inducers. Concomitant	t administration of valproid
	Torsemide Powered By Translational	titrated slowly, and dose adjustment must be considered in presence of inducers. Concomitant acid and topiramate has been associated with hyperammonemia with and without encephalop	t administration of valproic pathy.



SPECIMEN DETAILS

ORDERED BY

NAME: Patient m0bwvya SPECIMEN TYPE: COLLECTION DATE: ACC #: m0bwvya DOB: 1/1/1900 **RECEIVED DATE:** SEX: REPORT DATE: 11/11/2022 FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE Demadex[®] The patient's genotype predicts a normal exposure to torsemide and this drug can be prescribed at label-recommended dosage and administration. INFORMATIVE Trazodone Normal Response to Trazodone Oleptro® Pharmacogenetic guidance: Trazodone is metabolized to its active metabolite m-chlorophenylpiperazine by CYP3A4. This metabolite which may contribute to adverse events, is further metabolized by CYP2D6. The impact of genetic polymorphisms of this enzyme on the clinical response to trazodone is not well documented. No genetically guided drug selection or dosing recommendations are available. Polypharmacy guidance: It is likely that CYP3A4 inhibitors may lead to substantial increases in trazodone plasma concentrations with the potential for adverse effects. If trazodone is used with a potent CYP3A4 inhibitor, the risk of cardiac arrhythmia may be increased. Therefore coadministration of trazodone with drugs that are inhibit CYP3A4 should be approached with caution. INFORMATIVE **Trifluoperazine** Normal Response to Trifluoperazine Stelazine® Pharmacogenetic guidance: Thrifluoperazine extensively metabolized by oxidation, sulfoxidation, hydroxylation and direct glucuronidation catalyzed by UGT1A4. No genetically guided drug selection or dosing recommendations are available. Polypharmacy guidance: It is likely that strong enzyme inducers may lead to substantial decreases in trifluoperazine plasma concentrations with the potential for reduced effectiveness. Trimipramine INFORMATIVE Normal Trimipramine Exposure (CYP2C19: Intermediate Metabolizer) The patient's reduced CYP2C19 activity is unlikely to result in increased trimipramine exposure. Surmontil[®] Psychiatric Conditions: Trimipramine therapy can be prescribed according to standard recommended dosage and administration. Consider therapeutic drug monitoring to guide dose adjustments. INFORMATIVE Trospium Normal Response to Trospium Pharmacogenetic guidance: no genetically guided drug selection or dosing recommendations are available. Sanctura[®] Polypharmacy guidance: CYP enzymes do not contribute significantly to the elimination of trospium. No major drugdrug interactions are expected with CYP inhibitors or inducers. INFORMATIVE Valproic Acid Normal Response to Valproic acid Pharmacogenetic guidance: Genotype results obtained from the pharmacogenetic test performed in this patient cannot Depakene[®] be used to identify patients carrying mutations in mitochondrial DNA polymerase y (POLG). Valproic acid is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase y (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder. Valproic acid is extensively metabolized in the liver, which occurs primarily by glucuronidation with probable contributions of UGT1A6, UGT1A9, and UGT2B7. This drug is also metabolized by a minor CYP-dependent oxidation pathway, which includes multiple enzymes such as CYP2A6, CYP2C9, and CYP2C19. There are insufficient studies documenting the impact of genetic polymorphisms of these metabolizing enzymes on valproic acid response, and no genetically guided drug selection or dosing recommendations are available. Polypharmacy guidance: enzyme-inducing drugs increase valproic acid clearance 2-fold, and higher doses of this drug are required to maintain therapeutic concentrations when added to a therapy regimen containing enzyme-inducing antiepileptic drugs. Valsartan ACTIONABLE Normal Sensitivity to Valsartan Pharmacogenetic guidance: Valsartan is excreted largely as unchanged compound. CYP2C9 is responsible for the Diovan®, Entresto® formation of a minor metabolite, valeryl 4-hydroxy valsartan, which accounts for about 9% of a dose. Given the limited contribution of CYP2C9 in the overall disposition of valsartan, genetic variability of the CYP2C9 gene is not expected to affect the patient's response to valsartan. No genotype-based dosing adjustments are available. ACTIONABLE Vardenafil Normal Response to Vardenafil Levitra® Genetic Test Results For Patient m0bwvya Translational Page 31 of 57 FOR ACADEMIC PURPOSES ONLY - DO NOT DISTRIBUTE - NOT FOR CLINICAL USE

\bigtriangledown	Manaha	ator	PA
	Manche	SICT	NA
	Universi		AC
•			DO

PATIENT INFORMATION	SPECIMEN DETAILS
NAME: Patient m0bwvya	SPECIMEN TYPE:
ACC #: m0bwvya	COLLECTION DATE:
DOB: 1/1/1900	RECEIVED DATE:
SEX:	REPORT DATE:

ORDERED BY

SPECIMEN TYPE:	
COLLECTION DATE:	
RECEIVED DATE:	
REPORT DATE:	11/11/2022

FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE

		Pharmacogenetic guidance: Preliminary findings indicate that vardenafil exposure is 3 times higher in CYP3A5*3/*3 genotype compared to those with CYP3A5*1/*1 genotype. The clinical impact of this cha Polypharmacy guidance: The dosage of vardenafil may require adjustment in patients receiving stror inhibitors such as ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, atazanavir, or clarithromyce patients receiving moderate CYP3A4 inhibitors such as erythromycin. For ritonavir, a single dose of 2 should not be exceeded in a 72-hour period. For indinavir, saquinavir, atazanavir, or ketoconazole; For itraconazole: 400 mg daily. For clarithromycin: a single dose of 2.5 mg vardenafil should not 24-hour period. For ketoconazole: 200 mg daily. For itraconazole: 200 mg daily. For erythromycin 5 mg vardenafil should not be exceeded in a 24-hour period. Inducers of CYP3A4 may decrease th vardenafil.	nge is unknown. ng CYP3A4 cin, as well as in 2.5 mg vardenafil ole: 400 mg daily. t be exceeded in a in: a single dose of		
\	Vigabatrin	Normal Response to Vigabatrin	INFORMATIVE		
	Sabril®	Pharmacogenetic guidance: no genetically guided drug selection or dosing recommendations are available. Polypharmacy guidance: Vigabatrin is eliminated primarily through renal excretion and is not metabolized by CYPs. Therefore, genetic variations in these metabolizing enzymes are not expected to affect its efficacy or toxicity profiles. Vigabatrin can be prescribed at standard label-recommended dosage and administration.			
	Vilazodone	Normal Response to Vilazodone	INFORMATIVE		
		a minor role in the biotransformation of this drug. No genetically guided drug selection or dosing recc available. Polypharmacy guidance: It is likely that CYP3A4 inhibitors may lead to substantial increases plasma concentrations with the potential for adverse effects. Vilazodone should be reduced to 20 mg is with a strong inhibitor of CYP3A4 (e.g., ketoconazole). During coadministration with moderate inhibito erythromycin), the dose should be reduced to 20 mg for patients with intolerable adverse events. The readjusted to the original level when the CYP3A4 inhibitor is discontinued. Consider increasing the dos to 2-fold when concomitantly used with strong CYP3A4 inducers (e.g., carbamazepine). The maximum not exceed 80 mg. If CYP3A4 inducers are discontinued, reduce vilazodone dose to the original level.	s in vilazodone if co-administered ırs of CYP3A4 (e.g., dose can be se of vilazodone up		
\checkmark	Vorapaxar	Normal Response to Vorapaxar	ACTIONABLE		
	Zontivity®	Pharmacogenetic guidance: vorapaxar is metabolized primarily by CYP3A4, with contribution from CYP2J2. Genetic polymorphisms of these genes are not expected to affect the efficacy or safety profiles of this drug. Vorapaxar is contraindicated in people who have had a stroke, transient ischemic attack (TIA), or intracranial hemorrhage, (ICH) because of the increased bleeding risk. Polypharmacy guidance: Avoid concomitant use of vorapaxar with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, lopinavir/ritonavir, ritonavir, indinavir, and conivaptan). Significant increases in vorapaxar exposure may increase bleeding risk. Avoid concomitant use with drugs that are strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin, and St. John's wort).			
√	Voriconazole	Normal Sensitivity to Voriconazole (CYP2C19: Intermediate Metabolizer)	ACTIONABLE		
	. ,	Voriconazole can be prescribed at standard label-recommended dosage and administration.			
\checkmark	Warfarin Coumadin®	Average Dosing Requirements are Expected (CYP2C9 *1/*1; VKORC1 -1639G>A G/A)	ACTIONABLE		



SPECIMEN DETAILS

 NAME:
 Patient m0bwvya

 ACC #:
 m0bwvya

 DOB:
 1/1/1900

 SEX:
 Comparison

SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE:

DATE: 11/11/2022

FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE

When initiating warfarin treatment for indications with a target INR of 2-3, consider one of the following methods to estimate dosing requirements:

FDA Label: CYP2C9 and VKORC1 genotype results indicate an expected therapeutic dose of 5-7 mg/day.

Pharmacogenomics algorithms/calculators available at www.warfarindosing.org:

Caucasians and Asians: Use the patient's demographics and other clinical factors along with CYP2C9 and VKORC1 genotypes to calculate the expected therapeutic dose.

Africans and African Americans: Use the patient's demographics and other clinical factors along with CYP2C9 and VKORC1 genotypes to calculate the expected therapeutic dose.

The provided recommendations in Africans and African Americans apply only when all the following CYP2C9 alleles are tested: *5, *6, *8, *11.



Normal Response to Ziprasidone

Pharmacogenetic guidance: Ziprasidone is primarily cleared following extensive metabolism. CYP3A4 is the major CYP contributing to the oxidative metabolism of ziprasidone with minor involvement from CYP1A2. Less than one-third of ziprasidone metabolic clearance is mediated by cytochrome P450 catalyzed oxidation and approximately two-thirds via reduction involving glutathione as well as aldehyde oxidase. No genetically guided drug selection or dosing recommendations are available. Individualization of ziprasidone dose with careful weekly titration is required. Dosage adjustments should generally occur at intervals of no less than 2 days, as steady-state plasma concentrations are achieved within 1 to 3 days. In order to ensure use of the lowest effective dose, patients should ordinarily be observed for improvement for several weeks before upward dosage adjustment. When deciding among the alternative treatments available, the prescriber should consider the finding of **ziprasidone's greater capacity to prolong the QT/QTc interval** compared to several other antipsychotic drugs. **Polypharmacy guidance:** Although coadministration of strong CYP3A4 inhibitors are expected to result in modest increases in ziprasidone dose may need to be increased when used in combination with a chronic treatment of a potent CYP3A4 inducer (e.g., phenytoin, carbamazepine, rifampin, St. John's wort etc.).



INFORMATIVE



PATIENT INFORMATION

SPECIMEN DETAILS

 NAME:
 Patient m0bwvya

 ACC #:
 m0bwvya

 DOB:
 1/1/1900

 SEX:
 Comparison

SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE: 11/11/2022

Test Details

Gene Genotype Phenotype		Phenotype	Alleles Tested		
CYP2C9	*1/*1	Normal Metabolizer	*2, *3, *4, *5, *6, *8, *11, *12, *13, *15, *25		
CYP2C19	*2/*17	Intermediate Metabolizer	*2, *3, *4A, *4B, *5, *6, *7, *8, *17		
CYP3A5	*1/*3	Intermediate Metabolizer	*3, *6, *7		
СҮРЗА4	*1/*1	Normal Metabolizer	*2, *17, *22		
VKORC1	-1639G>A G/A	Intermediate Warfarin Sensitivity	-1639G>A		
APOE	ε3/ε3	Normal APOE function	ε2, ε4, (ε3 is reference)		
CYP2D6	Indeterminate	Unknown Phenotype	*2, *3, *4, *4M, *6, *7, *8, *9, *10, *11, *12, *14, *15, *17, *18, *19, *20, *29, *41, *114		
CYP2B6	*1/*6	Intermediate Metabolizer	*6, *9, *18, *18.002		
CYP1A2	*1A/*1F	Normal Metabolizer - Higher Inducibility	*1C, *1F, *1K, *1L, *7, *11		
СОМТ	Val158Met A/G	Intermediate COMT Activity	Val158Met		
OPRM1	A118G A/A	Normal OPRM1 Function	A118G		
SLCO1B1	*1/*5	Decreased Function	*5		
F2 F5	rs1799963 GG rs6025 CC	Normal Risk of Thrombosis	rs1799963, rs6025		
MTHFR	c.1286A>C AA c.665C>T CC	No Increased Risk of Hyperhomocysteinemia	c.1286A>C, c.665C>T		
MTHFR	c.665C>T CC	Normal MTHFR Activity	c.1286A>C, c.665C>T		

Limitation: This test will not detect all the known alleles that result in altered or inactive tested genes. This test does not account for all individual variations in the individual tested. Absence of a detectable gene mutation does not rule out the possibility that a patient has different phenotypes due to the presence of an undetected polymorphism or due to other factors such as drug-drug interactions, comorbidities and lifestyle habits.

Methodology: Array based assays detect listed alleles, including all common and most rare variants with known clinical significance at analytical sensitivity and specificity >99%.

Disclaimer: Manchester University developed the Genotype test. The performance characteristics of this test were determined by Manchester University. It has not been cleared or approved by the U.S. Food and Drug Administration.


Translational Software Disclaimer: The information presented on this report is provided as general educational health information. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Only a physician, pharmacist or other healthcare professional should advise a patient on the use of the medications prescribed.

The pharmacogenetic assay involves use of reporting software and genotype-phenotype associations performed by Translational Software (www.translationalsoftware.com). The software has not been evaluated by the Food and Drug Administration. The software, and the report generated by the software, is not intended to diagnose, treat, cure, or prevent any disease. A qualified designee within the lab uses Translational Software to generate and subsequently review the report. The pharmacogenetic report is one of multiple pieces of information that clinicians should consider in guiding their therapeutic choice for each patient. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to dose guidelines does not necessarily assure a successful medical outcome.

APOE Monograph

Clinical Utility





Apolipoproteins (APO) are structural constituents of lipoprotein particles that have critical roles in blood lipid metabolism and transport. Apolipoprotein E (APOE) is a major constituent of triglyceride-rich chylomicrons, very low-density lipoproteins (VLDL), and some subclasses of high-density lipoproteins (HDL). APOE acts as a lipid carrier and transports cholesterol from the cells in the blood vessel wall to the liver for excretion. It also binds to several cell surface receptors to support membrane homeostasis and injury repair in the brain. Defects in APOE can result in hyperlipidemia, which is an important risk factor in the genesis of atherosclerosis and subsequent development of cardiovascular disease (CVD).

Assay Interpretation

There are three common APOE alleles designated ϵ_2 , ϵ_3 , and ϵ_4 , resulting from combinations of the two common variants c.388T>C (rs429358, p.Cys130Arg) and c.526 C>T (rs7412, p.Arg176Cys). These alleles result in E2, E3, and E4 protein isoforms, respectively. The approximate allele frequencies for most populations are 8-12% for ϵ_2 , 74-78% for ϵ_3 , and 14-15% for ϵ_4 .

The reference ranges for both mutations of APOE are c.388T/T and c.526C/C. This is consistent with a ɛ3/ɛ3 genotype and a normal APOE function.

Clinical Implications





ρατι	ENT	INF	ORM	ΔΤΙ	ON
			- 1.11		U

NAME: Patient m0bwvya ACC #: m0bwvya DOB: 1/1/1900 SEX: SPECIMEN DETAILS

SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE: 11/11/2022

FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE

The apolipoprotein E3 is considered the normal isoform and is associated with normal lipid metabolism. The apolipoprotein E2 isoform shows defective binding of remnants to hepatic lipoprotein and delayed clearance from plasma. It is associated with a slower conversion of intermediate-density lipoproteins (IDL) to low-density lipoproteins (LDL), lower cholesterol, and higher triglycerides, compared to the normal apolipoprotein E3 isoform. The apolipoprotein E4 isoform results in the down regulation of the LDL receptor and is associated with increased total cholesterol, triglycerides, and LDL.

1 - Type III Hyperlipoproteinemia

<u>Result Interpretation</u>: APOE genotyping can be used to confirm the diagnosis of suspected type III hyperlipoproteinemia. Patients with symptoms (xanthomas) and with a lipid profile consistent with type III hyperlipidemia are candidates for APOE genotype analysis. Homozygosity for the APOE ϵ^2 allele is strongly associated with type III hyperlipoproteinemia. Over 90% of individuals presenting the clinical type III hyperlipoproteinemia have the rare ϵ^2/ϵ^2 genotype. These individuals have an increased risk of premature vascular disease.

Only 1-5% of individuals with the APOE ϵ^2/ϵ^2 genotype develop type III hyperlipoproteinemia, suggesting that other genetic, hormonal, or environmental factors must contribute the expression of this disease. Despite the accumulation of remnants in the circulation, most (>95%) APOE ϵ^2 homozygous subjects are normolipidemic or even hypolipidemic because of low LDL cholesterol levels. Other non- ϵ^2/ϵ^2 APOE genotypes (ϵ^3/ϵ^3 , ϵ^2/ϵ^3 ϵ^2/ϵ^4 ϵ^3/ϵ^4 ϵ^4/ϵ^4) are not associated with type III hyperlipoproteinemia.

Summary: patients with a lipid profile (tendinous/tuberous xanthomas, elevated cholesterol, triglycerides, very low density lipoprotein (VLDL)) consistent with type III hyperlipoproteinemia are candidates for APOE genotyping. Most patients with type III hyperlipoproteinemia are homozygous for the APOE ϵ^2 allele and homozygosity for ϵ^2 allele is the only genotype associated with type III hyperlipoproteinemia. Factors in addition to the defective receptor binding activity of the apolipoprotein E2 isoform are necessary for manifestation of this disorder and only 1-5% of APOE ϵ^2 homozygous develop type III hyperlipoproteinemia.

2 - Atherosclerotic Cardiovascular Disease

<u>Result Interpretation</u>: genetic testing of APOE genotyping has been proposed for individual cardiovascular risk assessment and/or to predict the response to statin therapy. APOE genotyping can be informative in individuals with premature coronary heart disease or a family history of premature coronary heart disease. The APOE ϵ 4 allele has been linked to pure elevations of low-density lipoproteins (LDL), and the ϵ 4/ ϵ 4 and ϵ 3/ ϵ 4 genotypes are associated with increased serum cholesterol levels.

Although the evidence is not fully consistent, it has been estimated that having the $\epsilon 3/\epsilon 4$ or $\epsilon 4/\epsilon 4$ genotype is associated with on average a 30 -40% increased risk of cardiovascular disease relative to the common $\epsilon 3/\epsilon 3$ genotype.

There is some evidence that having an ϵ^2/ϵ^2 or ϵ^2/ϵ^3 genotype may be associated with a lower CVD risk in Caucasians normolipidemic patients. A proposed explanation of such observation is the association between APOE2 allele and lower Lp(a) concentrations.

Summary: the APOE ϵ 4 allele results in the down regulation of the LDL receptor and is associated with increased total cholesterol, triglycerides, and LDL. Several studies indicate that the ϵ 3/ ϵ 4, ϵ 2/ ϵ 4 or ϵ 4/ ϵ 4 genotypes are associated with increased plasma cholesterol levels. The presence of the ϵ 3/ ϵ 4 or ϵ 4/ ϵ 4 genotype has been suggested as a risk factor for atherosclerosis and coronary heart disease. Thus, the APOE genotype may be useful and informative in individuals with a family history of coronary heart disease as an additional tool for assessing their risk in conjunction with other clinical or laboratory findings. No clinical practice guidelines or position statements from U.S. professional associations were identified that recommended the use of APOE genotyping in cardiovascular risk assessment, including but not limited to the following: the 2013 American College of Cardiology/American Heart Association guidelines for the assessment of cardiovascular risk in asymptomatic patients; the 2009 U.S. Preventive Services Task Force (USPSTF) recommendations on the use of nontraditional risk factors for the assessment of coronary heart disease; the American Diabetes Association and the American College of Cardiology Foundation consensus conference publication.





PATIENT INFORMATION

NAME: Patient m0bwvya ACC #: m0bwvya DOB: 1/1/1900 SEX:

SPECIMEN DETAILS

SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE: 11/11/2022 ORDERED BY

References

1: Eichner JE et al. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol. 2002 Mar 15;155(6):487-95. 2: Koch W et al. Apolipoprotein E gene epsilon2/epsilon3/epsilon4 polymorphism and myocardial infarction: case-control study in a large population sample. Int J Cardiol. 2008 Mar 28;125(1):116-7. 3: Hanis CL et al. Effects of the apolipoprotein E polymorphism on levels of lipids, lipoproteins, and apolipoproteins among Mexican-Americans in Starr County, Texas. Arterioscler Thromb. 1991 Mar-Apr;11(2):362-70. 4: Klos KL et al. Linkage analysis of plasma ApoE in three ethnic groups: multiple genes with context-dependent effects. Ann Hum Genet. 2005 Mar;69(Pt 2):157-67. 5: Bennet AM et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA. 2007 Sep 19;298(11):1300-11. 6: Ciftdoğan DY et al. The association of apolipoprotein E polymorphism and lipid levels in children with a family history of premature coronary artery disease. J Clin Lipidol. 2012 Jan-Feb;6(1):81-7. 7: Kofler BM et al. Apolipoprotein E genotype and the cardiovascular disease risk phenotype: impact of sex and adiposity (the FINGEN study). Atherosclerosis. 2012 Apr;221(2):467-70. 8: Carvalho-Wells AL et al. Interactions between age and apoE genotype on fasting and postprandial triglycerides levels. Atherosclerosis. 2010 Oct;212(2):481-7. 9: Sima A et al. Apolipoprotein E polymorphism--a risk factor for metabolic syndrome. Clin Chem Lab Med. 2007;45(9):1149-53. 10: Granér M et al. Apolipoprotein E polymorphism is associated with both carotid and coronary atherosclerosis in patients with coronary artery disease. Nutr Metab Cardiovasc Dis. 2008 May;18 (4):271-7. 11: Utermann G et al. Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man. Nature. 1977 Oct 13;269(5629):604-7. 12 : Blum CB. Type III Hyperlipoproteinemia: Still Worth Considering? Prog Cardiovasc Dis. 2016 Sep - Oct;59(2):119-124. 13: Harold D et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009 Oct;41(10):1088-93. 14: Hopkins PN et al. Type III dyslipoproteinemia in patients heterozygous for familial hypercholesterolemia and apolipoprotein E2. Evidence for a gene-gene interaction. Arterioscler Thromb. 1991 Sep-Oct;11(5):1137-46. 15: Wilson PW et al. Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. Arterioscler Thromb Vasc Biol. 1996 Oct;16(10):1250-5. 16: Brscic E et al. Acute myocardial infarction in young adults: prognostic role of angiotensin-converting enzyme, angiotensin II type I receptor, apolipoprotein E, endothelial constitutive nitric oxide synthase, and glycoprotein IIIa genetic polymorphisms at medium-term follow-up. Am Heart J. 2000 Jun;139(6):979-84. 17: Humphries SE et al. Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study. Lancet. 2001 Jul 14;358(9276):115-9. 18: Zhu H et al. The association of apolipoprotein E (APOE) gene polymorphisms with atherosclerosis susceptibility: a metaanalysis. Minerva Cardioangiol. 2016 Feb;64(1):47-54. 19: Song Y et al. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med. 2004 Jul 20;141(2):137-47. 20: Xu H et al. Meta-analysis of apolipoprotein E gene polymorphism and susceptibility of myocardial infarction. PLoS One. 2014 Aug 11;9(8):e104608. 21: Schaefer JR. Unraveling hyperlipidemia type III (dysbetalipoproteinemia), slowly. Eur J Hum Genet. 2009 May;17(5):541-2. 22: Khan TA et al. Apolipoprotein E genotype, cardiovascular biomarkers and risk of stroke: systematic review and meta-analysis of 14,015 stroke cases and pooled analysis of primary biomarker data from up to 60,883 individuals. Int J Epidemiol. 2013 Apr;42(2):475-92. 23: Zhang MD et al. Apolipoprotein E gene polymorphism and risk for coronary heart disease in the Chinese population: a meta-analysis of 61 studies including 6634 cases and 6393 controls. PLoS One. 2014 Apr 22;9(4):e95463. 24: Cheema AN et al. APOE gene polymorphism and risk of coronary stenosis in Pakistani population. Biomed Res Int. 2015;2015:587465. 25: Zhang Y et al. Meta-analysis for the Association of Apolipoprotein E ε2/ε3/ε4 Polymorphism with Coronary Heart Disease. Chin Med J (Engl). 2015 May 20;128(10):1391-8. 26: Zhao QR et al. Association between apolipoprotein E polymorphisms and premature coronary artery disease: a metaanalysis. Clin Chem Lab Med. 2017 Feb 1;55(2):284-298. 27: Xu M et al. Apolipoprotein E Gene Variants and Risk of Coronary Heart Disease: A Meta-Analysis. Biomed Res Int. 2016;2016:3912175. 28: Moriarty PM et al. Lipoprotein(a) Mass Levels Increase Significantly According to APOE Genotype: An Analysis of 431 239 Patients. Arterioscler Thromb Vasc Biol. 2017 Mar;37(3):580-588. 29: Mack S et al. A genome-wide association meta-analysis on lipoprotein(a) concentrations adjusted for apolipoprotein(a) isoforms. J Lipid Res. 2017 May 16.



PATIENT INFORMATION

SPECIMEN DETAILS

NAME: Patient m0bwvya ACC #: m0bwvya DOB: 1/1/1900 SEX: SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE:

E: 11/11/2022

COMT Monograph

Clinical Utility

Catechol-O-Methyltransferase (COMT) is an enzyme responsible for the metabolism of catecholamines and catechol-estrogens in the central nervous system and other organs. Dopamine is cleared mainly by COMT in the frontal cortex, and a reduced activity of this enzyme results in higher synaptic levels of dopamine, which affects prefrontal cortex cognitive response to certain drugs. A single nucleotide polymorphism of the COMT gene produces an amino acid change from valine to methionine (Val158Met) and reduces the enzyme activity by 3- to 4-fold.

Assay Interpretation

The most well studied COMT genetic variant (rs4680; 472G>A) is the one resulting in a valine to methionine change at codon 158. The variant allele called the Met allele is found in 30-47% of Caucasians, 23% of Africans, and 27-32% of Asians. The phenotype is defined by the presence of the reduced activity Met allele (A variant). The wild-type genotype (Val/Val; GG) predicts a high/normal COMT activity, the heterozygous genotype (Val/Met; GA) predicts an intermediate COMT activity, and the homozygous (Met/Met; AA) results in a low COMT activity.

The reference range for COMT metabolic status is COMT Val158Met GG (Val/Val) (wild-type), which is consistent with a high/normal COMT activity.

Clinical Implications

Several complex associations with the Val158Met variant as a risk factor for numerous diseases have been found, but seem to have limited predictive value. The response to some psychotropic medications seems to be dependent to some extent upon the COMT status. In general, the wild-type genotype result predicts a good response to methylphenidate and amphetamines in the treatment of attention deficit hyperactivity disorder. In the treatment of pain, patients who are homozygous for the Met allele require lower doses of morphine to achieve analgesia.

References

1: De Gregori et al. Genetic variability at COMT but not at OPRM1 and UGT2B7 loci modulates morphine analgesic response in acute postoperative pain. Eur J Clin Pharmacol. 2013 May 19. 2 : Hamidovic et al. Catechol-O-methyltransferase val158met genotype modulates sustained attention in both the drug-free state and in response to amphetamine. Psychiatr Genet. 2010 Jun;20(3):85-92. 3 : Blasi et al. Effect of catechol-O-methyltransferase val158met genotype on attentional control. J Neurosci. 2005 May 18;25(20):5038-45. 4 : Mattay et al. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci U S A. 2003 May 13;100(10):6186-91.





PATIENT INFORMATION

NAME: Patient m0bwvya ACC #: m0bwvya DOB: 1/1/1900 SEX: SPECIMEN DETAILS

SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE: 11/11/2022

CYP1A2 Monograph

Clinical Utility

The cytochrome P450 1A2 (CYP1A2) accounts for 13% of total CYP in the human liver, and is responsible for metabolizing 8-10% of commonly used drugs as well as natural compounds such as caffeine. A large inter-individual variability in the elimination of drugs that are metabolized by CYP1A2 has been observed, which has been ascribed to genetic variations and environmental factors. CYP1A2 activity is highly inducible (increased) by environmental factors including smoking (tobacco), some drugs, and several dietary compounds (cruciferous vegetables).

Assay Interpretation

More than 20 different alleles have been characterized for the CYP1A2 gene, and some have been shown to affect enzyme activity and its sensitivity towards inducers (inducibility). The CYP1A2*1F is the most studied allele and results in a rapid metabolizer phenotype in the presence of inducers, while CYP1A2*1K and *1C alleles result in enzymes that are less active and less sensitive to induction. The CYP1A2*1F allele is found in 25-50% of Caucasians, 30% of Asians, and 50% of Ethiopians. The genotype-phenotype relationship for CYP1A2 is not well established, and can be expressed in terms of metabolic capacity as well as sensitivity towards induction (inducibility). Individuals are predicted to have CYP1A2 normal, intermediate, or poor metabolic capacity, with high, possible, or low inducibility depending on their genotype.

The reference range for CYP1A2 metabolic status is CYP1A2 *1A/ *1A, which is consistent with a normal metabolizer that is possibly inducible.

Clinical Implications

CYP1A2 genotype can help identify patients with high or low sensitivity to inducing agents, especially those released during smoking. The clinical relevance of this sensitivity becomes important in patients who are smokers or who quit smoking. Patients with the highly inducible genotype CYP1A2*1F/*1F can experience loss of response to drug substrates while they are exposed to dietary or environmental inducers, and therefore may require higher doses.

The following drugs used in the management of pain and various psychiatric conditions are metabolized extensively by CYP1A2 and are sensitive to its function: clozapine (Clozaril), duloxetine (Cymbalta), olanzapine (Zyprexa), and tizanidine (Zanaflex). CYP1A2 also metabolizes other important drugs such as melatonin, ondansetron (Zofran), pirfenidone (Esbriet), pomalidomide (Pomalyst), ramelteon (Rozerem), ropivacaine (Naropin), and tasimelteon (Hetlioz).

CYP1A2 metabolism is highly sensitive to inhibition and induction, and the occurrence of drug-drug interactions can have profound effects on the pharmacokinetics, response, and safety profiles of many CYP1A2 drug substrates.

Inhibitors

Some known strong CYP1A2 inhibitors include: ciprofloxacin (Cipro), enoxacin (Penetrex), fluvoxamine (Luvox) and zafirlukast (Accolate).

Some known **moderate to weak** CYP1A2 inhibitors include: allopurinol (Zyloprim), mexiletine (Mexitil), norfloxacin (Norflox), peginterferon alfa-2a (Pegasys), obeticholic acid (Ocaliva), oral contraceptives, ticlopidine (Ticlid), vemurafenib (Zelboraf) and zileuton (Zyflo).

Inducers

Known CYP1A2 inducers include: carbamazepine (Tegretol), montelukast (Singulair), moricizine (Ethmozine), omeprazole (Prilosec), phenobarbital, phenytoin (Dilantin), primidone (Mysoline) and rifampin (Rifadin).

Some dietary and environmental compounds found in charcoal-grilled food, cigarette smoke and cruciferous vegetables can also increase CYP1A2 activity.

References

1: Metabolic Drug Interactions. RH Levy, KE Thummel, WF Trager. Publisher: Lippincott Williams & Wilkins (March 15, 2000). 2: Zhou et al. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009;41(2):89-295 3 : Thorn et al. PharmGKB summary: very important pharmacogene information for CYP1A2. Pharmacogenet Genomics. 2012 Jan;22(1):73-7. 4 : Aklillu et al. Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol Pharmacol. 2003 Sep;64(3):659-69. 5 : Zhou et al. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab Rev. 2010 May;42(2):268 -354.

CYP2B6 Monograph





NAME: Patient m0bwvya ACC #: m0bwvya DOB: 1/1/1900 SEX: SPECIMEN DETAILS

ORDERED BY

SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE: 11/11/2022

FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE

The cytochrome P450 2B6 (CYP2B6) enzyme is responsible for the metabolism of 4% of frequently used medications. It is expressed primarily in the liver and also in the brain. This enzyme is highly polymorphic: to date, a large number of variants have been identified. The CYP2B6 assay identifies some common variants that are associated with variability in enzyme activity, which has important clinical implications for efavirenz dosing.

Assay Interpretation

Genetic polymorphism in CYP2B6 result in different enzyme isoforms that are fully active (normal function), partially active (decreased function), inactive (no function), or have increased activity (increased function). The CYP2B6*1 allele is considered wild-type and encodes a functionally active enzyme (normal). Common decreased function alleles include the *6, *7, and *9 alleles. The *4 and *22 alleles are increased function alleles while the *18 allele is a no-function allele. Of note, common functional polymorphisms in CYP2B6 alter enzyme activity in a substrate-dependent manner. For most substrates, activity of the *9 variant is exceptionally low, activity of the *4 variant is similar or greater than that of the *1, while the activity of the *6 variant lies between *9 and *4, depending on substrate.

The most clinically relevant decreased function allele is the CYP2B6*6 allele. It is found in 7-18%, 10-17%, 23% and 33% of Caucasians, Asians, Mexican-Americans and African-Americans, respectively. The CYP2B6*18 allele is found only in individuals of African descent, with a frequency of 4-7%.

An individual carrying two normal function alleles is considered a normal metabolizer. An individual carrying one normal function allele and one decreased function allele OR one normal function allele and one no function allele OR one increased function allele and one decreased function allele OR one increased function allele and one no function allele is considered an intermediate metabolizer. An individual carrying two decreased function alleles OR two no function alleles OR one decreased function allele and one no function allele is considered a poor metabolizer. An individual carrying one normal function allele and one increased function allele is considered a rapid metabolizer. An individual carrying two increased function alleles is considered an ultra-rapid metabolizer.

The reference range for CYP2B6 metabolic status is CYP2B6 *1/ *1, which is consistent with a normal metabolizer.

Clinical Implications

CYP2B6 plays a role in the metabolism of the following drugs: artemisinin, bupropion (Wellbutrin), cyclophosphamide (Cytoxan), efavirenz (Sustiva), ketamine (Ketalar), meperidine (Demerol), methadone (Dolophine), nevirapine (Viramune), propofol (Diprivan), and selegiline (Eldepryl).

The impact of CYP2B6 polymorphism on pharmacokinetics and clinical response have been documented in adult and pediatric patients taking efavirenz. Patients who are intermediate or poor metabolizers are likely to have higher dose-adjusted trough concentrations of efavirenz following standard treatment when compared with normal metabolizers. Therefore, these patients are subject to increased risk of CNS adverse events. Decreased initial dosage and therapeutic monitoring are recommended for intermediate and poor metabolizers. Patients who are rapid or ultra-rapid metabolizers are likely to have slightly higher efavirenz clearance with no clinically significant effect on efficacy or toxicity. Efavirenz can be initiated with standard dosing for normal, rapid and ultra-rapid metabolizers. Specific dosing strategies for pediatric patients have been published by a panel of experts (Department of Human and Health Services-Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV). These are based and on CYP2B6 genotype, weight, age and comorbidities.

Inhibitors or inducers of the CYP2B6 enzyme may modify its activity and change the patient's metabolizer status. This can result in drug-drug interactions when a drug substrate is prescribed with known CYP2B6 inhibitors or inducers.

Inhibitors

Some known CYP2B6 inhibitors include: clopidogrel (Plavix), darunavir (Prezista), prasugrel (Effient), ritonavir (Norvir), thiotepa (Tepadina), ticlopidine (Ticlid) and voriconazole (Vfend).

Inducers

Some CYP2B6 inducers include: artemether (Coartem), carbamazepine (Tegretol), dabrafenib (Tafinlar), efavirenz (Sustiva), metamizole, nevirapine (Viramune), phenobarbital, phenytoin (Dilantin), rifampin (Rimactane), ritonavir (Norvir) and St. John's wort.





NAME: Patient m0bwvya ACC #: m0bwvya DOB: 1/1/1900 SEX: SPECIMEN DETAILS

SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE: 11/11/2022

FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE

References

1: CYP2B6 Allele Nomenclature: www.cypallele.ki.se/cyp2b6.htm. 2: Li J, Menard V, Benish RL, Jurevic RJ, Guillemette C, Stoneking M, Zimmerman PA, Mehlotra RK. Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment. Pharmacogenomics. 2012 Apr;13 (5):555-70. 3: Li Y, Coller JK, Hutchinson MR, Klein K, Zanger UM, Stanley NJ, Abell AD, Somogyi AA. The CYP2B6*6 allele significantly alters the N-demethylation of ketamine enantiomers in vitro. Drug Metab Dispos. 2013 Jun;41(6):1264-72. 4: Zanger and Klein. Zanger UM, Klein K. Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Front Genet. 2013 Mar 5;4:24. Front Genet. 2013;4:24. 5: Zanger UM, Klein K, Saussele T, Blievernicht J, Hofmann MH, Schwab M. Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics. 2007 Jul;8(7):743-59. 6: Zhu AZ, Cox LS, Nollen N, Faseru B, Okuyemi KS, Ahluwalia JS, Benowitz NL, Tyndale RF. CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion. Clin Pharmacol Ther. 2012 Dec;92(6):771-7. 7: Benowitz NL, Zhu AZ, Tyndale RF, Dempsey D, Jacob P 3rd. Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state. Pharmacogenet Genomics. 2013 Mar;23 (3):135-41. 8: Desta Z, Gammal RS, Gong L, Whirl-Carrillo M, Gaur AH, Sukasem C, Hockings J, Myers A, Swart M, Tyndale R, Masimirembwa C, Iwuchukwu OF, Chirwa S, Lennox J, Gaedigk A, Klein T, Haas DW. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Envirenz-containing Antiretroviral Therapy. Clin Pharmacol Ther. 2019 Apr 21. 9: Bloom AJ, Wang PF, Kharasch ED. Nicotine oxidation by genetic variants of CYP2B6 and in human brain microsomes. Pharmacol Res Perspect. 2019 Apr 21. 9: Bloom AJ, Wang PF, Kharasch ED. Nicotine oxidation by genetic variants of CYP2B6 and in human brain microsomes. Pharmacol Res Perspect. 2019 Apr 21. 9: Blo

CYP2C19 Monograph

Clinical Utility

The cytochrome P450 2C19 (CYP2C19) is involved in the metabolism of 10% of clinically important medications. This enzyme is highly polymorphic and more than 30 different alleles have been identified in various ethnicities. The CYP2C19 assay identifies common and rare variants that are associated with variability in CYP2C19 enzyme, which has important pharmacological and toxicological implications for antidepressants, benzodiazepines, antiplatelets, and proton-pump inhibitors.

Assay Interpretation

CYP2C19 enzyme activity defines a normal or abnormal (intermediate, poor, rapid or ultra-rapid) metabolizer status for a given individual. Several variant alleles have been identified and result in different isoforms of the CYP2C19 enzyme that functionally exhibit normal function, reduction function, no function or increased function. The CYP2C19*1 allele is considered wild-type/reference allele and CYP2C19 *11, *13 and *18 encodes a functionally active enzyme (normal function allele). The alleles *2, *3 *4-*8, *22, *24, and *35-*37 encode an inactive enzyme and are referred to as no function alleles while the *9, *10, *16,*19, *25 and *26 alleles are classified as reduced function alleles. The CYP2C19*17 is an increased function allele.

A new joint statement by the Association for Molecular Pathology (AMP) and the College of American Pathologists (CAP), provides a twotiered classification of CYP2C19 alleles for inclusion during clinical testing. Tier 1 alleles that should be included in all clinical tests, include CYP2C19 *2, *3 and *17. Tier 2 alleles which may also be included in clinical tests include CYP2C19 *4A, *4B, *5, *6, *7, *8, *9, *10 and *35.

The CYP2C19 genotype-phenotype relationship is established based on the allele's function. An Individual with two normal function alleles is considered a normal metabolizer while an individual carrying two no function alleles is considered a poor metabolizer. An individual carrying one normal function allele with one no function allele or one no function allele with one increased function allele is classified as an intermediate metabolizer. Individuals with two increased function alleles are considered ultra-rapid metabolizers and carriers of one increased function allele with one normal function allele are referred to as rapid metabolizers. Because of limited evidence, individuals carrying two decreased function alleles OR those carrying one normal or increased function allele with one decreased function allele are provisionally categorized as intermediate metabolizers.

The reference range for CYP2C19 metabolic status is CYP2C19 *1/*1 genotype, which is consistent with a normal metabolizer.

Clinical Implications





NAME: Patient m0bwvya ACC #: m0bwvya DOB: 1/1/1900 SEX: SPECIMEN DETAILS

ORDERED BY

SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE:

T DATE: 11/11/2022

FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE

There is substantial evidence linking the CYP2C19 polymorphisms to variability in the pharmacological and safety profiles of the following therapies used in psychiatric conditions and pain management: amitriptyline (Elavil), sertraline (Zoloft), clobazam (Onfi), citalopram (Celexa), escitalopram (Lexapro), diazepam (Valium), imipramine (Tofranil), and carisoprodol (Soma). CYP2C19 plays a minor role in the elimination of methadone (Dolophine).

Cardiovascular medications that are metabolized by CYP2C19 include the prodrug clopidogrel (Plavix), propranolol (Inderal), and cilostazol (Pletal). Proton-pump inhibitors such as omeprazole (Prilosec), esomeprazole (Nexium), lansoprazole (Prevacid), dexlansoprazole (Dexilant), and pantoprazole (Protonix) are major substrates of CYP2C19.

Brivaracetam (Briviact) is primarily metabolized by hydrolysis and by hydroxylation. The hydrolysis reaction is mediated by amidase and the hydroxylation is mediated by CYP2C19. Brivaracetam exposure is increased by 22% and 42%, in CYP2C19 intermediate and poor metabolizers, respectively. CYP2C19 poor metabolizers and patients using inhibitors of CYP2C19 may therefore require dose reduction to avoid concentration-dependent toxicity.

CYP2C19 is significantly involved in the metabolism of voriconazole (Vfend) and the disposition of this antifungal is affected by CYP2C19 genetic polymorphisms. The CPIC dosing guideline for voriconazole recommends selecting an alternative agent that is not dependent on CYP2C19 metabolism in adults who are CYP2C19 ultrarapid metabolizers, rapid metabolizers or poor metabolizers. In pediatric patients, an alternative agent should be used in patients who are ultrarapid metabolizers or poor metabolizers.

Inhibitors or inducers of CYP2C19 enzyme may modify its activity and change the patient's metabolizer status. This can result in drug-drug interactions when a drug substrate is prescribed with known CYP2C19 inhibitors or inducers.

Inhibitors

Some known CYP2C19 inhibitors include: armodafinil (Nuvigil), delavirdine (Rescriptor), esomeprazole (Nexium), etravirine (Intelence), felbamate (Felbatol), fluconazole (Diflucan), fluoxetine (Prozac), fluvoxamine (Luvox), moclobemide (Manerix), modafinil (Provigil), omeprazole (Prilosec), oxcarbazepine (Trileptal), ticlopidine (Ticlid), topiramate (Topamax) and voriconazole (Vfend).

Inducers

Some known CYP2C19 inducers include: apalutamide (Erleada), artemether (Coartem), carbamazepine (Tegretol), efavirenz (Sustiva), enzalutamide (Xtandi), fosphenytoin (Cerebyx), phenobarbital, phenytoin (Dilantin), primidone (Mysoline), rifampin (Rifadin) and St. John's wort.

References

1: Preskorn SH. Clinically important differences in the pharmacokinetics of the ten newer "atypical" antipsychotics: Part 2: Metabolism and elimination. J Psychiatr Pract. 2012 Sep;18(5):361-8. **2**: Preskorn SH. Clinically important differences in the pharmacokinetics of the ten newer "atypical" antipsychotics: part 1. J Psychiatr Pract. 2012 May;18(3):199-204. **3**: Hicks et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants. Clin Pharmacol Ther. 2013 Jan 16 **4**: Swen et al. Pharmacogenetics: from bench to byte--an update of guidelines. Clin Pharmacol Ther. 2011 May;89(5):662-73. **5**: Wilffert et al. KNMP working group Pharmacogenetics. From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics. Int J Clin Pharm. 2011 Feb;33(1):3-9. **6**: Psychiatric Pharmacogenomics. David A. Mrazek. Publisher: Oxford University Press, USA; 1 edition (May 28, 2010). **7**: Briviact Prescribing Label (label approved on 02/18/2016). **8**: Moriyama B, Obeng AO, Barbarino J, Penzak SR, Henning SA, Scott SA, Agúndez JA, Wingard JR, McLeod HL, Klein TE, Cross S, Caudle KE, Walsh TJ. Clinical Pharmacogenetics Implementation Consortium (CPIC®) Guideline for CYP2C19 and Voriconazole Therapy. Clin Pharmacol Ther. 2016 Dec 16. **9**: Pratt VM, Del Tredici AL, Hachad H, Ji Y, Kalman LV, Scott SA, Weck KE. Recommendations for Clinical CYP2C19 Genotyping Allele Selection: A Report of the Association for Molecular Pathology. J Mol Diagn. 2018 May;20 (3):269-276. **10**: Lima JJ, Thomas CD, Barbarino J, Desta Z, Van Driest SL, El Rouby N, Johnson JA, Cavallari LH, Shakhnovich V, Thacker DL, Scott SA, Schwab M, Uppugunduri CRS, Formea CM, Franciosi JP, Sangkuhl K, Gaedigk A, Klein TE, Gammal RS, Furuta T. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2020 Aug 8.

CYP2C9 Monograph

Clinical Utility

The cytochrome P450 2C9 (CYP2C9) is involved in the metabolism of 15% of clinically important medications. This enzyme is highly polymorphic: to date, 60 alleles have been identified. The CYP2C9 assay identifies some common variants that are associated with variability in CYP2C9 enzyme activity, which has important pharmacological and toxicological implications for anticonvulsants, anticoagulants, and certain antidiabetics.

Assay Interpretation





ρατι	FNT	INFO	RMAT	
~				

NAME: Patient m0bwvya ACC #: m0bwvya DOB: 1/1/1900 SEX:

SPECIMEN DETAILS

SPECIMEN TYPE: COLLECTION DATE: REPORT DATE:

RECEIVED DATE: 11/11/2022

FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE

CYP2C9 enzyme activity defines a normal or abnormal (intermediate and poor) metabolizer status for a given individual. Several variant alleles have been identified and result in different CYP2C9 isoforms that functionally are fully active, partially active, or inactive. The CYP2C9 *1 (wildtype) and CYP2C9*9 alleles encode functionally active enzymes. A number of CYP2C9 alleles such as *2, *4, *5, *8, *11, *12 and *31 encode partially active enzymes and are classified as decreased function alleles. Other CYP2C9 alleles such as *3, *6, *13, *15 and *25 are considered no -function alleles encoding inactive enzymes. Many other alleles with an unknown/uncertain functional effect have also been identified and can be revealed from testing.

A new joint statement by the Association for Molecular Pathology (AMP) and the College of American Pathologists (CAP), provides a twotiered classification of CYP2C9 alleles for clinical testing. Tier 1 alleles that should be included in all tests, these include CYP2C9 *2, *3, 5. *6, *8 and *11. Tier 2 alleles which may also be included in clinical tests include CYP2C9 *12, *13 and *15.

The genotype-phenotype relationship is established based on the allele's function. Individuals with two normal function alleles are considered normal (extensive) metabolizers (AS = 2.0). Individuals with one normal function allele with one decreased function allele are considered intermediate metabolizers (AS = 1.5). Individuals with one normal function allele and one no-function allele or two decreased function alleles are considered intermediate metabolizers (AS = 1.0). Individuals with one decreased function allele and one no function allele are considered poor metabolizers (AS = 0.5). Individuals with two no-function alleles are considered poor metabolizers (AS = 0). The phenotype of carriers of one or two CYP2C9 unknown/uncertain function alleles cannot be predicted accurately (unknown phenotype).

The reference range for CYP2C9 metabolic status is CYP2C9 *1/*1 genotype, which is consistent with an AS of 2.0 and a normal metabolizer.

Clinical Implications

Abnormal CYP2C9 activity affects the therapeutic outcome of a variety of drugs used to treat cardiovascular and other conditions. Following the administration of drug substrates, the clinical manifestation in a poor or an intermediate metabolizer depends on the characteristics of the drug (i.e., the amount of drug/metabolites that is cleared by the enzyme), and the safety and pharmacological profiles of the drug and its metabolites. Within the medications used to treat cardiovascular conditions, there is compelling evidence that the response to certain angiotensin II inhibitors, statins, and anticoagulants is altered in individuals exhibiting abnormal CYP2C9 activity.

CYP2C9 plays a role in the metabolism of the following psychotropic drugs: fluoxetine (Prozac), phenytoin (Dilantin), and primidone (Mysoline). Several NSAIDs and Cox-2 inhibitors are substrates of CYP2C9, and patients with reduced CYP2C9 activity may have higher plasma levels of celecoxib (Celebrex), flurbiprofen (Ocufen), piroxicam (Feldene), or meloxicam (Mobic). CYP2C9 plays a minor role in the elimination of diclofenac (Voltaren), sulindac (Clinoril), and naproxen (Aleve).

Cardiovascular medications that are metabolized by CYP2C9 include warfarin (Coumadin), fluvastatin (Lescol), losartan (Cozaar), and irbesartan (Avapro).

The FDA has added a contraindication on the use of siponimod (Mayzent) in patients with a CYP2C9 *3/*3 genotype.

Inhibitors or inducers of the CYP2C9 enzyme may modify its activity and change the patient's metabolizer status. This can result in drug-drug interactions when a drug substrate is prescribed with known CYP2C9 inhibitors or inducers.

Inhibitors

Some known CYP2C9 inhibitors include: amiodarone (Cordarone), capecitabine (Xeloda), chloramphenicol, cimetidine (Tagamet), co-trimoxazole (Septra), danazol (Danocrine), delavirdine (Rescriptor), disulfiram (Antabuse), efavirenz (Sustiva), etravirine (Intelence), fluconazole (Diflucan), 5-fluorouracil (Adrucil), fluoxetine (Prozac), fluvastatin (Lescol), fluvoxamine (Luvox), gemfibrozil (Lopid), lomitapide (Juxtapid), metronidazole (Flagyl), miconazole (Oravig), oxandrolone (Oxandrin), phenytoin (Dilantin), sulfamethoxazole (Bactrim), sulfinpyrazone (Anturane), tamoxifen (Nolvadex), tigecycline (Tygacil), toremifene (Fareston), voriconazole (Vfend) and zafirlukast (Accolate).

Inducers

Some known CYP2C9 inducers include: alpelisib (Pigray), apalutamide (Erleada), aprepitant (Emend), bosentan (Tracleer), carbamazepine (Tegretol), dabrafenib (Tafinlar), elvitegravir (Genvoya, Stribild), enzalutamide (Xtandi), phenobarbital, phenytoin (Dilantin), primidone (Mysoline), rifampin (Rifadin, Rimactane), rifapentine (Priftin), ritonavir (Norvir) and St. John's wort.





NAME: Patient m0bwvya ACC #: m0bwvya DOB: 1/1/1900 SEX: SPECIMEN DETAILS

SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE: 11/11/2022

FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE

References

1: Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GA, van Schaik RH, Schalekamp T, Touw DJ, van der Weide J, Wilffert B, Deneer VH, Guchelaar HJ. Pharmacogenetics: from bench to byte--an update of guidelines. Clin Pharmacol Ther. 2011 May;89(5):662-73. **2**: Wilffert B, Swen J, Mulder H, Touw D, Maitland-Van der Zee AH, Deneer V; KNMP working group Pharmacogenetics. From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics. Int J Clin Pharm. 2011 Feb;33(1):3-9. **3**: Wang B, Wang J, Huang SQ, Su HH, Zhou SF. Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance. Curr Drug Metab. 2009 Sep;10(7):781-834. **4**: Wyatt JE, Pettit WL, Harirforoosh S. Pharmacogenetics of nonsteroidal anti-inflammatory drugs. Pharmacogenomics J. 2012 Dec;12(6):462-7. **5**: Pratt VM, Cavallari LH, Del Tredici AL, Hachad H, Ji Y, Moyer AM, Scott SA, Whirl-Carrillo M, Weck KE. Recommendations for Clinical CYP2C9 Genotyping Allele Selection: A Joint Recommendation of the Association for Molecular Pathology and College of American Pathologists. J Mol Diagn. 2019 May 7. **6**: Daly AK, Rettie AE, Fowler DM, Miners JO. Pharmacogenetics of CYP2C9: Functional and Clinical Considerations. J Pers Med. 2017 Dec 28;8(1). **7**: Johnson JA, Caudle KE, Gong L, Whirl-Carrillo M, Stein CM, Scott SA, Lee MT, Gage BF, Kimmel SE, Perera MA, Anderson JL, Pirmohamed M, Klein TE, Limdi NA, Cavallari LH, Wadelius M. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017 Sep;102(3):397-404. **8**: Theken KN, Lee CR, Gong L, Caudle KE, Formea CM, Gaedigk A, Klein TE, Agúndez JAG, Grosser T. Clinical Pharmacogenetics Implementation Consortium GUICIC) Guideline for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020 Mar 19. **9**: Karnes JH, Rettie AE, Somogyi AA, Huddart R, Fohner AE, Formea CM, Ta Michael Lee M, Llerena A, Whirl-Carrillo M, Kl

CYP2D6 Monograph

Clinical Utility

The cytochrome P450 2D6 (CYP2D6) is involved in the metabolism of 20% of clinically important medications. This enzyme is highly polymorphic: more than 100 different variants have been identified. The CYP2D6 assay identifies common variants that are associated with variability in CYP2D6 enzyme activity, which has important pharmacological and toxicological implications for antidepressants, antipsychotics, opioids, beta-blockers, and antiarrhythmics.

Assay Interpretation





ρατι	FNT	INFO	RMA	τιον
~				

NAME: Patient m0bwvya ACC #: m0bwvya DOB: 1/1/1900 SEX:

SPECIMEN DETAILS

ORDERED BY

SPECIMEN TYPE: COLLECTION DATE: **RECEIVED DATE:** REPORT DATE: 11/11/2022

FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE

CYP2D6 enzyme activity defines a normal or abnormal (intermediate, poor, or ultra-rapid) metabolizer status for a given individual. Many alleles have been identified and result in different CYP2D6 isoforms that functionally have normal activity, decreased activity, no activity or in some cases unknown activity. The CYP2D6*1 (reference or wild-type allele) is inferred when no variants tested by the assay are detected. Genotyping tests usually interrogate for both sequence variants and structural variants and results are used to infer CYP2D6 alleles or haplotypes as defined by PharmVar. Sequence variants include single nucleotide polymorphisms (SNPs) and small insertions and deletions. Structural variations include entire gene deletions (CYP2D6*5), gene duplication/multiplication (CYP2D6*1xN, *2xN and *4xN), and hybrids with the CYP2D7 gene. Moreover, alleles that contain hybrids can be found on their own (as single entities) or in combination with other gene copies (tandems).

Commonly detected alleles include those with normal function (e.g. CYP2D6 *1, *2 and *35), increased function (e.g. CYP2D6*1xN, *2xN), reduced function (e.g. CYP2D6*9, *10, *10-*36, *17, *29, and *41) and no-function (e.g. CYP2D6 *3, *4, *4N, *5, *6, *7, *8, *11, *12, *36, *4xN).

The genotype-phenotype relationship is established using a scoring system that assigns an activity value to every CYP2D6 allele, in order to assign a predicted phenotype. For a given genotype, the activity values of the constituent alleles are added together to calculate the CYP2D6 activity score. This activity score (AS) is then used to assign a predicted phenotype. The AS system was first published in 2008 and was recently refined by an expert group that included both the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) members. The group reviewed recent findings and heterogeneities in phenotype assignment.

The consensus method jointly recommended by CPIC and the DPWG redefined the translation of CYP2D6 diplotypes to phenotype as follows:

- CYP2D6 ultra-rapid metabolizers (UMs) when the calculated AS is > 2.25
- CYP2D6 normal metabolizers (NMs) when the calculated AS = x is within the range of $1.25 \le x \le 2.25$
- CYP2D6 intermediate metabolizers (IMs) when the calculated AS = x is within the range of 0 < x < 1.25
- CYP2D6 poor metabolizers (PMs) when the calculated AS = 0

After literature review, the standardization expert group also obtained consensus to 'downgrade' the activity value for the CYP2D6*10 allele from 0.5 to 0.25 to better reflect the level of enzyme reduction that is observed with this allele. The group proposed the following activity value when the functional effect of the CYP2D6 allele is known:

- fully functional CYP2D6 alleles are assigned an activity value of 1.0 (e.g. CYP2D6 *2, *35).
- reduced function CYP2D6 alleles (except CYP2D6*10) have an activity value of 0.5 (Note that the value of 0.5 does not indicate a 50%) reduction in activity, but signals decreased function, i.e., has functional activity somewhere between no-function and full function).
- CYP2D6*10 reduced function allele is assigned an activity value of 0.25.
- non-functional CYP2D6 alleles are assigned an activity value of 0 (e.g. CYP2D6 *4, *5, *36, *36xN, *4x2N).

For alleles with two or more gene copies, the value of the allele is multiplied by the number of gene copies (e.g. AS of CYP2D6*1x3N = 3 calculated as the AS of *1 which is 1 multiplied by 3). For a tandem, the sum of each allele value is used to assign the score (e.g. AS of CYP2D6*36-*10 = 0.25 calculated as the sum of AS of CYP2D6*36 which is 0 and AS of CYP2D6*10 which is 0.25).

The reference range for CYP2D6 metabolic status is a CYP2D6 *1/ *1 genotype, which is consistent with an AS of 2.0 and a normal metabolizer status.

Clinical Implications





NAME: Patient m0bwvya ACC #: m0bwvya DOB: 1/1/1900 SEX: SPECIMEN DETAILS

SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE: 11/11/2022

FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE

There is substantial evidence linking the CYP2D6 polymorphisms to variability in the pharmacological and safety profiles of the following psychotropics: desipramine (Norpramin), imipramine (Tofranil), amitriptyline (Elavil), nortriptyline (Pamelor), haloperidol (Haldol), trimipramine (Surmontil), venlafaxine (Effexor), doxepin (Silenor), aripiprazole (Abilify), atomoxetine (Strattera), risperidone (Risperdal), clomipramine (Anafranil), and pimozide (Orap).

CYP2D6 polymorphisms have been shown to affect the pharmacological and safety profiles of the following analgesics: codeine, tramadol (Ultram), and hydrocodone (Vicodin). Codeine and tramadol are prodrugs that need to be activated by CYP2D6. Poor metabolizers are at high risk of therapy failure when given codeine or tramadol. On the other hand, ultra-rapid metabolizers may experience increased toxicity when given standard dosage of codeine or tramadol. Because CYP3A4 is also involved in the metabolism of oxycodone, patients with abnormal CYP2D6 activity may still experience adequate analgesia when taking this drug. CYP2D6 polymorphism has been shown to affect dihydrocodeine (Synalgos-DC) pharmacokinetics and can potentially alter the response to this drug.

Morphine, oxymorphone (Opana), hydromorphone (Dilaudid), butorphanol (Stadol), fentanyl (Duragesic), buprenorphine (Butrans), methadone (Dolophine), morphine (Avinza), and tapentadol (Nucynta) are not substrates of CYP2D6, and the patient's response to these drugs is not expected to be affected by polymorphisms in this enzyme.

Several important cardiovascular medications are metabolized by CYP2D6, and include: metoprolol (Lopressor), flecainide (Tambocor), and propafenone (Rythmol).

Eliglustat (Cerdelga) is a glucosylceramide synthase inhibitor used for the long-term treatment of adult patients with Gaucher disease type 1. Both the FDA-approved drug label and the EMA Summary of Product Characteristics for this drug state that CYP2D6 ultra-rapid metabolizers may not achieve adequate concentrations of eliglustat to achieve a therapeutic effect. Therefore this drug should not be used in these individuals. Patients who are CYP2D6 intermediate and normal metabolizers have a recommended dose of 84 mg twice daily, while poor metabolizers have a recommended dose of 84 mg once daily.

Cevimeline (Evoxac) is a muscarinic agonist indicated for the treatment of symptoms of dry mouth in patients with Sjögrens Syndrome. Both CYP2D6 and CYP3A are responsible for the metabolism of cevimeline, and this drug should be used with caution in individuals who are CYP2D6 poor metabolizers, as they may be at a higher risk of adverse events.

Inhibitors of the CYP2D6 enzyme may modify its activity and change the patient's metabolizer status. This can result in drug-drug interactions when a drug substrate is prescribed with known CYP2D6 inhibitors. Although there are no known clinical inducers of CYP2D6, the pharmacokinetics of a drug substrate can be affected by inducers of other enzymes (such as CYP3A) that are involved in the metabolism of that drug.

Inhibitors

Some known **strong and moderate** CYP2D6 inhibitors include: abiraterone (Zytiga), bupropion (wellbutrin), cinacalcet (Sensipar), cobicistat (Stribild), dacomitinib (Vizimpro), duloxetine (Cymbalta), ecstasy, fluoxetine (Prozac), paroxetine (Paxil), quinidine (Quinidex), rolapitant (Varubi), terbinafine (Lamisil), mirabegron (Myrbetriq), panobinostat (Farydak), peginterferon alfa-2b (Sylatron) and tipranavir/ritonavir (Aptivus).

Some known **weak** CYP2D6 inhibitors include: amiodarone (Cordarone), celecoxib (Celebrex), clobazam (Onfi), desvenlafaxine (Pristiq), diltiazem (Cardiazem), diphenhydramine (Benadryl), Echinacea, escitalopram (Lexapro), febuxostat (Uloric), gefitinib (Iressa), hydralazine (Apresoline), hydroxychloroquine (Plaquenil), imatinib (Gleevec), lorcaserin (Belviq), methadone (Dolophine), perphenazine (Trilafon), propafenone (Rythmol), ranitidine (Zantac), ritonavir (Norvir), sertraline (Zoloft), telithromycin (Ketek), venlafaxine (Effexor) and verapamil (Isoptin, Covera-HS).





References

1: Swen et al. Pharmacogenetics: from bench to byte--an update of guidelines. Clin Pharmacol Ther. 2011 May;89(5):662-73. 2: Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet. 2009;48(12):761-804. 3: Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009;48(11):689-723. 4: Preskorn SH. Clinically important differences in the pharmacokinetics of the ten newer "atypical" antipsychotics: Part 2. Metabolism and elimination. J Psychiatr Pract. 2012 Sep;18(5):361-8. 5: Preskorn SH. Clinically important differences in the pharmacokinetics of the ten newer "atypical" antipsychotics: part 1. J Psychiatr Pract. 2012 May;18(3):199-204. 6: D'Empaire et al. Antidepressant treatment and altered CYP2D6 activity: are pharmacokinetic variations clinically relevant? J Psychiatr Pract. 2011 Sep;17(5):330-9. 7: Hicks et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants. Clin Pharmacol Ther. 2013 Jan 16. 8: Gaedigk et al. The CYP2D6 activity score: translating genotype information into a gualitative measure of phenotype. Clin Pharmacol Ther. 2008 Feb;83(2):234-42. 9: Crews et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther. 2012 Feb;91(2):321-6. 10: Meyer et al. Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse. Pharmacogenomics. 2011 Feb;12(2):215-3. 11: Evoxac FDA Prescribing Label. 12: Cerdelga FDA Prescribing Label. 13: Brown JT, Bishop JR, Sangkuhl K, Nurmi EL, Mueller DJ, Dinh JC, Gaedigk A, Klein TE, Caudle KE, McCracken JT, de Leon J, Leeder JS. Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy. Clin Pharmacol Ther. 2019 Feb 22. 14: Pharmacogene Variation (PharmVar) Consortium. PharmVar CYP2D6. https://www.pharmvar.org/gene/CYP2D6. Published 2019. Accessed January 6, 2020. 15: Nofziger C, Turner AJ, Sangkuhl K, et al. PharmVar GeneFocus: CYP2D6. Clin Pharmacol Ther. 2020;107(1):154-170. 16: Gaedigk A. Complexities of CYP2D6 gene analysis and interpretation. Int Rev Psychiatry. 2013;25(5):534-553. 17: Pharmacogene Variation (PharmVar) Consortium. Structural Variation CYP2D6. 2019:9. https://a.storyblok.com/f/70677/x/2de9d1f5e1/cyp2d6_structural-variation_v1-7.pdf. Accessed January 6, 2020. 18: Caudle KE, Sangkuhl K, Whirl-Carrillo M, et al. Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clin Transl Sci. October 2019.

CYP3A4 Monograph

Clinical Utility

The cytochrome P450 3A4 and 3A5 (CYP3A4 and CYP3A5) account for 40-80% of total CYP in human liver and intestine, respectively. Most importantly, CYP3A enzymes metabolize 50% of commonly used drugs. CYP3A4 and CYP3A5 enzymes have overlapping substrate specificity, and the contribution of CYP3A5 in the overall metabolism is smaller than the one for CYP3A4. The overall CYP3A metabolism status is expected to affect drugs that have a narrow therapeutic index.

Assay Interpretation

A limited number of variants identified within the CYP3A4 and CYP3A5 genes have been associated with significant alterations in enzyme activity and subsequent variability in therapeutic response. For CYP3A5, individuals with the less prevalent "normal metabolizer phenotype" may metabolize drugs faster than those with the more common "poor metabolizer phenotype". This may result in increased toxicity or loss of efficacy.

The CYP3A4*1B variant is the most studied, and results in an enzyme with a moderately decreased activity. It occurs in 50% of African-Americans, 3-5% of Caucasians, and <1% of Asians. The CYP3A4*2, *3, *12, and *17 are also considered decreased activity alleles. Recently, the CYP3A4 *22 allele has been characterized as a decreased function allele that can be clinically relevant (associated with a decreased clearance of certain substrates). The genotype-phenotype relationship for CYP3A4 is not well established, and individuals are predicted to have a CYP3A4 normal or intermediate metabolic capacity.

The reference range for CYP3A4 metabolic status is CYP3A4 *1/ *1, which is consistent with a normal metabolizer.

The variant results in an enzyme with no activity, and is the most common variant in the general population. This variant is found on all the CYP3A5*3 alleles. The CYP3A5 *6 and *7 are also no function alleles. The functional effects of the CYP3A5 alleles *2, *4, *5 *8, and *9 are not well established. The CYP3A5 *1 functional allele produces an active enzyme, and is found in 5% of Caucasians, 20% of Asians, and 15-50% of Africans. Individuals with two CYP3A5 no function alleles are classified as poor metabolizers while those carrying one copy of a functional CYP3A5*1 allele are considered intermediate metabolizers. A subject carrying two copies of the functional CYP3A5*1 allele is considered a normal metabolizer. **CYP3A5 poor metabolizers represent 50% of Asians and 90% of Caucasians.**

The reference range for CYP3A5 metabolic status is CYP3A5 *1/*1, which is consistent with a normal metabolizer. This genotype is the least prevalent in Caucasians and Asians.

Clinical Implications



 NAME:
 Patient m0bwvya

 ACC #:
 m0bwvya

 DOB:
 1/1/1900

SEX:

PATIENT INFORMATION

SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE: 11/11/2022

SPECIMEN DETAILS



PATIENT INFORMA	TION
PATIENT INFORMA	

 NAME:
 Patient m0bwvya

 ACC #:
 m0bwvya

 DOB:
 1/1/1900

 SEX:
 Image: Market Market

SPECIMEN DETAILS

SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE: 11/11/2022

FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE

CYP3A4 and CYP3A5 genotypes can help identify patients with high or low overall CYP3A activity. Although these two enzymes metabolize many drugs, the response of only a few (such as narrow therapeutic index drugs) is expected to change significantly by genetic polymorphisms. Fentanyl (Duragesic) is a narrow therapeutic drug that is mainly metabolized by CYP3A. There is limited evidence suggesting that the response to this drug is altered in individuals with abnormal CYP3A activity.

The following drugs used in pain management and various psychiatric conditions are metabolized extensively by CYP3A: fentanyl (Duragesic), oxycodone (Oxycontin), buprenorphine (Suboxone), carbamazepine (Tegretol), quetiapine (Seroquel), ziprasidone (Geodon), alprazolam (Xanax), midazolam (Versed), triazolam (Halcion), nefazodone (Serzone), trazodone (Oleptro), vilazodone (Vibryd), zaleplon (Sonata), and zolpidem (Ambien). CYP3A contributes to a small extent in the elimination of methadone (Dolophine).

Within the major therapeutic classes used in cardiovascular conditions, the following drugs are substantially metabolized by CYP3A: atorvastatin (Lipitor), simvastatin (Zocor), lovastatin (Mevacor), nifedipine (Procardia), verapamil (Verelan), nicardipine (Cardene), felodipine (Plendil), nisoldipine (Sular), clopidogrel (Plavix), prasugrel (Effient), ticagrelor (Brilinta), cilostazol (Pletal), amiodarone (Cordarone), quinidine (Qualaquin), disopyramide (Norpace), losartan (Cozaar), rivaroxaban (Xarelto), and apixaban (Eliquis).

CYP3A metabolism is highly sensitive to inhibition and induction when a patient is taking multiple drugs. In this case, occurrence of drug-drug interactions can have profound effects on the pharmacokinetics, as well as the responses and safety profiles of many CYP3A drug substrates.

Inhibitors

Some known **strong** CYP3A inhibitors include: boceprevir (Victrelis), clarithromycin (Biaxin), clofazimine (Lamprene), conivaptan (Vaprisol), grapefruit juice (high dose), idelalisib (Zydelig), itraconazole (Sporanox), ketoconazole (Nizoral), lopinavir, (Kaletra), nefazodone (Serzone), nelfinavir (Viracept), paritaprevir (Technivie), posaconazole (Noxafil), ribociclib (Kisqali), ritonavir (Norvir), saquinavir (Invirase), telaprevir (Incivek), telithromycin (Ketek), tipranavir (aptivus), troleandomycin (TAO) and voriconazole (Vfend).

Some known **moderate** CYP3A inhibitors include: amprenavir (agenerase), aprepitant (Emend), atazanavir (Reyataz), ciprofloxacin (Cipro), darunavir (Prezista), diltiazem (cardizem), erythromycin (Eryc), fosamprenavir (Lexiva), fluconazole (Diflucan), grapefruit juice (low dose), imatinib (Gleevec), quinupristin/dalfopristin (Synercid) and verapamil (Isoptin, Covera-HS).

Some known **weak** CYP3A inhibitors include: amiodarone (Cordarone), amlodipine (Norvasc), atorvastatin (Lipitor), bicalutamide (Casodex), cilostazol (Pletal), cimetidine (Tagamet), fluoxetine (Prozac), fluoxamine (Luvox), ranitidine (Zantac), ranolazine (Ranexa), sertraline (Zoloft) and ticagrelor (Brilinta).

Inducers

Some known **strong** CYP3A inducers include: apalutamide (Erleada), carbamazepine (Tegretol), enzalutamide (Xtandi), fosphenytoin (Cerebyx), lumacaftor (Orkambi), phenobarbital, phenytoin (Dilantin), primidone (Mysoline), rifampin (Rifadin), rifapentine (Priftin) and St. John's wort.

Some known **moderate** CYP3A inducers include: artemether (Coartem), bosentan (Tracleer), dabrafenib (Tafinlar), efavirenz (Sustiva), etravirine (Intelence), ivosidenib (tibsovo), modafinil (Provigil), nafcillin (Unipen), nevirapine (Viramune) and rifabutin (Mycobutin).

Some known **weak** CYP3A inducers include: aprepitant (Emend), clobazam (Onfi), dexamethasone (Decadron), Echinacea, fosamprenavir (Lexiva), lesinurad (Zurampic), methylprednisolone (Medrol), midostaurin (Rydapt), oxcarbazepine (Trileptal), pioglitazone (Actos) and rufinamide (Banzel).

References

1- Metabolic Drug Interactions. RH Levy, KE Thummel, WF Trager. Publisher: Lippincott Williams & Wilkins (March 15, 2000). 2: Zhou et al. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009;41(2):89-295 3- Isoherranen et al. The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation. Drug Metab Dispos. 2008 Jan;36(1):146-54. 4- Williams et al. A significant drug-metabolizing role for CYP3A5? Drug Metab Dispos. 2003 Dec;31(12):1526-30. 5- Elens et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem. 2011 Nov;57(11):1574-83. 6- Elens et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics. 2011 Oct;12 (10):1383-96. 7-Lamba et al. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2002 Nov 18;54(10):1271-94.

CYP3A5 Monograph

Clinical Utility

The cytochrome P450 3A4 and 3A5 (CYP3A4 and CYP3A5) account for 40-80% of total CYP in human liver and intestine, respectively. Most importantly, CYP3A enzymes metabolize 50% of commonly used drugs. CYP3A4 and CYP3A5 enzymes have overlapping substrate specificity, and the contribution of CYP3A5 in the overall metabolism is smaller than the one for CYP3A4. The overall CYP3A metabolism status is expected to affect drugs that have a narrow therapeutic index.





NAME: Patient m0bwvya ACC #: m0bwvya DOB: 1/1/1900 SEX: SPECIMEN DETAILS

ORDERED BY

SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE: 11/11/2022

FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE

Assay Interpretation

A limited number of variants identified within the CYP3A4 and CYP3A5 genes have been associated with significant alterations in enzyme activity and subsequent variability in therapeutic response. For CYP3A5, individuals with the less prevalent "normal metabolizer phenotype" may metabolize drugs faster than those with the more common "poor metabolizer phenotype". This may result in increased toxicity or loss of efficacy.

The CYP3A4*1B variant is the most studied, and results in an enzyme with a moderately decreased activity. It occurs in 50% of African-Americans, 3-5% of Caucasians, and <1% of Asians. The CYP3A4*2, *3, *12, and *17 are also considered decreased activity alleles. Recently, the CYP3A4 *22 allele has been characterized as a decreased function allele that can be clinically relevant (associated with a decreased clearance of certain substrates). The genotype-phenotype relationship for CYP3A4 is not well established, and individuals are predicted to have a CYP3A4 normal or intermediate metabolic capacity.

The reference range for CYP3A4 metabolic status is CYP3A4 *1/ *1, which is consistent with a normal metabolizer.

The variant results in an enzyme with no activity, and is the most common variant in the general population. This variant is found on all the CYP3A5*3 alleles. The CYP3A5 *6 and *7 are also no function alleles. The functional effects of the CYP3A5 alleles *2, *4, *5 *8, and *9 are not well established. The CYP3A5 *1 functional allele produces an active enzyme, and is found in 5% of Caucasians, 20% of Asians, and 15-50% of Africans. Individuals with two CYP3A5 no function alleles are classified as poor metabolizers while those carrying one copy of a functional CYP3A5*1 allele are considered intermediate metabolizers. A subject carrying two copies of the functional CYP3A5*1 allele is considered a normal metabolizer. **CYP3A5 poor metabolizers represent 50% of Asians and 90% of Caucasians.**

The reference range for CYP3A5 metabolic status is CYP3A5 *1/*1, which is consistent with a normal metabolizer. This genotype is the least prevalent in Caucasians and Asians.

Clinical Implications

CYP3A4 and CYP3A5 genotypes can help identify patients with high or low overall CYP3A activity. Although these two enzymes metabolize many drugs, the response of only a few (such as narrow therapeutic index drugs) is expected to change significantly by genetic polymorphisms. Fentanyl (Duragesic) is a narrow therapeutic drug that is mainly metabolized by CYP3A. There is limited evidence suggesting that the response to this drug is altered in individuals with abnormal CYP3A activity.

The following drugs used in pain management and various psychiatric conditions are metabolized extensively by CYP3A: fentanyl (Duragesic), oxycodone (Oxycontin), buprenorphine (Suboxone), carbamazepine (Tegretol), quetiapine (Seroquel), ziprasidone (Geodon), alprazolam (Xanax), midazolam (Versed), triazolam (Halcion), nefazodone (Serzone), trazodone (Oleptro), vilazodone (Vibryd), zaleplon (Sonata), and zolpidem (Ambien). CYP3A contributes to a small extent in the elimination of methadone (Dolophine).

Within the major therapeutic classes used in cardiovascular conditions, the following drugs are substantially metabolized by CYP3A: atorvastatin (Lipitor), simvastatin (Zocor), lovastatin (Mevacor), nifedipine (Procardia), verapamil (Verelan), nicardipine (Cardene), felodipine (Plendil), nisoldipine (Sular), clopidogrel (Plavix), prasugrel (Effient), ticagrelor (Brilinta), cilostazol (Pletal), amiodarone (Cordarone), quinidine (Qualaquin), disopyramide (Norpace), losartan (Cozaar), rivaroxaban (Xarelto), and apixaban (Eliquis).

CYP3A metabolism is highly sensitive to inhibition and induction when a patient is taking multiple drugs. In this case, occurrence of drug-drug interactions can have profound effects on the pharmacokinetics, as well as the responses and safety profiles of many CYP3A drug substrates.





NAME: Patient m0bwvya ACC #: m0bwvya DOB: 1/1/1900 SEX: SPECIMEN DETAILS

SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE: 11/11/2022

FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE

Inhibitors

Some known **strong** CYP3A inhibitors include: boceprevir (Victrelis), clarithromycin (Biaxin), clofazimine (Lamprene), conivaptan (Vaprisol), grapefruit juice (high dose), idelalisib (Zydelig), itraconazole (Sporanox), ketoconazole (Nizoral), lopinavir, (Kaletra), nefazodone (Serzone), nelfinavir (Viracept), paritaprevir (Technivie), posaconazole (Noxafil), ribociclib (Kisqali), ritonavir (Norvir), saquinavir (Invirase), telaprevir (Incivek), telithromycin (Ketek), tipranavir (aptivus), troleandomycin (TAO) and voriconazole (Vfend).

Some known **moderate** CYP3A inhibitors include: amprenavir (agenerase), aprepitant (Emend), atazanavir (Reyataz), ciprofloxacin (Cipro), darunavir (Prezista), diltiazem (cardizem), erythromycin (Eryc), fosamprenavir (Lexiva), fluconazole (Diflucan), grapefruit juice (low dose), imatinib (Gleevec), quinupristin/dalfopristin (Synercid) and verapamil (Isoptin, Covera-HS).

Some known **weak** CYP3A inhibitors include: amiodarone (Cordarone), amlodipine (Norvasc), atorvastatin (Lipitor), bicalutamide (Casodex), cilostazol (Pletal), cimetidine (Tagamet), fluoxetine (Prozac), fluoxamine (Luvox), ranitidine (Zantac), ranolazine (Ranexa), sertraline (Zoloft) and ticagrelor (Brilinta).

Inducers

Some known **strong** CYP3A inducers include: apalutamide (Erleada), carbamazepine (Tegretol), enzalutamide (Xtandi), fosphenytoin (Cerebyx), lumacaftor (Orkambi), phenobarbital, phenytoin (Dilantin), primidone (Mysoline), rifampin (Rifadin), rifapentine (Priftin) and St. John's wort.

Some known **moderate** CYP3A inducers include: artemether (Coartem), bosentan (Tracleer), dabrafenib (Tafinlar), efavirenz (Sustiva), etravirine (Intelence), ivosidenib (tibsovo), modafinil (Provigil), nafcillin (Unipen), nevirapine (Viramune) and rifabutin (Mycobutin).

Some known **weak** CYP3A inducers include: aprepitant (Emend), clobazam (Onfi), dexamethasone (Decadron), Echinacea, fosamprenavir (Lexiva), lesinurad (Zurampic), methylprednisolone (Medrol), midostaurin (Rydapt), oxcarbazepine (Trileptal), pioglitazone (Actos) and rufinamide (Banzel).

References

1- Metabolic Drug Interactions. RH Levy, KE Thummel, WF Trager. Publisher: Lippincott Williams & Wilkins (March 15, 2000). 2: Zhou et al. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009;41(2):89-295 3- Isoherranen et al. The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation. Drug Metab Dispos. 2008 Jan;36(1):146-54. 4- Williams et al. A significant drug-metabolizing role for CYP3A5? Drug Metab Dispos. 2003 Dec;31(12):1526-30. 5- Elens et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem. 2011 Nov;57(11):1574-83. 6- Elens et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics. 2011 Oct;12 (10):1383-96. 7-Lamba et al. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2002 Nov 18;54(10):1271-94.





PATIENT INFORMATION

NAME: Patient m0bwvya ACC #: m0bwvya DOB: 1/1/1900 SEX: SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE:

REPORT DATE: 11/11/2022

Factor II Monograph

Clinical Utility

The F2 gene encodes the coagulation factor II, or prothrombin. It is a vitamin K–dependent proenzyme that functions in the blood coagulation cascade. It is a precursor to thrombin, which converts fibrinogen into fibrin, which in turn strengthens a protective clot.

The F2 c.*97G>A variant (also known as Factor II 20210G>A) in the F2 gene results in increased levels of plasma prothrombin and a concurrent increased risk for thrombosis. Prothrombin-related thrombophilia is characterized by venous thromboembolism (VTE). This risk of thrombosis is also increased when variants exist for other coagulation factors such as F5 c.1601G>A variant (also known as Factor V Leiden), or in presence of non-genetic risk factors such as obesity, injury, surgery, smoking, pregnancy, use of estrogen-containing contraceptives, or replacement therapy. The clinical expression of prothrombin-related thrombophilia is variable, and many individuals may never develop thrombosis, while others may experience venous thrombotic events or pregnancy complications.

Assay Interpretation

The Factor II thrombophilia is the second most common inherited risk factor for thrombosis. The F2 c.*97G>A variant (also known as Factor II 20210G>A) is associated with a hypercoagulable state. In the United States, the prevalence of this variant is 1.1% in Caucasians and Hispanics and 0.3% in African-Americans. The prevalence of heterozygosity is 2%-5% in whites and 0%-0.3% in African-Americans. The prevalence of homozygosity is approximately one in 10,000.

The reference range for F2 c.*97G>A variant is F2 c.*97G>A G/G.

Clinical Implications

The F2 c.*97G>A variant is associated with an elevation of plasma prothrombin levels to about 30% above normal in heterozygotes and to 70% above normal in homozygotes. Heterozygotes are at a 2- to 5-fold increased risk of an initial VTE. The risk for VTE in F2 c.*97G>A homozygotes is not well defined but is presumed to be higher than in F2 c.*97G>A heterozygotes. F2 c.*97G>A homozygotes tend to develop thrombosis more frequently and at a younger age. Individuals who are doubly heterozygotes for F5 c.1601G>A variant and F2 c.*97G>A variant have an estimated 20-fold increased risk when compared to individuals without either variant suggesting a multiplicative elevation in risk. Certain circumstantial factors can increase the risk of thrombosis, and include: travel, central venous catheter use, pregnancy, oral contraceptive use, hormone replacement therapy (HRT), selective estrogen receptor modulators (SERMs), organ transplantation, injury, age, and surgery.

References

1: Kujovich JL. Prothrombin-Related Thrombophilia. 2006 Jul 25 [updated 2014 Aug 14]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018. **2**: Grody WW, Griffin JH, Taylor AK, Korf BR, Heit JA; ACMG Factor V. Leiden Working Group. American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med. 2001 Mar-Apr;3(2):139-48. **3**: Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: routine testing for Factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members. Genet Med. 2011 Jan;13(1):67-76. **4**: Segal JB, Brotman DJ, Necochea AJ, Emadi A, Samal L, Wilson LM, Crim MT, Bass EB. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. JAMA. 2009 Jun 17;301(23):2472-85. **5**: Zhang S, Taylor AK, Huang X, Luo B, Spector EB, Fang P, Richards CS; ACMG Laboratory Quality Assurance Committee. Venous thromboembolism laboratory testing (factor V Leiden and factor II c.*97G>A), 2018 update: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2018 Oct 5. **6**: Promacta [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2017. **7** : Dopletet [package insert]. Durham, NC: Dova Pharmaceuticals, Inc.; 2018. **8**: Mulpleta [package insert]. Florham Park, NJ: Shionogi, Inc.; 2018.





PATIENT INFORMATION

NAME: Patient m0bwvya ACC #: m0bwvya DOB: 1/1/1900 SEX:

SPECIMEN DETAILS

SPECIMEN TYPE: COLLECTION DATE: **RECEIVED DATE:** REPORT DATE: 11/11/2022

Factor V Leiden Monograph

Clinical Utility

The F5 gene encodes the coagulation factor V. In normal conditions, Factor V is inactivated during the clotting process by the activated protein C (APC). In subjects with Factor V Leiden thrombophilia, a variant in the gene produces a Factor V that cannot be inactivated normally by APC. As a result, the clotting process remains active longer than usual, leading to more thrombin generation. This hypercoagulable state is also increased when other variants exist in other coagulation factors such as F2 c.*97G>A variant (also known as Factor II 20210G>A), or in the presence of non-genetic risk factors such as obesity, injury, surgery, smoking, pregnancy, or use of estrogen-containing contraceptive or estrogen containing replacement therapy. The clinical expression of Factor V Leiden thrombophilia is variable. Many individuals may never develop thrombosis, while others may experience venous thrombotic events or pregnancy complications. Certain circumstantial factors can increase the risk of thrombosis, and include: travel, central venous catheter use, pregnancy, oral contraceptive use, hormone replacement therapy (HRT), selective estrogen receptor modulators (SERMs), organ transplantation, injury, age, and surgery. These factors are associated with the first thrombotic episode in at least 50% of individuals with a F5 c.1601G>A variant.

Assay Interpretation

The F5 c.1601G>A variant (also known as Factor V Leiden) is the most common known inherited risk factor for thrombosis. The F5 c.1601G>A variant refers to a base change (from G to A at position 1691) in the gene. As a result, Factor V is inactivated to a lesser extent and persists for longer in the circulation, leading to hypercoagulability. In the US, the frequency of the F5 c.1601G>A variant varies by ethnicity, with about 5% of Caucasians, 2% of Hispanics, and 1% of African-Americans having one variant. Only 1 in 5000 individuals have two F5 c.1601G>A variants.

The reference range for F5 c.1601G>A variant is F5 c.1601G>A G/G.

Clinical Implications

About 1 in 1000 people in the U.S. experience a first venous thromboembolism (VTE) each year. VTE is caused by inherited and environmental factors, and while the F5 c.1601G>A variant is present in only 15-20% of individuals with a first VTE, it is found in 50% of individuals with recurrent VTE or estrogen-related thrombosis. The risk for VTE is increased 3- to 8-fold in F5 c.1601G>A heterozygotes and 9- to 80-fold in homozygotes. This risk is increased further if other genetic or circumstantial factors are present. A heterozygote individual for both the F5 c.1601G>A variant and the F2 c.*97G>A variant (compound heterozygote) has an even greater risk of VTE (20-fold) than an individual with a variant in only one factor. This illustrates the multiplicative effect of these two factors on overall thrombotic risk.

References

1: Kujovich JL. Factor V Leiden Thrombophilia. 1999 May 14 [updated 2018 Jan 4]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews @ [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018. 2: Grody WW, Griffin JH, Taylor AK, Korf BR, Heit JA; ACMG Factor V. Leiden Working Group. American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med. 2001 Mar-Apr;3(2):139-48. 3: Rosendaal FR, Reitsma PH. Genetics of venous thrombosis. J Thromb Haemost. 2009 Jul;7 Suppl 1:301-4. 4: Bezemer ID, van der Meer FJ, Eikenboom JC, Rosendaal FR, Doggen CJ. The value of family history as a risk indicator for venous thrombosis. Arch Intern Med. 2009 Mar 23;169(6):610-5. 5: Segal JB, Brotman DJ, Necochea AJ, Emadi A, Samal L, Wilson LM, Crim MT, Bass EB. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. JAMA. 2009 Jun 17;301(23):2472-85. 6: Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: routine testing for Factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members. Genet Med. 2011 Jan;13(1):67-76. 7: Zhang S, Taylor AK, Huang X, Luo B, Spector EB, Fang P, Richards CS; ACMG Laboratory Quality Assurance Committee. Venous thromboembolism laboratory testing (factor V Leiden and factor II c.*97G>A), 2018 update: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2018 Oct 5. 8: Promacta [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2017. 9: Dopletet [package insert]. Durham, NC: Dova Pharmaceuticals, Inc.; 2018. 10: Mulpleta [package insert]. Florham Park, NJ: Shionogi, Inc.; 2018.

MTHFR Monograph

Clinical Utility

Methylenetetrahydrofolate reductase (MTHFR) is involved in folate metabolism and is essential for the remethylation of homocysteine. Two common variants in the MTHFR gene: c.665C>T (legacy name 677C>T) and c.1286A>C (legacy name 1298A>C), result in an enzyme with decreased activity, which is linked to increased plasma homocysteine levels (i.e. hyperhomocysteinemia). Mild to moderate hyperhomocysteinemia has been identified as a risk factor for venous thromboembolism and other cardiovascular diseases such as coronary heart disease and stroke. Other conditions in which hyperhomocysteinemia is found, include recurrent pregnancy loss, placental infarction and birth defects. However, the causal role of MTHFR variants in these conditions is not well established.





SPECIMEN DETAILS

 NAME:
 Patient m0bwvya

 ACC #:
 m0bwvya

 DOB:
 1/1/1900

 SEX:

SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE: 11/11/2022

FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE

Assay Interpretation

The approximate minor allele frequencies for most populations are 30-50% for the MTHFR c.1286A>C variant and 18-30% for the MTHFR c.665C>T variant. Heterozygotes and homozygotes for the MTHFR c.665C>T variant have 60% and 30% of normal MTHFR activity, respectively. Heterozygotes and homozygotes for the MTHFR c.1286A>C variant have 80% and 60% of normal MTHFR activity, respectively.

The reference ranges for both variants of MTHFR are c.665C>T C/C and c.1286A>C A/A. This is consistent with a normal MTHFR activity.

Clinical Implications

The MTHFR assay provides information about potential causes of elevated homocysteine, and approaches for addressing it.

- Homozygosity for the MTHFR c.665C>T variant (individual with MTHFR c.665C>T T/T genotype) predisposes for hyperhomocysteinemia (especially during times of folate insufficiency) and an increase in premature cardiovascular disease. Measurement of total plasma homocysteine is informative in this case.
- Compound heterozygosity (individual with MTHFR c.665C>T C/T and MTHFR c.1286A>C A/C genotypes) is not associated with an increase in plasma homocysteine level. Measurement of total plasma homocysteine is informative in this case.
- Heterozygosity or homozygosity for the MTHFR c.1286A>C A>C variant alone (individual with MTHFR c.1286A>C A/C or MTHFR c.1286A>C C/C genotypes) does not increase homocysteine levels. Similarly, heterozygosity for the MTHFR c.665C>T variant alone (individuals with MTHFR c.665C>T C/T genotype) does not increase homocysteine levels.
- Hyperhomocysteinemia related to MTHFR genetic variants has been associated with neural tube defects, stillbirths and recurrent pregnancy loss. However, because hyperhomocysteinemia is multifactorial, involving a combination of other genetic, physiologic and environmental factors, the presence of MTHFR variants in an individual should not be used alone to predict the risk of these conditions.
- MTHFR in depression: Low MTHFR activity may exacerbate folate deficiency in patients with depression and may increase the risk of depressive relapse or delay the response to antidepressants. Testing for homocysteine levels and serum folate levels are recommended in patients with depression. Methylfolate may substantially benefit patients with hyperhomocysteinemia and depression when used as an adjuvant to antidepressant medication.
- The response to methotrexate, a drug used in cancer and autoimmune diseases, is affected by the presence of MTHFR genetic variants. Methotrexate intolerance is observed in individuals that are heterozygous or homozygous for the MTHFR c.665C>T variant.

References

1: van der Put, A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet. 1998 May;62(5):1044-51. 2: Lewis et al. Meta-analysis of MTHFR 677C->T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate? BMJ. 2005 Nov5;331(7524):1053. 3: Kluijtmans et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet. 1996 Jan;58(1):35-41. 4: Hickey et al. ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing. Genet Med. 2013 Feb;15(2):153-6. 5: Grody et al. ACMG Factor V. Leiden Working Group. American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med. 2001 Mar-Apr;3(2):139-48. 6: Gatt et al. Hyperhomocysteinemia and venous thrombosis. Semin Hematol. 2007 Apr;44(2):70-6. 7: De Mattia E, Toffoli G. C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation. Eur J Cancer. 2009 May;45(8):1333-51. 8: Toffoli et al. Pharmacogenetic relevance of MTHFR polymorphisms. Pharmacogenomics. 2008 Sep;9(9):1195-206. 9: Clarke et al. MTHFR Studies Collaborative Group. Homocysteine and coronary heart disease: meta-analysis of MTHFR case-control studies, avoiding publication bias. PLoS Med. 2012 Feb;9 (2) 10: Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab. 1998 Jul;64(3):169-72. 11: Weisberg et al. The 1298A-->C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine. Atherosclerosis. 2001 Jun;156(2):409-15. 12: Papakostas GI, Shelton RC, Zajecka JM, Etemad B, Rickels K, Clain A, Baer L, Dalton ED, Sacco GR, Schoenfeld D, Pencina M, Meisner A, Bottiglieri T, Nelson E, Mischoulon D, Alpert JE, Barbee JG, Zisook S, Fava M. L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry. 2012 Dec;169(12):1267-74. 13: Coppen A, Bolander-Gouaille C. Treatment of depression: time to consider folic acid and vitamin B12. J Psychopharmacol. 2005 Jan;19(1):59-65. 14: Reynolds EH. Methylfolate as adjunctive treatment in major depression. Am J Psychiatry. 2013 May;170(5):560. 15: Lewis SJ, Araya R, Leary S, Smith GD, Ness A. Folic acid supplementation during pregnancy may protect against depression 21 months after pregnancy, an effect modified by MTHFR C677T genotype. Eur J Clin Nutr. 2012 Jan;66(1):97-103. 16: Delport D, Schoeman R, van der Merwe N, van der Merwe L, Fisher LR, Geiger D, Kotze MJ. Significance of dietary folate intake, homocysteine levels and MTHFR 677 C>T genotyping in South African patients diagnosed with depression: test development for clinical application. Metab Brain Dis. 2014 Jun;29(2):377-84. 17: Shelton RC, Sloan Manning J, Barrentine LW, Tipa EV. Assessing Effects of I-Methylfolate in Depression Management: Results of a Real-World Patient Experience Trial. Prim Care Companion CNS Disord. 2013;15(4). 18: Mischoulon D, Lamon-Fava S, Selhub J, Katz J, Papakostas GI, Iosifescu DV, Yeung AS, Dording CM, Farabaugh AH, Clain AJ, Baer L, Alpert JE, Nierenberg AA, Fava M. Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment. CNS Spectr. 2012 Jun;17 (2):76-86.





PATIENT INFORMATION

NAME: Patient m0bwvya ACC #: m0bwvya DOB: 1/1/1900 SEX:

SPECIMEN DETAILS

SPECIMEN TYPE: COLLECTION DATE: **RECEIVED DATE: REPORT DATE:**

11/11/2022

OPRM1 Monograph

Clinical Utility

"Mu" opioid receptors are the most important site of action of opioid drugs. Single polymorphisms in the human mu-opioid receptor (OPRM1) have been investigated for their role in human nociception, opiate efficacy, and addiction.

Assay Interpretation

The variant mostly studied is a single substitution at position 118, from an adenine to a quanine (A118G). This variant reduces the OPRM1 receptor signaling efficiency induced by exogenous opioids. Reduced OPRM1 mRNA expression levels were observed in carriers of the G variant. The variant allele (G) is present in 7-15% of Caucasians, 1.5% of African-Americans, and up to 48.5% of Asians. The major interest of this particular SNP is due to its pharmacological and physiological consequences; however the exact mechanism by which the altered receptor influences opioid analgesia is still unresolved. The presence of the G allele seems to reduce the effect of exogenous agonists but increase the effects of exogenous antagonists.

The reference range for the A118G SNP is A118G AA, and is associated with a normal OPRM1 receptor signaling efficiency.

Clinical Implications

The presence of the G allele (A118G) seems to be associated with pain sensitivity as well as opioid dosage requirements. But only weak evidence of these associations is available to date. It is suggested that patients carrying the G allele report higher intensity pain. In terms of drug response, patients with the G allele have a favorable response to the anti-addictive drug naltrexone. Several studies conducted in postsurgical settings or in cancer analgesia showed that G allele carriers require slightly higher doses of morphine or fentanyl. This association still needs to be confirmed in larger studies and does not hold in other situations such as labor pain.

References

1: Wu et al. Polymorphism of the micro-opioid receptor gene (OPRM1 118A>G) affects fentanyl-induced analgesia during anesthesia and recovery. Mol Diagn Ther. 2009;13(5):331-7. 2: Menon et al. The human µ-opioid receptor gene polymorphism (A118G) is associated with head pain severity in a clinical cohort of female migraine with aura patients. J Headache Pain. 2012Oct;13(7):513-9. 3: Olsen et al. Pain intensity the first year after lumbar disc herniation is associated with theA118G polymorphism in the opioid receptor mu 1 gene: evidence of a sex and genotype interaction. J Neurosci. 2012 Jul 18;32(29):9831-4. 4: Reyes-Gibby et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain. 2007 Jul;130(1-2):25-30. 5: Lötsch et al. Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenet Genomics. 2009 Jun;19(6):429-36. 6: Walter C, Lötsch J. Metaanalysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment. Pain. 2009 Dec;146(3):270-5. 7: Zhang et al. Association of human micro-opioid receptor gene polymorphism A118G with fentanyl analgesia consumption in Chinese gynaecological patients. Anaesthesia. 2010Feb;65(2):130-5. 8: Zhang et al. Study of the OPRM1 A118G genetic polymorphism associated with postoperative nausea and vomiting induced by fentanyl intravenous analgesia. Minerva Anestesiol. 2011 Jan;77 (1):33-9. 9: Oertel et al. The mu-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet Genomics. 2006 Sep;16(9):625-36. 10: Zwisler et al. Lack of Association of OPRM1 and ABCB1 Single-Nucleotide Polymorphisms to Oxycodone Response in Postoperative Pain. J Clin Pharmacol. 2011 Mar 24. 11: Klepstad et al. Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients. Pain. 2011 May;152(5):1139-45. 12: Kadiev E, et al. Role of pharmacogenetics in variable response to drugs: focus on opioids. Expert Opin Drug Metab Toxicol. 2008 Jan:4(1):77-91. 13: Vuilleumier et al. Pharmacogenomic considerations in opioid analgesia. Pharmagenomics Pers Med. 2012;5:73-87. 14: Walter et al. µ-opioid receptor gene variant OPRM1 118 A>G: a summary of its molecular and clinical consequences for pain. Pharmacogenomics. 2013 Nov;14(15):1915-25. 15: Thorsell A. The µ-opioid receptor and treatment response to naltrexone. Alcohol Alcohol. 2013 Jul-Aug;48(4):402-8. 16: Setiawan et al. Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone. Pharmacogenomics. 2012 Jul;13(10):1161-72. 17: Kranzler et al. Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment. Addict Biol. 2013 Jan;18 (1):193-201. 18: Chamorro et al. Association of µ-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis. Addict Biol. 2012 May;17(3):505-12.

SLCO1B1 Monograph

Clinical Utility

The SLCO1B1 gene encodes a liver-specific transporter involved in the removal of endogenous compounds (bile acids, bilirubin) and drugs such as statins from the blood to the liver. Some variants of the SLCO1B1 gene result in a low-functioning protein, which impairs statin clearance, and may lead to an increased risk of muscle pain, tenderness, or weakness, called myopathy. Certain medications can potently inhibit SLCO1B1, causing clinically significant drug interactions.

Assay Interpretation





 NAME:
 Patient m0bwvya

 ACC #:
 m0bwvya

 DOB:
 1/1/1900

 SEX:
 Image: Marcine Marcine

SPECIMEN DETAILS

SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE: 11/11/2022

FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE

The functional SLCO1B1 activity (phenotype) is estimated from the genotype at 521T>C. Non-carriers of the 521T>C variant are predicted to have a SLCO1B1 normal function, those with one copy of the 521T>C variant have a SLCO1B1 decreased function, and those with two copies of the variant have poor SLCO1B1 function.

There are several variants of the SLCO1B1 that define over 15 alleles. One relatively common variant 521T>C (rs4149056) results in SLCO1B1 decreased function, which affects the transport of drug substrates such as statins. This variant is present alone on the *5 allele and in presence with another variant (388A>G; rs2306283) on the *15 allele. Both alleles are low-activity alleles (reduced hepatic uptake), and have a combined frequency of 15-20% in Caucasians, 10-15% in Asians, and 2% in sub-Saharan Africans and African-Americans.

The reference range for the 521T>C mutation of SLCO1B1 is 521 TT. This is consistent with normal SLCO1B1 function.

Clinical Implications

All statins are substrates of SLCO1B1, but the effects of SLCO1B1 genetic polymorphism differ between individual statins. The effect is the largest on simvastatin, and individuals with the 521T>C variant have increased levels of the active simvastatin form. The variant is strongly associated with simvastatin-induced myopathy (with or without CK elevation), especially with high-dose simvastatin therapy. More than 60% of the myopathy cases could be attributed to its presence. The clinical spectrum of statin-induced myopathy ranges from a mild and common myalgia to a life-threatening and rare rhabdomyolysis. Other known risk factors for statin-induced myopathy include a high-statin dose, interacting drugs that raise statin levels, age, hypothyroidism, and certain inherited muscle disorders.

At therapeutic doses, the apparent sensitivity levels of the five statins to the presence of the 521T>C variant are

simvastatin>pitavastatin>atorvastatin>pravastatin>rosuvastatin. Carriers of the 521 T>C variant should avoid high-dose simvastatin therapy. These patients can take other statins, such as atorvastatin, pitavastatin, rosuvastatin, or pravastatin, but at reduced doses. Fluvastatin is not affected by the 521 T>C variant and could therefore be considered a suitable alternative.

Other drugs that are substrates of SLCO1B1 transporter include enalapril, olmesartan, valsartan, atrasentan, repaglinide, nateglinide, methotrexate, and bosentan. However, there is insufficient evidence documenting the impact of the 521 T>C variant on the systemic exposure and safety profile of these drugs.

Inhibitors

Inhibitors of SLCO1B1 transporter may alter its activity and result in increased levels of drug substrates. These include boceprevir (Victrelis), clarithromycin (Biaxin), cyclosporine (Gengraf, Neoral, Restasis, Sandimmune), eltrombopag (Promacta), gemfibrozil (Lopid), paritaprevir (Technivie), protease inhibitors, simeprevir (Olysio), telaprevir (Incivek) and teriflunomide (Aubagio).

Inducers

Inducers of SLCO1B1 transporter include: apalutamide (Erleada).

References

1: FDA Zocor Prescribing Label: http://www.accessdata.fda.gov 2: 1: Wilke et al. Clinical Pharmacogenomics Implementation Consortium (CPIC). The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther. 2012 Jul;92(1):112-7. 2: Feng et al. Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions. Pharmacogenomics.2012 Apr;13 (5):579-94. 3: Elsby et al. Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1. Clin Pharmacol Ther. 2012 Nov;92(5):584-98. 4: SEARCH Collaborative Group, Link E. SLCO1B1 variants and statin-induced myopathy--a genome wide study. N Engl J Med. 2008 Aug 21;359(8):789-99. 5: Nies et al. Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1. Genome Med. 2013 Jan 11;5(1):1. 6 : Niemi M. Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther. 2010 Jan;87(1):130-3. 7 : Niemi et al. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81. 8: Neuvonen et al. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006 Dec;80(6):565-81.





PATIENT INFORMATION

NAME: Patient m0bwvya ACC #: m0bwvya DOB: 1/1/1900 SEX: SPECIMEN DETAILS

SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE: 11/11/2022

VKORC1 Monograph

Clinical Utility

The Vitamin K epoxide reductase complex, subunit 1 (VKORC1) is the target of anticoagulants such as warfarin, acenocoumarol and phenprocoumon. VKORC1 catalyzes the conversion of oxidized Vitamin K to reduced Vitamin K. By inhibiting this conversion, warfarin leads to decreased availability of the reduced Vitamin K that serves as a cofactor for gamma-glutamyl carboxylase and blocks the formation of functionally-active clotting factors, resulting in reduced coagulation. Polymorphisms within the VKORC1 gene result in variable expression levels of the VKORC1 enzyme and altered response towards coumarin anticoagulants. VKORC1 genetic testing defines three clinical phenotypes: high, moderate, and low sensitivity to warfarin. VKORC1 genetic testing is usually used in conjunction with CYP2C9 and CYP4F2 genetic testing to optimize warfarin dosing and minimize the risks of bleeding or thrombotic complications.

Assay Interpretation

Several relevant variants in the VKORC1 gene have been identified and correlate well with warfarin dose requirements. In Europeans, the genotype for a single variant (-1694G>A; rs9923231) accounts for 25% of variability in warfarin dose requirements, with the minor A allele associated with lower doses. This association is also observed in East Asians, where the minor allele occurs more frequently than in Europeans (88% vs 41%). In Africans, the minor allele frequency for VKORC1 -1639G>A is 10% which is considerably lower than in Europeans. Several studies in Africans and African-Americans identified common variants that are associated with higher warfarin dose requirements in patients of African descent.

The reference range for VKORC1 -1639G>A is G/G and is associated with a normal VKORC1 enzyme expression phenotype.

Clinical Implications

The common VKORC1 -1639G>A variant is associated with low-dose warfarin requirements. When CYP2C9 and VKORC1 genotypes are combined with other patient-specific parameters such as demographic (age, weight, height), clinical (disease, co-medications), and environmental factors (smoking), they account for 50% of warfarin dose variation between individuals. Several validated warfarin pharmacogenetic dosing algorithms have been developed and are available to calculate initial and maintenance warfarin doses in both adults and children. Moreover, the FDA prescribing label for warfarin includes genotype-specific dose ranges based on CYP2C9 and VKORC1 genotypes.

References

1: Food and Drug Administration: Coumadin® Label accessed on Jan 2013. 2: Gage et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008 Sep;84(3):326-31 3: Schelleman et al. New genetic variant that might improve warfarin dose prediction in African Americans. Br J Clin Pharmacol. 2010 Sep;70(3):393-9 4: Johnson et al. Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther. 2011 Oct;90(4):625-9. 5: Klein et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. International Warfarin Pharmacogenetics Consortium. N Engl J Med. 2009 Feb 19;360 (8):753-64 6: Rieder et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005 Jun 2;352(22):2285-93. 7: Johnson JA, Caudle KE, Gong L, Whirl-Carrillo M, Stein CM, Scott SA, Lee MT, Gage BF, Kimmel SE, Perera MA, Anderson JL, Pirmohamed M, Klein TE, Limdi NA, Cavallari LH, Wadelius M. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017 Sep;102(3):397-404.





SPECIMEN DETAILS

 NAME:
 Patient m0bwvya

 ACC #:
 m0bwvya

 DOB:
 1/1/1900

 SEX:

SPECIMEN TYPE: COLLECTION DATE: RECEIVED DATE: REPORT DATE: 11/

11/11/2022

FOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USE

Patient Information Card

This is a summary genetic report for your patient to share with other healthcare providers. The card can be cut out along the dashed line and carried with the patient.

REPORT DETAILS Patient: Patient m0bwvya DOB: 1/1/1900 ACC #: m0bwvya Pharmacogenetic Test Summary		REPORT DETAILS Patient: Patient m0bwvya	VKORC1	-1639G>A G/A Intermediate Warfarin Sens	sitivity	
		DOD : 1/1/1500	MTHFR	c.1286A>C AA No Increased Risk of c.665C>T CC Hyperhomocysteinemia		
		MTHFR	c.665C>T CC Normal MTHFR Activity			
CYP2C19	*2/*17	Intermediate Metabolizer				
CYP2C9	*1/*1	Normal Metabolizer	For a complete report contact Manchester University Master of Sc in Pharmacogenomics Program www.manchester.edu/pgx		f Scienc	
CYP2D6	Indeterminate	Unknown Phenotype				
CYP3A4	*1/*1	Normal Metabolizer			ered By nslational	
CYP3A5	*1/*3	Intermediate Metabolizer		Software Sof	vare	

